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Bacterial infections have long been an ever-emerging problem with the 
appearance of antibiotic resistant bacteria which is deteriorating with the misuse and 
abuse of antibiotics. As infections of these emerging bacteria can hardly be treated, we 
are seeking a protective method to fight bacteria by the development of glycoconjugate 
vaccines. Chemical syntheses to obtain pure structures of the target antigens are 
essential for further glycobiology and immunity studies.  
 
Figure 1 Repeating unit of KPST258 antigen Gal-III and designed epitopes as vaccine candidates 
Chapter 2 describes my work on the development of the vaccine candidates 
against Klebsiella pneumoniae sequence type 258 (KPST258). This “super bug” can 
produce K. pneumoniae carbapenemases (KPC) to protect it from almost all the 
available antibiotics. I designed and synthesized the two structures, trisaccharide 2-1 
containing one repeating unit and hexasaccharide 2-2 containing two repeating units. 
(Figure 1) The repeating unit contains a C3, C4-branched galactose with a 
galactofuranose connected to its C3 position. This kind of oligosaccharide had never 
been well studied and chemical synthesis to obtain such a dense branched structure in 
the hexasaccharide bridged via a galactofuranose at C1 and C3 positions has never been 
reported either. Each oligosaccharide carries an amino linker, making it possible for 
further glycan array tests or conjugation for immunization and other biological 
evaluations. In collaboration with Bruna M. S. Seco, we performed glycan array tests 
and found sera from infected patients contained antibodies against both 2-1 and 2-2. The 
glycans were further conjugated to carrier protein CRM197 for immunization tests. 
CRM197-2-2 triggered a robust immune response in rabbits, indicating that it is a 





Figure 2 Antigens of S. suis serotypes 3 and 18 
Chapter 3 describes my work regarding an important swine pathogen 
Streptococcus suis. This bacterium exists in almost every pig farm around the world. 
Huge economic loss has been caused every year in swine industry and humans can also 
be infected. We became interested in S. suis serotypes 3 and 18, and the antigens I have 
been developing contain rare and interesting bacillosamine residues. Chemical 
modification of L-Bacillosamine has never been reported before, so I did some 
pioneering study on this sugar structure, hoping to achieve a better understanding of its 
properties and provide some reference for possible future study. The experience with 
monosaccharide modifications can be applied in D-bacillosamine modification for the 
synthesis of S. suis antigens. The final antigens are not finished yet, but most of the 
synthetic problems have been solved including the most complicated parts to establish 
the synthesis routes to the target molecules. The last stage of the antigen syntheses and 







Bakterielle Infektionen sind durch das Auftreten von antibiotikaresistenten 
Bakterien zu einem zunehmenden Problem geworden. Dieser Prozess wird durch 
Fehlgebrauch und missbräuchlichen Einsatz von Antibiotika zusätzlich beschleunigt. 
Um ein wirksames Mittel gegen diese sich ausbreitenden, schwer zu behandelnden 
Bakterien zu haben, arbeiten wir an der Entwicklung von Glykokonjugat-Impfstoffen. 
Dabei liegt der Fokus auf der chemischen Synthese, da es essentiell ist, die Ziel-
Antigene als reine Substanzen zu erhalten, um diese für biologische und 
immunologische Studien einsetzen zu können.  
 
Abbildung 1 Wiederhohleinheit des KPST258 Antigen Gal-III und Epitop-Fragmente, die potentielle 
Impfstoffe darstellen. 
Kapitel 2 dieser Arbeit beschreibt die Entwicklung eines Impfstoff-Kandidaten 
gegen  Klebsiella pneumoniae Sequenztyp 258 (KPST258). Dieses Bakterium wird 
auch als „Super-Keim“ bezeichnet, da es K. pneumoniae Carbapenemasen (KPC) 
produziert und es so gegen fast alle verfügbaren Antibiotika resistent ist. Es wurden 
zwei Verbindungen, das Trisaccharid 2-1, das aus einer Wiederholeinheit besteht, und 
das Hexasaccharid 2-2, das aus zwei Wiederholeinheiten aufgebaut ist, konzipiert und 
synthetisiert (Abbildung 1). Die Wiederholeinheit enthält eine Galactose, die an C3 und 
C4 verzweigt ist; in Position C3 ist eine Galactofuranose verknüpft. Diese Art von 
Struktur wurde noch nicht umfangreich untersucht und auch die Synthese des 
Hexasaccharids, das eine hohe Verzweigungs-Dichte aufweist und über die C1 und C3 
Positionen in der Galactofuranose verknüpft ist , oder ähnlicher Strukturen  wurde bis 
jetzt nicht in der Literatur beschrieben. Am reduzierenden Ende jedes Oligosaccharids 
wurde ein Linker mit einer Aminofunktion eingeführt, um die Glykane einfach an 




koppeln zu können.  In Zusammenarbeit mit Bruna M. S. Seco wurden Glykan-Arrays 
durchgeführt, die gezeigt haben, dass Seren von infizierten Patienten Antikörper 
enthalten, die die Strukturen 2-1 und 2-2 binden. Die Glykane wurden im nächsten 
Schritt für Immunisierungen an das Träger-Protein CRM197 gekoppelt. Das 
CRM197-2-2-Konjugat hat eine stabile Immunantwort in Kaninchen ausgelöst, was die 
Vermutung nahelegt, dass es sich bei dieser synthetischen Struktur um einen 
vielversprechenden Impfstoff-Kandidaten gegen KPST258 handelt.  
 
Abbildung 2 Antigene der S. suis Serotypen 3 und 18 
In Kapitel 3 wird die Arbeit an dem wichtigen porzinen Pathogen Streptococcus 
suis beschrieben. Dieses Bakterium kann in nahezu jeder Schweinemast weltweit 
nachgewiesen werden. Dadurch kommt es jedes Jahr zu großen finanziellen Verlusten 
in der Schweinemast und auch Menschen können sich mit diesem Bakterium infizieren. 
Unser Interesse an S. suis Serotyp 3 und Sereotyp 18 wurde geweckt, da die Antigene 
seltene Bacillosamin-Reste tragen. L-Bacillosamin ist nicht literaturbekannt, so dass in 
der vorliegenden Dissertation Pionierarbeit geleistet wurde, um die Eigenschaften dieser 
Struktur zu verstehen und um Referenzen für mögliche Arbeiten in der Zukunft zu 
liefern. Die Modifikationen des Monosaccharids könnten auch für die Synthese von S. 
suis Antigenen bei D-Bacillosamin zum Einsatz kommen. Aufgrund des begrenzten 
Zeitrahmens dieser Arbeit sind die finalen Antigene noch nicht fertiggestellt. Allerdings 
liegen für alle Probleme, die während der Synthese auftreten, Lösungsansätze bereit, 
inklusive den komplexesten Schritten, um die Syntheserouten für die Zielmoleküle zu 
etablieren. Die letzten Schritte der Antigen-Synthese und die immunologische 





1.1 Multidrug-Resistant Infectious Bacteria 
1.1.1 Bacteria and Infectious Diseases 
Bacteria are ubiquitous around the world.1 They were among the earliest forms 
of life that appeared on earth and nowadays they are not only everywhere in the 
environment: in soil, air, water etc., but also in plants and animals symbiotically or 
parasitically. While most bacteria are harmless to the human body thanks to our 
immunogenic system, many species are pathogenic and may cause infectious diseases 
like pneumoniae or meningitis. We call them pathogenic bacteria.2  
Infectious diseases can be caused by different microbiomes among which 
pathogenic bacteria have been threatening human health worldwide since long ago.3 
Invasions by bacteria into the host result in the host's disorders such as pneumonia, 
meningitis and food poisoning.4 Pathogens can be passed from one to another directly or 
indirectly causing disease outbreaks as well as deaths.5 A famous case was the infection 
of cholera that happened in September 1854 around Broad and Cambridge Streets in 
London. Water was polluted with the bacterium Vibrio cholerae (Figure 3) and within 
10 days, more than 500 people were infected and killed. Though cholera infection is no 
longer a problem nowadays, a lot of other infectious diseases are still problematic 
around the world.6 
 
Figure 3 Electron micrograph of Vibrio cholera* 
 
                                                 




1.1.2 Antibiotics and Antibiotic Resistance 
The discovery of Penicillin by Alexander Fleming, the earliest antibiotic used to 
cure bacterial infections in the 1920s, was a milestone in human history.7 The core 
structure of penicillin is the β-lactam 4-membered ring colored in red in Figure 4. 
β-Lactams can inhibit the cell wall synthesis of the bacteria and prevent them from 
reproducing.8  
 
Figure 4 Structures of β-lactam antibiotics9 
A lot of other antibiotics have been developed after penicillin and due to their 
wide-spectrum as well as high efficiency against different types of bacteria, they soon 
became widely used medicines for the prevention and treatment of almost all kinds of 
bacterial infections.10  
However, there is the other side of the coin: the development of antibiotics 
resistance of the bacteria. Antibiotic resistance appears naturally as a result of the 
selection of survived bacteria by the antibiotics, but has been greatly accelerated 
because of people's misuse and abuse of these drugs.11 Although regulations have been 
established to prevent antibiotic resistance from developing too fast among the bacteria, 
it has already been a threat to human health worldwide: more multidrug resistant (MDR) 
bacteria are identified and infections of these bacteria become more and more 
challenging for treatment.12  
Bacteria have several mechanisms to resist antibiotics: a) they can produce 
antibiotic hydrolyzing enzymes such as β-lactamases that can catalyze the hydrolysis of 




targeted; c) they can change the metabolic pathways that are inhibited by antibiotics; d) 
they can pump the antibiotic molecules out of their cells to avoid the damage they might 
suffer.13 (Figure 5) 
 
Figure 5 Antibiotic targets and mechanisms of resistance14 
 
1.1.3 Emergence of the Current Situation and Possible Solutions 
Decades have passed since the golden era of antibiotics from 1930s to 1960s, yet 
research into new antibiotic development has failed to follow the pace of the bacteria 
that are becoming increasingly resistant. At the end of April 2014, the world health 
organization (WHO) revealed its first report to the public on the antibiotic resistance 
with data of more than 100 countries, announcing the emergency of new methods to 
control the lethal and worldwide spread MDR bacteria or “superbugs”.15  
Antibiotics are vital in preventing infections following surgeries. It is estimated 
that almost half of the surgical infections are caused by resistant bacteria; they also 
make infections more difficult to treat thus higher morbidity and mortality; domestic 
animals like pets or livestock can be infected as well, causing huge economic loss 
worldwide. A study has shown that almost 2 million people in the US get infected under 




resistant pathogens play an important role in most cases; in Europe, 25,000 people die 
every year because of MDR bacterial infections.16  
Besides controlling the infections by regulation to limit the use of antibiotics to 
proper situations, many people are also trying to develop new kinds of antibiotics. 
However, risks still exist that bacteria soon gain resistance again and it becomes even 
harder to treat the infection. A better way to fight against the superbugs could be a 
protective way to help us prevent the infection of bacteria through vaccination.17 
1.2 Immune System and Vaccines 
Vaccines are used to trigger the immune system by simulating the invasion of 
pathogens so the body can get prepared and respond fast once the specific pathogens are 
detected in the future. To explain the mechanism of how a bacterial vaccine works, I 
start from bacterial polysaccharides and the immune response. 
1.2.1 Antigens and Immune Response 
The surface of the bacterial cell is covered with a thick layer of conjugated 
sugars, including capsular polysaccharides (CPS) and lipopolysaccharides (LPS).18 
These sugars are important virulence factors as well as recognition receptors for the 
immune system, termed antigens.19 Antigens can be unspecifically recognized by the 
innate immune system via pattern recognition receptors (PRR) and thus eliminated.20 In 
some cases, the innate immune response is not efficient enough. In addition, non-
specific recognition does not have memory effect. In order to provide efficient and long-
period protection against some particular bacteria, we need to take advantage of the 
adaptive immune system. After a B cell has digested the antigen, it can produce a 
complex containing the antigen fragments called major histocompatibility complex 
(MHC) molecules.21 Helper T cells can not recognize antigens directly but can mature if 
prompted by MHC molecules. 
Differing from innate immune system, the adaptive immune system is specific in 
dealing with foreign antigens. Antigen presentation mediated by MHC can initiate this 
process where both B and T lymphocytes (white blood cells) are involved. B cells 
mature into plasma cells which can produce antibodies to mark or block the invader 




lymphocytes or CTLs). Helper T cells are able to help activate B cells to produce 
antibodies, macrophages to smash target cells, and killer T cells can interact directly 
with the tagged cells and destroy them.22 (Figure 6) 
 
Figure 6 A brief progress of the adaptive immune response.22 1. An antigen is digested by a 
macrophage or a B cell; 2. The antigen fragments are bounded to its MHC molecules; 3. The MHC 
molecules are displayed to a T cell helping it mature with the presence of lymphokines; 4. When a T cell is 
activated, it will secrete lymphokines; 5. Lymphokines will accelerate more T cells to mature; 6. 
Lynphokines will direct more other immune cells as fresh macrophages, granulocytes and other 
lynphocytes to the infection site to kill the infected cells; 7. Some T cells become killer T cells and kill the 
infected cells. 
Importantly in addition, memory B cells and T cells will be generated during the 
initial response to the antigen. As a result, once the same antigen is recognized in the 
future, the immune response will be significantly accelerated, and this is the base of 
vaccination aiming to provide a protective way to fight against infectious diseases.23 
1.2.2 Vaccines and Glycoconjugate Vaccines 
People in ancient China had already learned to prevent smallpox by inoculating 
the pus from smallpox patients.24 The scientific practice was adopted by Edward Jenner, 
who studied the prevention of smallpox by inoculating his family with cowpox pus.25 
Since then, a large number of vaccines have been developed to help us control the 




vaccines, inactivated vaccines, subunit vaccines, recombinant vaccines and DNA 
vaccines, and for bacterial vaccines one of the most successful stories belongs to the 
glycoconjugate vaccines.27 
As mentioned in the previous part, bacterial pathogens are usually covered by 
capsular sugars that are essential in protecting these organisms and acting as a 
recognizer of specific antibodies.28 Different kinds of bacterial vaccines were developed 
for preventing infectious diseases such as pneumonia and meningitis, using the 
unconjugated capsular polysaccharides based on this knowledge in the late 20th 
century.29 However, it was soon noticed that these vaccines were unable to trigger the 
immune response of young children, infants or immune-compromised individuals. 
Polysaccharide vaccines did not raise memory effect after repeated doses which 
prevented people in gaining long-period protection.30 
Glycoconjugate vaccines where the antigens were conjugated with carrier 
proteins solved this problem.31 Polysaccharides (PS) are T cell independent antigens and 
only stimulate B cells by cross-linking their receptors. B cells are able to process 
glycoconjugate vaccines on the other hand, by internalizing them into the specific 
MHC II molecules and presenting them to T cells. In this case, B cells can mature into 
memory cells and produce antigen-specific IgG to help with long-term protection.32 
The development of glycoconjugate has succeeded in helping people fight 
against bacterial infections and many vaccines are already commercially available. 
Examples of the glycoconjugate vaccines licensed by FDA as well as some brief 





Table 1 Glycoconjugate vaccines licensed by FDA33 
Pathogen 
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The most important part of the glycoconjugate vaccines are the antigens where 
specific oligosaccharides are conjugated to non-toxic carrier proteins.34 We can get the 
specific oligosaccharides needed for conjugation from natural sources. However, 
isolation and purification remain the most challenging steps even today.35 Synthetic 
carbohydrate chemistry is promising in the search for a more efficient way to access the 




process can provide a precise structure thus much better reproducible biological 
properties and safety.36 
 
1.3 Development of the Vaccines via Chemical Synthesis 
Sugar chemistry is the key to obtaining an oligosaccharide with the desired 
structure by chemical synthesis. Figure 7 shows a brief process step by step of how to 
develop glycoconjugate vaccines via chemical synthesis in the Seeberger lab.  
 
Figure 7 Development of the vaccine via chemical synthesis* 
Based on the knowledge from the characterization work where the structures of 
promising antigens were determined, we start by chemical syntheses of the 
oligosaccharides to obtain the sugar candidates which usually contain one or two 
repeating units. The advantage of chemical synthesis is that we are able to determine the 
structure using modern analyzing methods such as mass spectroscopy (MS), optical 
rotation (OR), infrared spectroscopy (IR) and nuclear magnetic resonance (NMR) to 
make sure the compounds we have prepared are correct and pure.  
Unlike the isolated oligosaccharides, the high purity and homogeneity of the 
glycan synthesized allows for a better repeatability in further immunological 
experiments. Chemical synthesis also allows us to study the properties of the glycan 
more flexibly by doing modification at the positions we wish, changing the length of the 
sugar chain or switching the order of the monosaccharide residues in the repeating unit.  
The reducing end of the oligosaccharide is usually anchored to the hydroxyl 
group of a bifunctionalized alkyl linker, where the other end is an amino group. 
Immobilization of the amino end makes it possible for us to evaluate the sugar with 
                                                 




glycan array technology, or conjugate it to a carrier protein for further immunization 
and other biological evaluations. 
Glycan array screening is a standard technology to study the interactions 
between glycans and proteins, and a very useful high-throughput method to identify 
biomarkers or help vaccine development. With the glycan array screening platform 
established by the Seeberger group, it is very efficient to perform first immune tests of 
our synthetic sugars. First, the glycans are covalently immobilized onto a surface 
modified glass slide. Subsequent incubation with glycan-binding antibodies, labelling 
with a fluorescent secondary antibody and washing of unbound reagent is followed by 
further fluorescent read-out. The intensity of the fluorescence is quantified.37  
 
Scheme 1 Conjugation of the glycan to carrier protein CRM197 
Promising glycans will be conjugated to carrier proteins for further 
immunization and other biological experiments in animal models. Several different 
carrier proteins have already been applied in licensed vaccines such as TT (tetanus 
toxoid), DT (diphtheria toxoid) and CRM197 (cross-reacting material 197).38 The 
Seeberger group is using CRM197 as the carrier protein which is a commercially 
available non-toxic mutant of diphtheria toxin isolated from Corynebacterium 
diphtheria strain C7 (β197) cultures.39 Scheme 1 shows a commonly used method for 
the preparation of neo-glycoprotein. In this method, the linker is a homobifunctional 
reagent, p-nitrophenyl adipate ester (PNP), which performs as a bridge between the 




CRM197 protein molecule can react with several glycans to mimic the pathogen and to 
trigger an immune response. 
With aluminum-based adjuvants such as Al(OH)3,40 the conjugated glycoprotein 
can be inject into animal models (most commonly mice or rabbits) for further 
immunological evaluation. The immune test usually includes prime injection of the 
vaccine candidate and a second injection after about two weeks to boost the immunity. 
Blood samples are collected at different time points and the immune response is 
indicated by the concentration of the corresponding antibody, which is determined by an 
enzyme-linked immunosorbent assay (ELISA).41 Effective vaccine candidates could go 
further for industrial vaccine development or monoclonal antibody development. 
The chemical synthesis to provide the target oligosaccharide is vital within the 
workflow. Unlike DNA or protein where the primary structures of the molecules are 
linear, the number of potential linkages between sugar residues can be countless, with 
different hydroxyl groups and α/β selection on each sugar residue.42 The complexity 
grows exponentially if the glycan is highly branched. Chemical synthesis is a time-
consuming step but the most important one from a chemistry point of view to approach 
the chemical synthesized glycoconjugate vaccine, and requires a deep understanding of 
the structure, careful design of the synthetic route, and many trials and modifications of 
reaction conditions or even pathway of synthesis. The knowledge of carbohydrate 
synthesis as well as practical experience is essential in performing experiments in this 
field.43 
1.4 Synthetic Sugar Chemistry 
Synthetic sugar chemistry is the key to accomplishing the syntheses of different 
structurally well-defined oligosaccharides. Numerous complex glycans have been 
achieved including glycoprotein and mycobacterial arabinogalactan.44,45,54,46–53 The 
synthetic progress usually consists of two main parts before final deprotection to get the 
target molecule: modification of the monosaccharides to get desired building blocks, 




1.4.1 Monosaccharide Modifications  
Monosaccharides are the simplest sugar molecules that cannot be further 
hydrolyzed to smaller sugars.55 The most common configurations of bacterial sugar 
residues appearing in bacterial epitopes are in cyclic pyranose or furanose forms. 
Scheme 2 shows the reversible cyclization reactions of D-galactose as an example.56 
 
Scheme 2 Cyclization of acyclic D-galactose to form pyranose and furanose structures 
Cyclization reactions usually produce both α and β anomers. 
A significant feature of the sugar molecules is the high density of hydroxyl 
groups. The reactivity of these hydroxyl groups differs but without dramatic distinction. 
The building blocks can be used for further glycosylations as donors (which react at 
position 1) or acceptors (which react at other positions). Building block design often 
requires the arming of all the undesired hydroxyl groups of the acceptor with protective 
groups except the only hydroxyl group needed for further coupling.  
 
Scheme 3 The selectivity in protecting the methyl α-D-galactopyranoside as an example57 
Selective protection of particular hydroxyl groups is vital in shielding these 




different reagents and catalysts to protect some of the hydroxyl groups and leave others 
free. The protective groups could be divided into two types: permanent and temporary 
protective groups. Permanent protective groups are functional groups that are relatively 
stable when modifications on other positions or glycosylations are taking place. They 
will only be removed during global deprotection when the final deprotected sugar is 
prepared. On the other hand, temporary protective groups are more fragile and can be 
cleaved under specific conditions where other functional groups are not affected. 
Sometimes, two or even more protective groups can be orthogonal to allow for the 
building block to be used in various situations to fulfill different requirements.  
Blocking specific hydroxyl groups is not the only effect of protective groups; 
they will also introduce electronic and spatial effects into the sugar molecule, change 
the sugar ring conformation or participate in the reaction directly, thus possibly bringing 
significant difference of the sugar’s chemistry properties and reactivity. Many selective 
reactions are based on these effects. A commonly acknowledged example is to 
introduce an acetyl group for 2-OH protection in a glucopyranose which will result in β 
product in the glycosylation reaction from neighboring participation effect.58 An 
example with detailed mechanism is shown in Scheme 5. 
Besides hydroxyl groups, there are also amino groups in amino sugars where 
modifications are needed as well during synthesis. Acetyl-derivatives protected amino 
groups or more stable azido groups are commonly utilized in the synthesis and they will 
finally be converted into acetyl amino or free amino groups in the target molecule. 
Many useful strategies and methods have been developed through the past 
decades and simple sugar molecules can be converted into almost any building blocks 
required for the synthesis of our target molecule. Yet, many unexpected problems may 
occur when running reactions. A tiny change of the structure, even at a far-away 
position, might bring about a totally different result. Even equipped with knowledge of 
many similar examples as well as relative experience, a successful synthesis route can 





1.4.2 Glycosylations to Construct Complex Oligosaccharides 
 
Scheme 4 General mechanism of a glycosylation reaction 
The glycosylation is the key step in oligosaccharide synthesis where a glycosidic 
bond is formed to connect the glycosyl donor and acceptor. The majority of the 
glycosylation methods start from the activation of the leaving group in the glycosyl 
donor at anomeric position. It forms an oxocarbenium intermediate that can be attacked 
by the nucleophilic acceptor to form the glycoside product.59 (Scheme 4) The 
glycosylation mechanism is still not completely understood but some new technologies 
such as ion mobility–mass spectrometry and cold-ion infrared spectroscopy have 
provided more solid mechanistic insights of glycan synthesis.60,61  
A lot of work has been done since the pioneering approach of Hermann Emil 
Fischer and Arthur Michael who performed the first glycosylation experiments. 
Chloride was used as the leaving group and the reaction proceeded with a nucleophilic 
substitution just as many modern glycosylations do.62 Nowadays, commonly used donor 
types include glycosyl halides, thioglycosides, glycosyl imidates,63 glycosyl 
phosphates,64 glycosyl O-alkynyl benzoates65–67 and others.68 The leaving groups for 
glycosylation frequently applied in this thesis include thioglycosides and glycosyl 
imidates. 
Thioglycosides can be prepared by the nucleophilic attack of thiol on the 
anomeric position of the sugar in the presence of Lewis acids as BF3·Et2O, TMSOTf, 
SnCl4, etc. They can be stored for a long time and are chemically stable during many 
other protection and deprotection reactions as well as some glycosylation procedures. 
However, they are also excellent donors and can be easily activated with NIS and TfOH, 
which makes them quite versatile for oligosaccharide syntheses. Compared to 
thioglycosides, glycosyl imidates, usually 2,2,2-trichloroacetimidate or 2,2,2-trifluoro-




are more reactive and could still be smoothly obtained from the coupling of numerically 
hydrolyzed sugar and the imidate precursor. Glycosylation of the imidate donor takes 
place with catalytic amount of Lewis acid. This very reliable reaction has already been 
used in the syntheses of a number of glycoconjugate natural products and the activation 
condition can be distinguished from thioglycoside donors. New glycosylation methods 
are being developed. Gold(I) catalyzed glycosylations are applied when the building 
blocks are very labile in acidic conditions;69,70 enzyme mediated glycosylations are used 
for the installation of sialic acid.71 Reagents are also updated to improve the reaction 
yields or selectivity, or reduce the reagent cost or toxicity. Examples include the usage 
of 1,3-dibromo-5,5-dimethylhydantoin instead of NIS or NBS as promoter to activate 
thioglycosides,72 and the introduction of cheap metal to reduce the amount of gold(I) 
catalyst needed in the gold catalyzed glycosylation.67 
 
Scheme 5 Proposed mechanism of the neighbouring group participating effect to form a 1,2-trans 
glycoside 
The control of regioselective and stereoselective glycosylations is essential for 
the chemical synthesis of oligosaccharides. Apart from the different types of leaving 
groups, glycosylation reactions can be affected by many other factors such as 
temperature, solvents, promoters, substituents especially at the C2 position of the donor 
(Scheme 5), distortion of the sugar rings and so on.  
Recently, the Seeberger group reported using computer learning to fit the 
parameters in the glycosylation and was able to predict the α/β selectivity with given 
data of glycosylation conditions.73 A long way remains to go before a general solution 
can be reached. Many real structures are much larger and far more complex, making it 
overwhelmingly beyond the limit of the computer to make reliable predictions. While 
we have made many complex sugar molecules and their derivatives, the famous lines by 




“Although we have now learned to synthesize oligosaccharides, it should be 
emphasized that each oligosaccharide synthesis remains an independent problem, whose 
resolution requires considerable systematic research and a good deal of knowhow. 
There are no universal reaction conditions for oligosaccharide syntheses.”74 
Each oligosaccharide synthesis is a journey to explore the nature’s unknown. 
And I will provide a lot of details of my exploration in Chapter 2 and Chapter 3. 
 
1.5 Goal and Objectives of This Thesis 
The overall goal of the thesis is the development of vaccines against emerging 
bacteria that are threatening humans as well as other species all around the world. My 
target bacteria are Klebsiella pneumoniae sequence type 258 in Chapter 2 and 
Streptococcus suis serotypes 3 and 18 in Chapter 3. 
The last few decades have witnessed the discovery and worldwide spread of 
drug resistant bacteria including Klebsiella pneumoniae and no effective treatment has 
been found yet to combat these “super bugs” since they can produce K. pneumoniae 
carbapenemases (KPC) which can protect them from almost all available antibiotics. 
The lethal infection caused by the KPC producing bacteria prompted us to seek a 
protective method to fight against them through the development of a vaccine. The first 
objective of Chapter 2 is to prepare pure antigen of the bacteria by chemical synthesis 
according to the literature75 where the structure of the most predominant antigen was 
determined. The second objective is the biological evaluation of the synthetic antigen. 
The antigen needs to be conjugated to a carrier protein to obtain the candidate of the 
vaccine against this KPC producing bacteria. In collaboration with Bruna M. S. Seco, a 
biologist, we tested glycan arrays and further immunized rabbits as our animal model. 
Different lengths of the oligosaccharides not only helped us to find the best solution in 
this project, but also provided us with a deeper understanding of the structure factor 
related to the vaccine effectiveness and will be a useful reference for future vaccine 
development.  
Chapter 3 focuses on Streptococcus suis bacteria, a very important swine 




huge economic losses in the swine industry every year. What’s worse, human beings 
also have a chance to get infected by direct contact with the carrier pigs or contaminated 
derived products. The objective of this chapter is to synthesize the antigens from 
Streptococcus suis serotypes 3 and 18 as vaccine candidates. Although the final 
compounds have not been obtained, the strategy has been established and the target 
molecules are within reach. Some serendipity worth further investigation during the 
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2 Development of a Vaccine Candidate against 
Klebsiella pneumoniae ST 258 
2.1 Introduction 
 
Figure 8 Carbapenem-resistant Klebsiella pneumoniae bacteria, on a green-colored neutrophil* 
Klebsiella pneumoniae is a Gram-negative bacterium named after Edwin Klebs, 
a 19th century German microbiologist. The non-motile, rod-shaped bacteriu are covered 
by a prominent polysaccharide capsule. Klebsiella pneumoniae exists ubiquitously in 
the environment, and is asymptomatically part of the human microbiome, on the skin, in 
the mouth, and mostly in the intestines. However, Klebsiella pneumoniae is an 
opportunistic pathogen that can cause pneumonia, urinary tract infections, bacteremia 
and liver abscesses in immunocompromised people. Conventionally, antibiotics have 
been applied to treat Klebsiella pneumoniae. However, recent studies have shown the 
development of drug-resistance in them which has been accelerated by the antibiotics 
abuse.76 
Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections have raised 
global apprehension with high morbidity and mortality resulting from the bacterium's 
extraordinary resistance to almost all currently available antibiotics. The first case 
where Klebsiella pneumoniae carbapenemases (KPCs) were identified was in the USA 
in 1996.77 The bacteria could produce KPCs to hydrolyze almost all the available 
                                                 
* Scanning electron microscopic (SEM) image, by National Institute of Allergy and Infectious 
Diseases (NIAID), digitally recolored. 
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antibiotics: penicillins, cephalosporins, monobactems, carbapenems and even 
β-lactamase inhibitors.75  
Difficulties in treating these bacteria have helped them to spread very quickly 
around the world in the past two decades and cases have been reported globally with the 
ST258 lineage being the predominant clone worldwide.78 (Figure 9) As the outbreaks 
become increasingly frequent, no efficient therapeutic method is available yet. A 
solution needs to be found soon. Vaccination is an advantageous preventive way to fight 
against the KPC producing K. pneumoniae.79 
 
Figure 9 Epidemiology of KPC producing bacteria by original countries78 
Other carbapenemase types: VIM, OXA-48, or NDM 
Capsular polysaccharides (CPS, K-antigens) and lipopolysaccharides (LPS, O-
antigens) are the most important virulent factors of KPST258. Fragments of these 
antigens may be used for the development of glycoconjugate vaccines for KPST258 
infections. More than 77 CPS structures have been discovered and a pioneering vaccine 
candidate based on a K-antigen has already been reported by the Seeberger group.80 
However, the high diversity of K-antigens makes it laborious to cover all the serotypes 
and many newly-appearing CPS structures are yet unidentified.81 On the other hand, O-
antigens have a quite limited variation of structures.82 The O-antigens are classified to 
nine serotypes, and among them O2afg, or Gal-III was figured out to be preponderant 
in the KPST258 isolates.  
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The repeating unit (RU) of Gal-III, shown in Figure 10-a, is a branched frame 
of two galactopyranose and one galactofuranose, and an oligosaccharide based on this 
structure might be able to stimulate the immune response.75,83 A synthetic epitope would 
also include an aminoalkyl linker attached to its anomeric carbon from the hydroxyl end 
and the other NH2 end of the linker could be applied to glycan array immobilization or 
conjugation to CRM197 for immunization investigations.  
 
Figure 10 Structures of target oligosaccharides for KPST258 vaccine development. a) Trisaccharide 
repeating unit of Gal-III from KPST258. b) Chemical synthetic trisaccharide repeating unit 1 and 
hexasaccharide 2 containing two repeating units, each connected to a fluorinated linker. 
In this thesis work, the chemical syntheses of the trisaccharide KPST258 
repeating unit 2-1 and hexasaccharide 2-2 consisting of two repeating units (Figure 10-
b) as well as their conjugation followed by glycan arrays and immunization tests were 
performed. The evaluations of the two vaccine candidates CRM197-2-1 and CRM197-2-2 
were carried out so we could compare the influence of the sugar chain length to the 
immunization results which would allow us to gain a better understanding of how the 
antigens work and benefit in further vaccine development against KPST258. 
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2.2 Results and Discussions 
2.2.1 Retro-synthetic Analysis of Oligosaccharides 2-1 and 2-2 
Retrosynthetic analyses of 2-1 and 2-2 are depicted in Scheme 6. The target 
molecules were obtained from global deprotection of the protected compounds 2-3 and 
2-4 separately, where the protective groups were carefully designed for successful 
assembly of the monosaccharide building blocks.  
 
Scheme 6 Retrosynthetic analysis of trisaccharide 2-1 and hexasaccharide 2-2 
The core residue of the challenging target trisaccharide 2-1 is a galactopyranose 
where the linker and both of the other two sugar residues are connected at C1, C3 and 
C4 positions independently. The key element of the strategy was how to assemble the 
linker (2-8) and two terminal sugar building blocks (2-5SEt and 2-6STol) to the core 
2-7SPh at the right locations with proper stereoselectivity. To assemble hexasaccharide 
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2-2, different strategies could be employed. The first trial was to synthesize the 
backbone tetrasaccharide before installation of the two branched galactopyranoses. 
Unfortunately, the installation of galactopyranoses was not working well. In order to 
solve the problem, an alternative extendable 3+3 strategy (trisaccharide plus 
trisaccharide strategy) was applied in designing the synthesis of hexasaccharide 2-2 
containing two trisaccharide repeating units.  
By changing the C3 protective group of 2-6STol from permanent protecting 
benzoyl group to a temporary protective group, a further glycosylation of 2-10 was 
possible with 2-9SPh as a donor, whose difference from 2-3 was that the trisaccharide 
was not connected to the linker but had a thiol leaving group. In this case, assembly of 
the building blocks required the tolerance of glycosylation conditions by the thiol 
leaving group. The solution to this problem was to use more reactive leaving groups on 
monosaccharide donors 2-5a and 2-6a so the glycosylation could be performed at 
milder conditions where the thiol could tolerant.  
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2.2.2 Total Synthesis of the Trisaccharide Epitope 2-1 
 
Scheme 7 Preparation of 2-5SEt, 2-6Tol and 2-884,85 
To synthesize trisaccharide 2-1, the galactopyranose building blocks 2-5SEt, 
2-7SPh, galactofuranose building block 2-6STol and the fluorinated linker 2-8 had to be 
prepared. The fluorinated linker 2,2-difluoro-3-aminopropanol (2-8) was a newly 
developed linker favoring α-glycosylation.84 The stereo control of α-glycosylation with 
linker is not easy in many cases and we mostly rely on the reaction conditions to 
enhance α-selectivity. After introduction of the fluorine atoms to the linker, the 
nucleophilicity of the linker would be reduced dramatically and hence much better α-
selectivity duo to the anomeric effect.84  
2-5SEt was first reported in the Automation Glycan Assembly (AGA) strategy 
where pure α-glycosylation was observed.85 Synthesis of 2-5SEt started from β-D-
galactopyranose pentaacetate which was a very cheap commercially available starting 
material. After several modification steps, C2 and C3 positions were protected with 
benzyl groups while C4 and C6 were acetate protected. The α-selection when 
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performing glycosylation was favored probably because of the remote participating of 
C4 and C6 acetyl groups. Although situations might be different between automated 
synthesis and solution synthesis, we still assume that a good α selectivity could be 
achieved.85  
2-6STol is a galactofuranose that has different properties compared to the other 
galactopyranose building blocks. I started from unprotected galactose and the first step 
was tert-butyldimethylsilyl (TBS) protection on every hydroxyl group. TBS group is a 
very bulky protective group. The cis-positions of C3 and C4 hydroxyl groups would 
severely repulse each other in pyranose configuration after TBS protection, distort the 
sugar ring and raise the energy to a very high level. On the other hand, the neighboring 
hydroxyl groups on the sugar ring of galactofuranose are all trans-positioned and this 
galactofuranose configuration has a lower energy which will push the reaction 
equilibrium to the major galactofuranose product 2-16 which was further converted to 
2-6STol after a few steps. β-Glycosylation selectivity of 2-6STol as the donor was 
guaranteed by the benzoyl participating group at C2 position.  
 
Scheme 8 Synthesis of the core building block BB2SPh 
The core building block 2-7SPh was synthesized from commercially available 
β-D-galactose pentaacetate. (Scheme 8) Following a described procedure, we prepared 
2,6-benzylthiolgalactose 2-25 and the problem was to distinguish the C3 and C4 
positions.86 A linker usually has a higher activity than a sugar building block as an 
acceptor, especially for less reactive 4-hydroxyl group, we only selectively protected C3 
position with fluorenylmethyloxycarbonyl group (Fmoc) and left the 4-OH unprotected 
via dimethyltin dichloride catalyzed conditions.87 The building block 2-7SPh can first 
react as donor with 2-8 followed by another glycosylation with 2-5SEt on its C4 
position to obtain the disaccharide intermediate. Subsequent deprotection of Fmoc and 
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glycosylation with 2-6STol at C3 position could then provide the desired protected 
trisaccharide 2-3. 
 
Scheme 9. Assembly of the building blocks to form protected trisaccharide 2-3.  
After I obtained all the required building blocks, 2-7SPh was first coupled with 
2-8. The α-product was favored because of a weaker nucleophilicity of the acceptor, the 
solvent effect and higher temperature. These factors led to a slower nucleophilic attack 
during the glycosylation hence thermodynamic control of the reaction to give a much 
better α-selection. β-Isomer could not be identified by NMR in the previous step as it 
was produced in trace amount only. The α/β ratio of the glycosylation reaction was 36/1, 
indicated by HPLC of the product, which was very encouraging (Figure 11).  




Figure 11 HPLC trace of the glycosylation to obtain 2-26; α/β = 36 
However, the product was unable to be purified until 2-5SEt was installed at the 
C4 position and Fmoc was cleaved. Both of the glycosidic linkages in the disaccharide 
2-26 were confirmed α according to the H-C coupling constant (~170 Hz). We assumed 
that the excellent α-stereoselectivity in the second glycosylation came from the 4,6-
acetyl groups on 2-5SEt via remote participation. Next, β-glycosylation with 2-6STol 
gave us the protected trisaccharide 2-3.  
 
Scheme 10 Global deprotection of 3. Galactofuranose partially cleaved during hydrogenation. 
With the protected trisaccharide 2-3 in hand, global deprotection with commonly 
used conditions was carried out, and the cleavage of ester groups was working well. 
However, partially decomposition of the product was observed in the hydrogenation 
step where the galactofuranose was cleaved. (Scheme 10) We tried to change Pd/C into 
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Pd(OH)2/C as we assumed the hydrogenation environment might become acidic during 
the reaction and result in the cleavage of the galactofuranose. Since the furanose residue 
cleavage was not avoided, I tried to reduce the reaction time, trying to stop 
hydrogenation before the start of the cleavage. Unfortunately, mass spectra of the 
reaction solution during hydrogenation monitored by MALDI showed that the cleavage 
happened before 2-29 was fully converted.  
 
Scheme 11 One-pot deprotection of 2-3 by Birch reduction 
I moved to the alternative Birch reduction conditions where all the protective 
groups can be cleaved in one pot. This was a reaction in whose first stage a strong basic 
and reductive environment created by Na(NH3) could deprotect Bn and Cbz groups, and 
after being quenched by methanol, sodium methoxide formed and could disarm the acyl 
groups in the second stage to obtain the desired trisaccharide 2-1. (Scheme 11) The 
NMR spectra of the product indicated an agreement with the data from the natural 
isolated epitopes. (See experimental section.) 
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2.2.3 Total Synthesis of the Hexasaccharide Epitope 2-2 
 
Scheme 12 The 3+3 strategy for the synthesis of hexasaccharide 2-4  
Synthesis of hexasaccharide 2-2 followed an extendable 3+3 strategy based on 
the successful assembly of trisaccharide 2-1. As specified in Scheme 12, the 
hexasaccharide could be synthesized through glycosylation between donor 2-9SPh and 
acceptor 2-10. Syntheses of 2-9SPh and 2-10 were based on the previous strategy but 
more complicated, and modifications of the building blocks were required. For the 
acceptor 2-10, only one place needed to be changed. The C3 position of 2-6STol needed 
to be replaced by a temporary protective group which could be deprotected selectively 
to form a hydroxyl group for further extension with the trisaccharide donor.  
 
Scheme 13 Synthesis of the modified galactofuranose building block 2-6MSTol.  
The key step to achieve the modified building block 2-6MSTol was to 
distinguish the C2 and C3 positions. Benzoylation of 2-31 with 1.1 eq. of benzoyl 
chloride (BzCl) gave C2 benzoylated product 2-32, after which the C3 position could be 
protected by a silyl group,88 and subsequently C5 and C6 were changed to benzoyl 
group due to the vulnerability of the isopropylidene under acidic glycosylation 
conditions to obtain the modified building block 2-6MSTol. (Scheme 13) More 
hindered bases (DIPEA, 2,4,6-collidine and TTBP) were tried in order to improve the 
yield or regioselectivity from 2-31 to 2-32, yet neither of them worked better and the 
original conditions were kept.  




Scheme 14 Assembly of trisaccharide fragments 2-10 as acceptor and 2-9SPh as donor. 
The installation of 2-6MSTol on disaccharide 2-28 allowed us to prepare the 
trisaccharide 2-35 without any problem. TBAF was then used to deprotect the TBS 
group on the galactofuranose. However, under basic conditions, the acetyl groups would 
be cleaved. This issue was solved by the addition of acetic acid together with TBAF to 
adjust the pH to neutral, and the modified conditions yielded trisaccharide acceptor 2-10 
in a surprisingly high yield.  
Meanwhile, the trisaccharide donor 2-9SPh was synthesized from 2-7SPh. 
Without the linker's attachment on its anomeric position, 2-7SPh must carry the thiol 
leaving group during the following assembly steps, which required a compatible 
glycosylation condition with thiol. To solve the problem, 2-5SEt and 2-6STol were 
converted to glycosyl trifluoroacetimidates89 2-5a and 2-6a separately by hydrolysis and 
installation of the N-phenyl trifluoroacetimidate. The glycosylation steps to 2-9SPh 
were performed under milder conditions where TMSOTf was used instead of TfOH and 
NIS, and thiol was steady enough to stay unaffected. (Scheme 14) 




Scheme 15 Synthesis of the protected hexasaccharide 2-4 and further deprotection to get final 
hexasaccharide target 2-2 
With both the trisaccharides 2-9SPh and 2-10 in hand, I first did the 3+3 
glycosylation under standard thiol activation conditions, but did not obtain the desired 
hexasaccharide. The acceptor 2-10 remained unreacted while 2-9SPh was hydrolyzed. 
The hydrolyzed donor 2-9OH was detected, indicating that the activation happened as 
expected, yet the following nucleophilic attack by the acceptor 2-10 didn't occur. The 
unsuccessful reaction might result from the mismatch of the reactivity of the donor and 
acceptor.  
This type of mismatch was previously observed during the synthesis of the N. 
meningitidis LPS by Dr. You Yang, in the Seeberger group. He solved the problem by 
changing the leaving group from thiol to imidate.49 Fortunately, 2-9OH was recovered 
and 2-9a was acquired by introduction of the N-phenyl trifluoroacetimidate. This 
imidate was successfully coupled with 2-10 with an appealing yield to get protected 
hexasaccharide 2-4. Deprotection of 2-4 by Birch reduction was successful and after 
desalting by size exclusion column (Sephadex G25) and HPLC purification, the 
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deprotected hexasaccharide 2-2 was obtained. Hexasaccharide 2-2 was ready for glycan 
array screening and protein conjugation. (Scheme 15) 
2.2.4 Evaluation of the Synthesized Epitopes by Glycan Array* 
Glycan arrays are high throughput method to evaluate the glycan-antigen 
binding. The glycans 2-1 and 2-2 I prepared were printed on the glass plate through 
immobilization of the amino end.  
 
Figure 12 Glycan array evaluation of the synthesized epitopes 2-1 (left) and 2-2 (right)† 
Figure 12 shows the glycan array results of synthetic trisaccharide 2-1 and 
hexasaccharide 2-2. The epitopes were immobilized and evaluated by sera from 20 
patients infected by Klebsiella pneumoniae. Seventeen of the twenty sera contained 
antibodies that bound both 2-1 and 2-2, indicating the positive immune activity of our 
synthetic antigens. Negative results of the three sera (KPC2, KPC5 and KPC10) resulted 
from the immunosuppression of the patients. 
With these fast and exciting results, we were able to continue further evaluation 
of the synthesized epitopes in animal models to provide us with more detailed 
information for the development of the vaccine against KPST258. 
                                                 
* Printing of the glycan array was performed by Ms. Katrin Sellrie. Glycan array evaluation and 
data analysis was performed by Ms. Bruna M. S. Seco. 
† Figure by Bruna M. S. Seco. Sera provided by Prof. Dr. Bettina Fries, Stony Brook University, 
NY, USA. 
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2.2.5 Immunological Evaluation of Epitopes 2-1 and 2-2* 
 
Scheme 16 Conjugation of the trisaccharide 2-1 and hexasaccharide 2-2 to carrier protein CRM197 
Since the glycan arrays showed good binding results for 2-1 and 2-2, we moved 
on to further immune tests which required the glycoconjugate of our sugar to a carrier 
protein, in our case CRM197. Conjugation of the sugar epitopes 2-1 and 2-2 contained 
two steps. The first was the coupling between the oligosaccharide and p-nitrophenyl 
adipate ester (PNP) as a linker or spacer; the second was a further conjugation to the 
commercially available protein CRM197 in PBS solution with a pH at around 8. 
Each CRM197 molecule was conjugated to several epitopes and the average 
number of the epitopes attached to each CRM197 molecule is the loading number. The 
mass of unconjugated CRM197 and conjugated CRM197-2-1 or CRM197-2-2 were 
determined by matrix-assisted laser desorption/ionization-time of flight mass 
spectrometry (MALDI-ToF MS) so the loading number was calculated.  
                                                 
* Unless otherwise stated, all the immunization experiments mentioned in this chapter were 
performed by Ms. Bruna M. S. Seco. 




Figure 13 MALDI results of the Mass Spectra of CRM197, CRM197-2-1 and CRM197-2-2 
The CRM197 protein itself is not a single structure, as well as the conjugated 
glycoproteins. (Figure 13) We picked the average value and the loading numbers were 
calculated as 4.1 for CRM197-2-1 and 5.2 for CRM197-2-2. (For details see 
Experimental Section.) The conjugated glycoproteins we got were stored in PBS buffer 
at 4 °C, and was used for further immunological evaluations.  
As the immunization evaluation experiments are the work of Ms. Bruna M. S. 
Seco, the results are only briefly described in this thesis. 




Figure 14 SDS-PAGE of CRM197-2-1 and CRM197-2-2* 
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) was 
used for further confirmation of the conjugated glycoproteins CRM197-2-1 and 
CRM197-2-2. The band of these two glycoconjugates shifted to a higher molecular 
weight when compared to CRM197 alone. This result indicated the successful 
introduction of the epitopes onto the carrier protein. (Figure 14) Due to the limitation of 
available materials, we immunized rabbits with only CRM197-2-2. 
 
Figure 15 Immunization of rabbits with CRM197-2-2. a) Formulation: 1 µg of CRM197-2-2 with Al(OH)3 
as adjuvant; b) Immunization schedule: 3 doses were injected on days 0, 14 and 28. Rabbit sera 
were collected weekly; c) Concentrations of antibodies were detected by Glycan array and mean 
fluorescence intensities (MFI) were calculated.† 
Five rabbits were immunized with CRM197-2-2 (formulation: 100 µL dose, 1 µg 
of CRM197-2-1 + 125 µg of aluminum hydroxide). In a control group, three rabbits were 
injected with PBS and aluminum hydroxide as negative control. The rabbits were 
injected on days 0, 14 and 28 and blood was taken every week until day 35. From the 
                                                 
* Figure by Bruna M. S. Seco. 
† Procedure, data and Figure 15-c from Bruna M. S. Seco. 
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results shown in Figure 15, we can see that the concentration of antibodies rose after 
two doses and reached a very high level on day 35 after the third dose on day 28. This 
indicated that rabbits could be efficiently immunized by CRM197-2-2. 
 
2.3 Conclusion and Outlook 
After retro-synthetic analysis of the structure of the antigen Gal-III from the 
emerging bacterium Klebsiella pneumoniae ST 258, I designed and synthesized the two 
structures, trisaccharide 2-1 containing one repeating unit and hexasaccharide 2-2 
containing two repeating units. The repeating unit contained a 3,4-branched galactose 
and galactofuranose connected to its C3 position had never been studied before and the 
chemical synthesis of the high density branched structure in the hexasaccharide bridged 
via a galactofuranose at C1,C3 positions was never reported for any similar structures. 
After significant efforts, the structural barriers were crossed and the problem of the 
instability of many intermediates was solved, to accomplish the total syntheses of 2-1 
and 2-2. At the end of each oligosaccharide, an amino linker was connected for printing 
onto glycan arrays and for conjugation for immunization and other biological tests. 
In collaboration with Ms. Bruna M. S. Seco, we performed immunological 
evaluations of the antigens. Glycan array test showed sera from infected patients 
contained antibodies binding to both 2-1 and 2-2. Conjugation of the glycans to CRM197, 
a commonly used protein carrier for glycoconjugate vaccines, worked well to obtain 
glycoconjugates CRM197-2-1 and CRM197-2-2. Rabbits were immunized with 
CRM197-2-2 and this antigen triggered a robust immune response after initial injection 
and two boosts, indicating that the structures I synthesized are promising vaccine 
candidates against Klebsiella pneumoniae. Hopefully, development of the vaccine can 
help people fight against KPC-producing KPST258 and provide an example of a 
possible solution to other drug-resistant emerging bacteria.  
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3 Development of Vaccine Candidates against 
Streptococcus suis 3 and 18 
3.1 Introduction 
 
Figure 16 TEM of S. suis from recent isolated strains. Red arrows: fimbria-like structures.90 
Streptococcus suis (S. suis) is a Gram-positive, peanut-shaped bacterium and an 
important swine pathogen that exists in almost all pig farms throughout the world. It 
causes huge economic losses for the swine industry by causing meningitis, septicemia, 
endocarditis, deafness etc. in infected pigs. It has been reported that the bacteria can 
infect humans by direct contact with the diseased pigs or contaminated products.91,92  
Capsular polysaccharides (CPS) have been considered one of the most important 
virulence factors of S. suis93,94 and so far 35 serotypes have been determined. S. suis 
serotype 3 (SS3) is among the most problematic serotypes causing clinical swine 
disease, yet not much information has been revealed.95 During the structural 
determination by the Segura group, a rare bacterial sugar, bacillosamine, was found 
involved in the antigen, which may be responsible for its virulence.96 This rare sugar 
also exists in another serotype, S. suis serotype 18 (SS18), whose antigen had a more 
complicated structure.97 
Here, we wanted to synthesize the antigens containing the oligosaccharide 
repeating units of SS3 and SS18 in order to reveal more information about the bacteria 
as well as to provide promising candidates in the development of vaccines against them. 
 




Figure 17 Structures of antigens from S. suis serotypes 3 and 18. a) Repeating units determined by 
Segura group;97 b) Chemical synthetic antigens designed for SS3, 3-1 contains one repeating unit and 3-2 
contains two repeating units; c) Chemical synthetic antigen 3-3 designed for SS18. 
The structures of the repeating units from SS3 and SS18 determined by Segura 
group and the conjugate-ready glycans I planned to make are shown in Figure 17.97 The 
structure of SS3 is linear but contains the rare bacillosamine residue. During assembly 
of the sugar building blocks, the stereo selectivity of glycosylations and reactivity of 
monosaccharides also needs to be considered. SS18 has a more complicated structure. It 
is a branched pentasaccharide including rare sugar residues of bacillosamine and a 
galacturonic acid as the branching center with tis C4 position acetylated. 
Regioselectivity and stereoselectivity must be carefully designed especially at the 
galacturonic acid residue and the global deprotection should avoid basic conditions to 
prevent the cleavage of the acetyl group. 
As bacillosamine is a rare amino sugar found in bacteria, its properties are 
poorly studied. Most sugars exist with both L- and D- configurations naturally, just with 
different abundances. However, only D-bacillosamine has been reported so far. Since 
we had a precursor directly available in stock which could be easily converted to 
L-bacillosamine, here I also inadvertently did some work on L-bacillosamine which 
could possibly be a useful reference for future study. 
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The synthesis work has not been finished but my study has established the main 
route towards the target molecules and the final compounds are within reach. 
 
3.2 Retrosynthetic Analysis of the Chemical Syntheses of 3-1, 3-2 and 3-3 
Disaccharide 3-1 and tetrasaccharide 3-2 are from S. suis serotype 3 containing 
one repeating unit and two repeating units respectively.  
 
Scheme 17 Retrosynthetic analysis of the epitopes 3-1 and 3-2 form SS3 
Scheme 17 shows an extendable strategy to synthesize 3-1 and 3-2. Both 
protected oligosaccharides 3-4 and 3-5 before global deprotection could be synthesized 
using the disaccharide building block 3-6 and a commonly used amino linker, C-5 linker 
(3-7). Glycosylation between the two sugar building blocks 3-8 and 3-9 required β 
selectivity by a neighboring participating group. Mechanism of the participating of 2-
NHTroc group is similar as described in Scheme 5. The 2-NHAc group can also act as a 
participating group, but it would significantly decrease the reactivity of the donor and 
lead to an extremely low yield of the glycosylation reaction. Alternative protective 
groups also include TCA instead of Troc and can be used in different strategies 
according to the conditions needed.  
After the synthesis of disaccharide 3-4 and TBS deprotection at C3 position of 
the bacillosamine residue, another disaccharide could be glycosylated to obtain 
tetrasaccharide 3-5. The target molecules 3-1 and 3-2 could then be realized after 
deprotection. 




Scheme 18 Retrosynthetic analysis of the epitope 3-3 form SS18 
As the structure of 3-3 from SS18 is more complicated, I decided to divide the 
protected pentasaccharide 3-10 into three parts, 3-11, 3-12 and 3-13 which could be 
synthesized from monosaccharide building blocks and C-5 linker. All the sugar building 
blocks to form residues with 2-amino group in the final compound, 3-14, 3-15 and 3-18 
were donors for α glycosylations, so their C2 positions were all converted to azido 
groups for better α selectivity. Compounds 3-15 and 3-18 were quite similar building 
blocks and 3-18 could just be obtained from 3-15 by the installation of 4-acetate group. 
The most complicated part as shown in Scheme 18 was 3-12. As 3-17 was 
connected to 3-16 with a β glycosylation bond, I planned to use per-acetylated glucose 
to do the reaction and change all of its Ac groups into Bn groups on the disaccharide 
before the acetylation at C4 position of 3-16 residue. Oxidation at the C6 position and 
selective acetylation at the C4 position at the galacturonic acid residue could produce 
the core 3-12 disaccharide building block. 
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3.3 Results and Discussions 
3.3.1 Study of the Synthesis of the Epitopes from SS3 
 
Scheme 19 Synthesis of L-bacillosamine building block 3-8L 
Commercially available 3-19L is an L-fucose building block which could be 
converted to L-bacillosamine by the inversion of 4-OH into 4-azido group. Before 
conversion of the C4 position, the 3-hydroxyl group was first protected with TBS. 
Excess TBSCl and DMAP were used for a higher yield and 4-OH was safe to stay 
unprotected. After 3-21L was made, the two azido groups were reduced by 
hydrogenation and protected with a 2,2,2-trichloroethoxycarbonyl group (Troc) to 
obtain 3-8L for further β-glycosylation. 
 
Scheme 20 Synthesis of the glycuronic acid building block 3-9 
Another building block 3-9 was synthesized from a glucose intermediate 3-23 
that was prepared by Dr. Someswara R. Sanapala. The acetyl group at the C2 position 
was changed to benzoyl since deacetylation occurred during glycosylations with the 
bacillosamine building block. The cleavage mechanism was not clear, but the benzoyl 
group at the C2 position was stable during glycosylations. The C6 position was oxidized 
to carboxyl group and protected with a benzyl group. As glucuronic acid is a relatively 
unreactive building block for glycosylation, the 3-OBn and 6-COOBn were used instead 
of 3-OBz and 6-COOMe to enhance the reactivity for a better glycosylation yield. The 
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benzoyl group at the C2 position was kept for neighboring participating effect in future 
glycosylation to ensure β selection as a donor. 
 
 
Scheme 21 Assembly of the disaccharide 3-31 
Glycosylation of 3-8L and 3-9 gave mixed α and β disaccharide products. 
Although more β product was produced, the existence of α product was unexpected 
considering the participation of the 2-NHTroc group. Further replacement of OMP at 
the anomeric position was modified to imidate and glycosylation with C-5 linker gave 
the disaccharide 3-31.  
 
Table 2 Different conditions for TBS deprotection of 3-8L 
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Cleavage of TBS on 3-31 would allow for further coupling of another 
disaccharide to obtain tetrasaccharide. Different conditions were first tested on the 
monosaccharide model molecule 3-8L. (Table 2) Regular deprotection of TBS did not 
work well in this case as Troc groups were deprotected at the same time. As TBS is an 
acidic labile protecting group, different acids were used for its cleavage. After different 
trials, I found that 10 eq. of CSA worked excellently for the TBS deprotection and this 
condition was used on 3-31. 
 
 
Scheme 22 TBS deprotection of 3-31 
Unfortunately, the deprotection on the disaccharide 3-31 did not work as 
planned. The product was observed but the yield was quite low compared to the model 
reaction. In order to improve the yield, the trichloroacetyl group (TCA) was used 
instead of Troc to protect the amino groups. 
 
Scheme 23 Synthesis of 3-34L 
TCA protected 3-34L could be easily made from 3-22L for next steps.  
 
 
Scheme 24 Synthsis of disaccharide 3-41 
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With the new bacillosamine building block 3-34L in hand, I made 3-40 with 
similar procedure for TBS deprotection and this time the yield improved to 75% so that 
I had 3-41 ready for further coupling of another molecule of disaccharide 3-30.  
 
 
Scheme 25 A 2+2 glycosylation to get tetrasaccharide, but product not pure. 
With 3-30 and 3-41 in hand, a 2+2 glycosylation was performed to obtain 
tetrasaccharide 3-42. The mass of 3-42 could be nicely detected. However, isolation was 
quite problematic. TLC showed severe tailing of the spots with different eluent systems, 
and the product could not be purified using a normal silica gel column or even HPLC. 
Further reaction with activated zinc powder in acetic anhydride over night gave 3-43 
where the amino groups all became NHAc. But the problematic tailing was still 
observed. Based on experience of previous work, these isolation difficulties were 
assumed to be from too many amino groups. 
 
 
Scheme 26 Remodification of the L-bacillosamine to obtain 3-46L 
Remodification of the L-bacillosamine building block is shown in Scheme 26 
where the reduction of the 2-azido group was performed before the inversion of 4-OH. 
In the reduction step, mild conditions were applied to avoid the cleavage of TBS and 
SePh groups to get 3-44L. Following TCA protection on 2-amino group and inversion 
of 4-OH gave the desired structure 3-46L.  
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The assembly of the tetrasaccharide was similar as before, shown in Scheme 27. 
This time the product of the 2+2 glycosylation could be isolated but the yield was still 
very low.  
 
Scheme 27 Synthesis of tetrasaccharide 3-52 
Since the study showed a low yield of the 2+2 glycosylation, it was assumed that 
this result came from the configuration of the disaccharide with the unnatural 
L-bacillosamine. 
 
Figure 18 Different configurations will affect the glycosylation result. 
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If I change the L-bacillosamine into natural D-bacillosamine, the situation would 
probably be different. More importantly, it is also needed to synthesize the final 
compounds 3-1 and 3-2 as epitopes of vaccine candidates against SS3. 
 
Scheme 28 Synthesis for D-fucose building block 3-19 
Reactions for modification of the monosaccharide building block would be just 
the same as L- or D- configurations for the same sugar. To synthesize the 
D-bacillosamine, I made 3-19 (the D-configuration of 3-19L), starting from 
commercially available 3-53. The C6 position was first converted to 6-OTs by 
toluenesulfonation, followed by the substitution of iodine to provide 3-55. The 2-azido 
group was sensitive to strong reductive reagents, and benzeneselenol leaving group at 
the anomeric position was incompatible with nBu3SnH/AIBN conditions. In order to 
convert 3-55 into a 6-deoxy sugar, a mild reductive reagent NaCNBH3 was applied and 
3-19 was obtained in good yield. 
 
 
Figure 19 Optical rotations of 3-19L and 3-19 
The optical rotation values of 3-19L and 3-19 were almost the opposite. 
Together with the same NMR data, we concluded that these two structures were 
enantiomers. Further modification procedures on monosaccharide will be the same for 
3-19 and 3-19L, and the final compound could hopefully be obtained without much 
difficulty. 
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3.3.2 Study of the Synthesis of the Epitope from SS18 
To synthesize the epitope from SS18, I started form the most challenging part, 
3-12 where the most complicated modifications were required.  
 
 
Scheme 29 Synthesis of 3-17 
Glycosyl acetimidate 3-17 was easily made from β-D-glucose pentaacetate, 
through a selective hydrolysis at the anomeric position and the installation of the 
imidate leaving group. The acetyl group at the C2 position guaranteed the β 
glycosylation and acetyl groups could also be easily changed into other protective 
groups needed at a later stage of the synthesis route. 
 
 
Scheme 30 Synthesis of 3-16 
Scheme 30 shows the modification of building block 3-16, which was the core 
residue in the final compound of SS18. During the modification, the C6 position was 
selectively protected with bulky triisopropylsilyl group (TIPS), followed by 
isopropylidene protection at C3 and C4 positions. The unprotected 2-hydroxyl group 
would be glycosylated by 3-17 and the disaccharide building block could be further 
modified. 
 




Scheme 31 Glycosylation to get 3-60 and first modification strategy 
The glycosylation between 3-16 and 3-17 was smooth to give β–selective 
disaccharide 3-60. After the deprotection of TIPS at the C6 position, oxidation of the 
primary 6-OH mediated by (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO) and 
bis(acetoxy)iodobenzene (BIAB) gave 3-62. In order to protect all the hydroxyl groups 
on the glucose residue as well as the 6-carboxyl position with benzyl groups, I cleaved 
the acetyl groups first to get 3-63 and tried to do perbenzylation at all the unprotected 
positions all at once. Unfortunately, the desired product 3-64 was not observed, while 
cleavage of the glycosidic bond was observed by the detection of the mass of 3-65. 
 
 
Scheme 32 Second modification strategy of 3-60 
An alternative strategy was used where the acetyl groups were changed into 
benzyl groups before deprotection of TIPS. This time, the glycosidic remained intact 
during the benzylation and further modification of the C6 position did not cause any 
problem. Benzylation of the carboxyl group only required mild base such as NaHCO3 
and other places would not be affected under these conditions. After 3-64 was obtained, 
isopropylidene was cleaved and the next step was to selectively put a temporary 
protective group at the C3 position that must be orthogonal to acetyl group. This was 
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Scheme 33 Selective TBS protection of 3-70 
I first tried selective TBS protection as the C4 position is usually much less 
reactive than the C3 position. In this case, however, I did get more desired compound 
3-71 but the selectivity was not very good.  
 
 
Scheme 34 Selective acetylation of 3-70 
After literature research, I thought the selective acetylation at C4 position 
mediated by an orthoester intermediate method was worth trying.98 The orthoester is 
installed under similar conditions as the isopropylidene protection, and with TFA to 
open the 5-membered ring, I only obtained the desired product 3-74. I assume that the 
reason was that the oxygen at the C3 position was much easier to be protonated and 
after cleavage the acetyl group would stay at C4 position. Fmoc protection of 3-74 using 
pyridine could keep 4-OAc to get the desired core disaccharide 3-12. 
Successful synthesis of the most complicated disaccharide part 3-12 gave me 
confidence to prepare the target pentasaccharide 3-3 and the next step is the syntheses of 
the other two parts 3-13 and 3-11. 




Scheme 35 Synthesis of 3-7 
Synthesis of 3-13, a 2-azido galactose connected to the C-5 linker, started from 
3-53 which was also used in the SS3 part. The C4 and C6 positions were protected with 
benzylidene, followed by the installation of TBS at the C3 position. After benzylidene 
was cleaved, the C4 and C6 positions were benzylated to get 3-78. 2-Azido group was 
kept as it favored α-glycosylation. As TBS was labile in acidic conditions, it was 
changed into 3-OAc and the glycosylation of 3-18 with the linker 3-7 provided 3-13. 
The intermediate of the synthesis, 3-15 could also be used in the synthesis of the third 
part 3-11. 
With the most challenging problem of the synthesis route solved, after synthesis 
of the bacillosamine building block 3-14, the assembly of the saccharides and 
deprotection, 3-3 will be obtainable. 
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3.4 Conclusion and Outlooks 
In this chapter, I have described some initial study by chemical synthesis of the 
antigens for the development of the vaccine candidates against the important swine 
pathogen Streptococcus suis. The unique character of the serotypes I focused on, SS3 
and SS18, was the bacillosamine they contained. Bacillosamine is considered as an 
important virulence factor of the bacteria, but has been studied poorly before, especially 
for its L-configuration. My work on the L-bacillosamine provided some initial 
understanding of its structure and properties. 
I also established the synthetic route to get the final epitopes 3-1, 3-2 and 3-3 for 
the development of the vaccines against SS3 and SS18. Although the final compounds 
were not obtained due to time limitation, most of the obstacles had been overcome 
through my study.  
 
Scheme 36 3-46 and 3-80 could be made from 3-19 for syntheses of final epitopes. 
Based on the work in this chapter, future work will be the synthesis of the 
D-bacillosamine building blocks and finally target epitopes 3-1, 3-2 and 3-3 for further 






4 Experimental Section 
4.1 Reagents and General Procedures 
Commercially available reagents were used without further purification except 
otherwise indicated. All batch reactions were conducted under an N2 or Ar atmosphere. 
1H-NMR and 13C-NMR spectra were measured with an Ascend 400-MHz, Agilent 400-
MHz, Agilent 600-MHz or Ascend 700-MHz spectrometer. The proton signal of 
residual, non-deuterated solvent (δ 7.26 ppm for CHCl3; δ 4.87 ppm for Methanol; δ 
4.79 ppm for H2O) was used as an internal reference for 1H spectra. For 13C spectra, the 
chemical shifts were reported relative to the respective solvent (δ 77.16 ppm for CHCl3). 
Coupling constants were reported in Hertz (Hz). The following abbreviations are used 
to indicate the multiplicities: s, singlet; d, doublet; t, triplet; m multiplet. Infrared (IR) 
spectra were recorded as thin films on a Perkin Elmer Spectrum 100 FTIR 
spectrophotometer. Optical rotations (OR) were measured with a Schmidt & Haensch 
UniPol L 1000 at 589 nm and a concentration (c) expressed in g/100 mL. High-
resolution mass spectra (HRMS) were recorded with an Agilent 6210 ESI-ToF mass 
spectrometer. MALDI-ToF spectra were recorded on a Bruker Daltonics Autoflex 
Speed, using a 2,5-dihydroxybenzoic acid (DHB) or 2’,6’-dihydroxyacetophenone 
(DHAP) matrix. Analytical thin layer chromatography (TLC) was performed on 
Macherey-Nagel pre-coated TLC plates SIL G-25 UV254. The TLC plates were 
visualized with UV light and by staining with CAM (ceric sulfate and ammonium 
molybdate in aqueous sulfuric acid) or sugar stain (2N H2SO4 and resorcinol 
monomethyl ether (0.2%) in ethanol). Column chromatography was performed using 
silica gel 60 (230–400 mesh). Size exclusion chromatography (SEC) was performed 






4.2 Chemical Synthesis for the Epitopes from KPST258 
Ethyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranoside (2-11) 
 
1,2,3,4,6-Penta-O-acetyl-β-D-galactose (5.3 g, 13.6 mmol) was dissolved in 
anhydrous DCM (65 mL). EtSH (1.4 mL) was added and the mixture was cooled to 
0 °C (water-ice bath). BF3·OEt2 (2.8 mL, 22.5 mmol) was then added and the mixture 
was allowed to be stirred at that temperature for 5 h. TLC showed the starting material 
was fully converted and the reaction was quenched by NaHCO3(aq.) The product was 
extracted with DCM for three times and the organic layer was combined and washed 
with brine, dried with Na2SO4(s) and concentrated in vacuo. The product was further 
purified by flash chromatography to get 2-11 (4.9234 g, 92%, white solid, β:α = 5:1). 1H 
NMR (400 MHz, Chloroform-d) δ 5.42 (dd, J = 3.4, 1.1 Hz, 1H), 5.23 (t, J = 10.0 Hz, 
1H), 5.04 (dd, J = 10.0, 3.4 Hz, 1H), 4.49 (d, J = 10.0 Hz, 1H), 4.19 – 4.06 (m, 2H), 
3.93 (td, J = 6.7, 1.2 Hz, 1H), 3.19 (qd, J = 7.3, 4.8 Hz, 1H), 2.83 – 2.61 (m, 2H), 2.15 
(s, 3H), 2.06 (s, 3H), 2.04 (s, 3H), 1.98 (s, 3H), 1.39 (t, J = 7.3 Hz, 1H), 1.28 (t, J = 7.5 
Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 170.6, 170.4, 170.2, 169.7, 84.2, 77.5, 
77.4, 77.2, 76.8, 74.5, 72.0, 67.4, 67.3, 61.6, 47.1, 24.5, 21.0, 20.8, 20.8, 15.0, 8.9. Data 
compatible with literature reported.99 
 
Ethyl 1-thio-β-D-galactopyranoside (2-12) 
 
Thioglycoside 2-11 (5.2238 g) was dissolved in methanol (120 mL) and MeONa 
(0.5 M in MeOH, 3 mL) was added to the mixture. The solvent was stirred at r.t. and the 
reaction was monitored by TLC. After the starting material was disappeared, the 
reaction was quenched with Amberlite and the pH of the mixture was adjusted to 7. 




2.9620 g. Yield: 99%. 1H NMR (400 MHz, CD3OD) δ 4.32 (d, J = 9.5 Hz, 1H), 3.92 – 
3.83 (m, 1H), 3.71 (qd, J = 11.4, 6.1 Hz, 2H), 3.58 – 3.49 (m, 2H), 3.46 (dd, J = 9.2, 3.3 
Hz, 1H), 2.83 – 2.66 (m, 2H), 1.29 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CD3OD) δ 
87.4, 80.6, 76.3, 71.4, 70.5, 62.6, 49.6, 49.4, 49.2, 49.0, 48.8, 48.6, 48.4, 24.9, 15.5. 
Data compatible as reported.100 
 
Ethyl 4,6-O-benzylidene-1-thio-β-D-galactopyranoside (2-13) 
 
Thioglycoside 2-12 (2.0934g, 9.33 mmol) was put into a flask and anhydrous 
MeCN (80 mL) was added as solvent. The white solid didn't dissolve well. CSA (1.0917 
g, 4.7 mmol) and benzaldehyde dimethyl acetal (2.80 mL, 18.67 mmol) was then added. 
Shortly after that, the solid totally dissolved and after 10 min, TLC showed that the 
starting material was fully conversed. Et3N was added to quench the reaction and the 
mixture was evaporated in vacuo. After most of the solvents were gone, the mixture 
(colorless syrup) was extracted with EtOAc and washed with water (100 mL) and brine 
(100 mL). The organic layer was then evaporated and the resultant (white solid) was put 
under vacuum overnight to get 2.3930 g 2-13, 82%. 1H NMR (400 MHz, Chloroform-d) 
δ 7.56 – 7.45 (m, 2H), 7.41 – 7.33 (m, 3H), 5.54 (s, 1H), 4.35 (d, J = 10.8 Hz, 2H), 4.25 
(d, J = 3.7 Hz, 1H), 4.03 (d, J = 12.6 Hz, 1H), 3.81 (t, J = 9.3 Hz, 1H), 3.69 (td, J = 8.9, 
3.6 Hz, 1H), 3.52 (s, 1H), 3.33 (s, 1H), 2.94 – 2.70 (m, 2H), 2.70 – 2.44 (m, 2H), 1.35 (t, 
J = 7.4 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 137.7, 129.5, 128.4, 126.5, 
101.6, 85.4, 77.5, 77.4, 77.2, 76.8, 75.7, 74.0, 70.2, 69.8, 69.4, 23.6, 15.4. Data 





Ethyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio-β-D-galactopyranoside (2-14) 
 
Thioglycoside 2-13 (2.8942 g, 9.26 mmol, 1 eq.) was dissolved in anhydrous 
DMF (45 mL) and cooled to 0 °C using ice-water bath. NaH (60% in mineral oil, 1.112 
g, 27.8 mmol, 3.0 eq.) was then added to the solution and the resultant suspension was 
stirred for 15 min before BnBr (3.31 mL, 27.8 mmol, 3 eq.) was injected slowly into the 
mixture. After 10 min, the ice-water bath was removed and the mixture was allowed to 
be stirred overnight. TLC showed that the starting material was totally conversed and 
the reaction was quenched by MeOH at 0 °C. After the solvents were evaporated, the 
product was extracted with EtOAc, washed with water and brine, dried with Na2SO4(s), 
and concentrated in vacuo. The product was further purified by silica gel 
chromatography (hexane:EtOAc = 6:1) to get 2-14, 3.604 g, white solid, Yield: 79%. 1H 
NMR (400 MHz, Chloroform-d) δ 7.59 – 7.44 (m, 2H), 5.47 (s, 1H), 4.95 – 4.81 (m, 
2H), 4.80 – 4.71 (m, 2H), 4.43 (d, J = 9.6 Hz, 1H), 4.30 (dd, J = 12.3, 1.6 Hz, 1H), 4.15 
(dd, J = 3.5, 1.0 Hz, 1H), 3.96 (dd, J = 12.4, 1.8 Hz, 1H), 3.89 (t, J = 9.4 Hz, 1H), 3.59 
(dd, J = 9.2, 3.5 Hz, 1H), 3.35 (q, J = 1.5 Hz, 1H), 2.80 (ddq, J = 44.0, 12.5, 7.4 Hz, 2H), 
1.33 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 138.5, 138.4, 138.1, 
129.2, 128.5, 128.5, 128.4, 128.3, 127.9, 127.9, 127.8, 126.7, 101.6, 84.6, 81.3, 77.5, 
77.2, 77.0, 76.8, 75.8, 74.1, 71.9, 69.9, 69.6, 23.9, 15.2. Data compatible as reported.102 
 
Ethyl 2,3-di-O-benzyl-1-thio-β-D-galactopyranoside (2-15) 
 
Thioglycoside 2-14 (0.8494g, 1.724 mmol, 1 eq.) was dissolved in 15 mL DCM. 
Ethane thiol (3.73 mL, 51.7 mmol, 30 eq.) and TsOH.H2O (0.066g, 0.345 mmol, 0.2 eq.) 
was then added to the solution. The mixture was stirred at room temperature until the 




EtOAc, washed with water, NaHCO3 and brine, dried with Na2SO4(s) and concentrated 
in vacuo. 2-15 was then purified by FC to get 0.676 g white solid. Yield: 97%. 1H NMR 
(400 MHz, Chloroform-d) δ 7.42 – 7.36 (m, 2H), 7.36 – 7.25 (m, 8H), 4.88 (d, J = 10.3 
Hz, 1H), 4.75 (d, J = 10.3 Hz, 1H), 4.71 (s, 2H), 4.42 (d, J = 9.7 Hz, 1H), 4.04 (dd, J = 
3.3, 1.1 Hz, 1H), 3.94 (dd, J = 11.8, 6.6 Hz, 1H), 3.78 (dd, J = 11.8, 4.5 Hz, 1H), 3.66 (t, 
J = 9.3 Hz, 1H), 3.54 (dd, J = 9.0, 3.3 Hz, 1H), 3.47 (ddd, J = 6.3, 4.6, 1.1 Hz, 1H), 2.75 
(qq, J = 12.5, 7.4 Hz, 2H), 2.25 (s, 3H), 1.30 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, 
Chloroform-d) δ 138.3, 137.8, 128.7, 128.5, 128.5, 128.2, 128.0, 128.0, 85.3, 82.4, 78.0, 
78.0, 77.5, 77.2, 76.8, 76.0, 72.4, 67.6, 62.9, 25.0, 15.3. Data compatible as reported.85 
Ethyl 2,3-di-O-benzyl-4,6-di-O-acetyl-1-thio-β-D-galactopyranoside (2-5SEt) 
 
Thioglycoside 2-15 (0.6878 g, 1.7 mmol, 1 eq.) was dissolved in 10 mL 
anhydrous DCM and Et3N (0.71 mL, 5.1 mmol, 3 eq.), Ac2O (0.96 mL, 10.2 mmol, 6 
eq.) and DMAP (0.042 g, 0.34 mmol, 0.2 eq.) were added sequentially into the solvent. 
After the starting material was disappeared, the mixture was diluted with EtOAc, 
washed with water twice, NaHCO3 (aq.) and brine, dried with Na2SO4 (s) and 
concentrated in vacuo. 2-5SEt was further purified by silica gel chromatography to get 
0.778 g whitish syrup. Yield: 94%. 1H NMR (400 MHz, Chloroform-d) δ 7.41 – 7.36 
(m, 2H), 7.36 – 7.27 (m, 8H), 5.55 (d, J = 2.8 Hz, 1H), 4.82 (d, J = 10.2 Hz, 1H), 4.76 
(d, J = 10.8 Hz, 2H), 4.52 (d, J = 11.1 Hz, 1H), 4.48 (d, J = 8.8 Hz, 1H), 4.15 (d, J = 2.0 
Hz, 1H), 4.14 (d, J = 1.2 Hz, 1H), 3.78 (t, J = 6.4 Hz, 1H), 3.68 – 3.55 (m, 2H), 2.87 – 
2.65 (m, 2H), 2.16 (s, 3H), 2.07 (s, 3H), 1.33 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, 
d2o) δ 170.7, 170.6, 138.2, 137.7, 128.5, 128.5, 128.5, 128.3, 128.0, 128.0, 85.6, 81.0, 
77.8, 77.5, 77.2, 76.8, 76.0, 74.6, 72.2, 66.8, 62.4, 25.3, 21.1, 20.9, 15.2. Data 







Galactose (10.0 g, 55.5 mmol, 1 eq.) was dissolved in 250 mL anhydrous DMF 
before imidazole (56.7 g, 833 mmol, 15 eq.) and TBSCl (52 g, 345 mmol, 6.22 eq.) was 
added to the solution. The mixture was stirred at room temperature overnight. The next 
day it became yellow transparent solution with white ball-like solid floating inside. TLC 
showed that the starting material was totally converted. The mixture was filtrated and 
washed with MeOH to get 25.5 g (33.9 mmol) white solid 2-16. Yield: 61.1%. 1H NMR 
(400 MHz, Chloroform-d) δ 5.15 (d, J = 2.4 Hz, 1H), 4.09 (dd, J = 4.8, 2.9 Hz, 1H), 
4.00 (dd, J = 4.8, 3.4 Hz, 1H), 3.91 (t, J = 2.7 Hz, 1H), 3.74 (td, J = 6.0, 3.3 Hz, 1H), 
3.67 (dd, J = 9.8, 6.4 Hz, 1H), 3.55 (dd, J = 9.8, 5.7 Hz, 1H), 0.91 – 0.86 (m, 46H), 0.11 
– 0.03 (m, 35H). 13C NMR (101 MHz, Chloroform-d) δ 103.0, 86.0, 84.5, 79.6, 77.5, 
77.4, 77.2, 76.8, 74.2, 64.8, 26.2, 26.1, 26.1, 26.0, 25.9, 25.9, 25.8, 18.5, 18.5, 18.1, 





Compound 2-16 (9.5 g, 12.64 mmol, 1 eq.) and p-toluenesulfonic acid (48.1 g, 
253 mmol, 20 eq.) was put into a 500 mL flask and 100 mL anhydrous DCM was added 
as solvent. The mixture was stirred at r.t. and Ac2O (59.6 mL, 632 mmol, 50 eq.) was 
dropped slowly into the mixture. It became transparent after 90 min. After 72 h, the 
TLC showed that the starting material was fully conversed. The reaction was quenched 
by Et3N and extracted using DCM. After being washed with H2O (2 x 250mL), 
NaHCO3 and brine, the organic layer was dried by Na2SO4(s) and concentrated in vacuo. 
The product 2-17 was further purified by flash chromatography to get light yellow syrup 




6.9, 4.1 Hz, 1H), 5.18 (dd, J = 2.1, 0.7 Hz, 1H), 5.08 (dd, J = 5.4, 2.0 Hz, 1H), 4.39 – 
4.33 (m, 1H), 4.32 (d, J = 4.0 Hz, 1H), 4.21 (dd, J = 11.9, 6.8 Hz, 1H), 2.12 (dd, J = 5.9, 
2.2 Hz, 14H), 2.08 (d, J = 2.2 Hz, 1H), 2.05 (s, 4H), 2.04 (s, 1H). 13C NMR (101 MHz, 
Chloroform-d) δ 171.2, 170.6, 170.4, 170.1, 169.9, 169.9, 169.9, 169.8, 169.5, 169.3, 
169.1, 99.1, 93.1, 82.1, 80.6, 79.1, 77.4, 77.2, 77.0, 76.7, 76.3, 75.3, 73.4, 70.3, 69.2, 
62.6, 62.1, 60.4, 21.1, 21.0, 20.8, 20.8, 20.7, 20.7, 20.7, 20.5, 14.2. Data compatible as 
reported.103  
 
p-Tolyl 2,3,5,6-tetra-O-acetyl-1-thio-β-D-galactofuranoside (2-18) 
 
2-17 (1.9772 g, 5.07 mmol, 1 eq.) was put into a flask with a stirring bar. 
p-Toluenethiol (1.573 g, 12.66 mmol, 2.5 eq.) was added and anhydrous DCM (35 mL) 
was added as solvent. After cooled with ice-water bath and stirred for 5 min, the 
mixture was added BF3·OEt2 (0.963 mL, 7.60 mmol, 1.5 eq.) dropwise and stirred at 
0 °C until the starting material was fully conversed. The reaction was then quenched 
with Et3N, extracted with EtOAc, washed with water and brine, dried with Na2SO4(s) 
and concentrated in vacuo. The product was further purified with silica gel 
chromatography to get 2-18 as light yellow syrup. 1.048 g, 2.307 mmol, yield: 50%. 1H 
NMR (400 MHz, Chloroform-d) δ 7.41 – 7.34 (m, 2H), 7.12 (d, J = 7.9 Hz, 2H), 5.43 (d, 
J = 2.6 Hz, 1H), 5.39 (dt, J = 7.5, 4.2 Hz, 1H), 5.21 (t, J = 2.6 Hz, 1H), 5.08 (dd, J = 6.1, 
2.7 Hz, 1H), 4.47 (dd, J = 6.2, 3.8 Hz, 1H), 4.32 (dd, J = 11.8, 4.6 Hz, 1H), 4.18 (dd, J = 
11.7, 7.0 Hz, 1H), 2.34 (s, 3H), 2.12 (d, J = 0.7 Hz, 3H), 2.10 (d, J = 1.1 Hz, 6H), 2.05 
(s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 170.6, 170.1, 170.1, 169.7, 138.4, 133.1, 
129.9, 129.3, 90.8, 81.3, 79.7, 77.5, 77.4, 77.2, 76.8, 76.6, 69.2, 62.7, 60.5, 21.3, 20.9, 





p-Tolyl 1-thio-β-D-galactofuranoside (2-19) 
 
Thioglycoside 2-18 (1.0483 g, 2.307 mmol, 1 eq.) was put into a flask and 
MeOH was added as solvent. MeONa (25 mg, 0.461 mmol, 0.2 eq.) was added and the 
mixture was allowed to be stirred at r.t.. After the full conversion of the starting material, 
Amberlite was added to the mixture and the pH was adjusted to 7. After filtration and 
the evaporation of the solvent, 2-19 (0.618 g, 2.158 mmol, yield: 99%) was obtained as 
white solid. 1H NMR (400 MHz, Methanol-d4) δ 7.41 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 
7.8 Hz, 2H), 4.14 – 4.05 (m, 1H), 3.99 – 3.90 (m, 2H), 3.74 (td, J = 6.4, 2.7 Hz, 1H), 
3.62 (d, J = 6.4 Hz, 2H), 2.31 (s, 3H). 13C NMR (101 MHz, CD3OD_SPE) δ 138.9, 
133.7, 131.7, 130.6, 93.0, 82.8, 82.7, 77.5, 71.8, 64.4, 49.6, 49.4, 49.3, 49.2, 49.0, 48.8, 
48.6, 48.4, 21.1. Data compatible as reported.105 
 
p-Tolyl 2,3,5,6-tetra-O-benzoyl-1-thio-β-D-galactofuranoside (2-6STol) 
 
Thioglycoside 2-19 (0.0710 g, 0.248 mmol, 1 eq.) was dissolved in pyridine (2 
mL), BzCl (l, 0.138 mL, 1.190 mmol, 4.8 eq.) was added dropwise into the solvent and 
the resulted mixture was stirred at r.t. until the TLC showed a full conversion of the 
starting material. The mixture was concentrated, extracted with EtOAc, dried with 
Na2SO4 (s) and concentrated in vacuo. 2-6STol was then purified by FC to get colorless 
syrup 0.164 g, 0.234 mmol. Yield: 94%. 1H NMR (400 MHz, Chloroform-d) δ 8.07 (ddt, 
J = 8.4, 7.1, 1.6 Hz, 4H), 8.00 – 7.93 (m, 2H), 7.91 – 7.84 (m, 2H), 7.59 (ddt, J = 8.8, 
7.1, 1.3 Hz, 1H), 7.52 (dddd, J = 8.6, 5.1, 2.4, 1.4 Hz, 3H), 7.48 – 7.41 (m, 4H), 7.41 – 
7.27 (m, 6H), 7.11 – 7.04 (m, 2H), 6.14 – 6.06 (m, 1H), 5.77 (dt, J = 1.6, 0.7 Hz, 1H), 
5.69 (ddd, J = 5.1, 1.6, 0.9 Hz, 1H), 5.65 (t, J = 1.6 Hz, 1H), 4.94 (ddd, J = 4.9, 3.8, 0.7 
Hz, 1H), 4.73 (qd, J = 11.8, 5.8 Hz, 2H), 2.31 (s, 3H). 13C NMR (101 MHz, 




130.2, 130.1, 130.0, 129.9, 129.6, 129.5, 129.3, 129.0, 128.9, 128.7, 128.6, 128.5, 128.5, 
91.7, 82.4, 81.5, 78.0, 77.5, 77.4, 77.2, 76.8, 70.4, 63.5, 60.6, 21.3, 21.2, 14.3. Data 




Fluorinated linker 2-8 was prepared following reported procedure and data were 
also matched.84 Dimethyl 2,2-difluoromalonate (3.123 g, 18.58 mmol, 1.3 eq.) was 
dissolved in MeOH (100 mL) and the mixture was cooled to 0 °C using water-ice bath. 
A solution of BnNH2 in MeOH (10 mL) was then added dropwise into the mixture. The 
ice-water bath was removed and the reaction was put at r.t. overnight. The mixture was 
filtrated, concentrated in vacuo, and purified by FC to get colorless syrup 2-20, 1.808 g, 
7.44 mmol. Yield: 52.1%. 2-20 (1.172 g, 4.82 mmol, 1.0 eq.) was dissolved in 25 mL 
MeOH. The mixture was cooled to 0 °C and NaBH4 (0.911 g, 24.09 mmol, 5 eq.) was 
added. After 2 h, the reaction was quenched with water and the mixture was 
concentrated and extracted with EtOAc. The organic layer was washed with water and 
brine, dried with Na2SO4(s), filtrated and evaporated to get a crude product of 2-21. The 
crude product was used at the next step without further purification. Crude 2-21 
(0.854 g, 3.97 mmol, 1.0 eq.) was dissolved in THF (20.0 mL) and borane 
dimethylsulfide (2 M in THF, 5.95 mL, 11.9 mmol) was added to the solution. The 
mixture was refluxed for 3 h, quenched with MeOH and cooled to r.t.. After being 
stirred overnight, the mixture was evaporated to get 0.954 g crude 2-22 as colorless oil. 
To a stirred solution of 2-22 from last step in EtOAc (10 mL) was added NaHCO3 (aq., 
sat., 10 mL) and CbzCl (0.744 mL, 5.21 mmol) at ambient temperature. After 90 min, 
TLC showed the full conversion of the starting material. The mixture was transferred to 
a separator and the the inorganic layer was extracted with EtOAc (20 mL x 3). The 
organic fractions were combined together, dried with Na2SO4(s) and concentrated in 




4.01 mmol). Yield: 85%. 1H NMR (400 MHz, Chloroform-d) δ 7.42 – 7.27 (m, 8H), 
7.22 – 7.10 (m, 2H), 5.23 (s, 2H), 4.60 (s, 2H), 3.66 (td, J = 12.0, 10.3 Hz, 4H). 13C 
NMR (101 MHz, Chloroform-d) δ 158.3, 136.2, 135.7, 129.0, 128.8, 128.6, 128.2, 
128.0, 127.7, 77.5, 77.2, 76.8, 68.7, 61.4, 51.8, 47.0. 
 
Phenyl 3,4-O-isopropylidene-1-thio-β-D-galactopyranoside (2-23) 
 
Thioglycoside 2-7 was synthesized and provided by Mr. Shuo Zhang from the 
Seeberger group via a known procedure.105 2-7 (2.027 g, 7.5 mmol, 1.0 eq.) was 
dissolved in 2,2-dimethoxypropane (40 mL). TsOH·H2O (152 mg, 0.8 mmol, 0.1 eq.) 
was added to the solution and the mixture was stirred at r.t. until TLC showed a full 
conversion of the starting material. The reaction was quenched with TEA and the 
solvent was evaporated in vacuo. The crude product was extracted with EtOAc 
(100 mL), washed with water (100 mL) and brine (100 mL), dried with Na2SO4(s), 
concentrated and further purified with FC to get 2-23 (1.488 g, 4.77 mmol, yield: 64%). 
Data compatible as reported.106 
 
Phenyl 3,4-O-isopropylidene-2,6-di-O-benzyl-1-thio-β-D-galactopyranoside (2-24) 
 
Thioglycoside 2-23 (3.415 g, 10.9 mmol, 1.0 eq.) was dissolved in anhydrous 
DMF (50 mL). The mixture was cooled to 0 °C and NaH (60% in mineral oil, 1313 mg, 
32.8 mmol, 3.0 eq.) was added to the mixture. BnBr (4.0 mL, 32.8 mmol, 3.0 eq.) was 
added dropwise, the cooling bath was removed and the mixture was stirred overnight. 
TLC showed a full conversion of the starting material and the reaction was quenched 
with MeOH. Most of the solvent was removed by evaporation in vacuo and the residue 




concentrated and further purified by FC to obtain 2-24 (5.288 g, 10.7 mmol, yield: 98%). 
2-24 was used in the next step directly. 
 
Phenyl 2,6-di-O-benzyl-1-thio-β-D-galactopyranoside (2-25) 
 
Thioglycoside 2-24 (2.160 g, 5.6 mmol) was dissolved in a mixed solvent of 
AcOH/H2O (40 mL/10 mL). The mixture was stirred at 60 °C until the starting material 
was fully converted. The temperature was cooled to r.t. and the product was extracted 
with EtOAc (200 mL), washed with water (200 mLx2), NaHCO3 (sat. aq., 200 mL) and 
brine (200 mL), dried with Na2SO4(s), concentrated and purified by FC to get 2-25 
(1.806 g, 3.99 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.49 – 7.42 (m, 2H), 7.33 – 
7.14 (m, 13H), 4.73 (d, J = 10.3 Hz, 1H), 4.65 (d, J = 10.4 Hz, 1H), 4.60 (d, J = 3.0 Hz, 
2H), 4.56 (d, J = 9.7 Hz, 1H), 3.96 (d, J = 3.2 Hz, 1H), 3.85 (dd, J = 11.7, 6.6 Hz, 1H), 
3.76 – 3.63 (m, 2H), 3.48 (dd, J = 8.9, 3.1 Hz, 1H), 3.38 (dd, J = 6.6, 4.4 Hz, 1H), 2.61 
(s, 2H). 13C NMR (101 MHz, Chloroform-d) δ 138.1, 137.6, 133.8, 131.7, 129.1, 128.6, 
128.5, 128.3, 128.1, 128.0, 127.9, 127.5, 87.6, 82.4, 78.1, 77.5, 77.2, 77.0, 76.8, 75.8, 





Thioglycoside 2-25 (1.806 g, 3.99 mmol, 1.0 eq.) was put into a flask and Ag2O 
(1.017 g, 4.38 mmol, 1.1 eq.) and Me2SnCl2 (44 mg, 0.199 mmol, 0.05 eq.) were added. 
After MeCN (anhydrous, 35 mL) was added as solvent, FmocCl (1.576 g, 6.09 mmol, 
1.5 eq.) was added to the suspension and the mixture was allowed to be stirred at r.t. 




filtrated with Celite and concentrated in vacuo. Thioglycoside 2-7SPh was further 
purified with FC to get white solid 1.906 g (2.82 mmol), yield: 71%.1H NMR (400 MHz, 
Chloroform-d) δ 7.77 (d, J = 7.5 Hz, 2H), 7.65 – 7.56 (m, 4H), 7.44 – 7.22 (m, 18H), 
4.86 (d, J = 10.5 Hz, 1H), 4.80 (dd, J = 9.5, 3.0 Hz, 1H), 4.70 (d, J = 9.7 Hz, 1H), 4.66 
(d, J = 10.5 Hz, 1H), 4.64 – 4.54 (m, 2H), 4.45 (dd, J = 10.5, 7.2 Hz, 1H), 4.37 (dd, J = 
10.4, 7.4 Hz, 1H), 4.29 (d, J = 3.0 Hz, 1H), 4.23 (t, J = 7.2 Hz, 1H), 3.93 (t, J = 9.6 Hz, 
1H), 3.82 (qd, J = 10.2, 4.9 Hz, 2H), 3.69 (t, J = 4.9 Hz, 1H), 2.81 (s, 1H). 13C NMR 
(101 MHz, Chloroform-d) δ 154.5, 143.4, 143.2, 141.4, 137.9, 137.6, 133.3, 132.3, 
129.1, 128.7, 128.5, 128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 127.8, 127.3, 127.3, 125.3, 
125.2, 120.2, 120.2, 87.8, 80.9, 77.5, 77.4, 77.2, 76.8, 76.5, 75.8, 75.2, 74.0, 70.3, 70.0, 






The donor 2-7SPh (68 mg, 100 µmol, 1 eq.) and the acceptor 2-8 (40 mg, 
120 µmol, 1.2 eq.) were coevaporated with toluene and put under high vacuum to 
remove trace water. After being dissolved in a mixed solvent (1,4-Dioxane:Toluene = 
4:1), 4 Å AWMS was added and the system was cooled to 0 °C. NIS (34 mg, 150 µmol, 
1.5 eq.) and TfOH (1 μL, 10 µmol, 0.1 eq.) was added and the temperature was raised to 
r.t.. The reaction was put overnight but some starting material was still left. The reaction 
was quenched with NaHCO3 (sat. aq.), extracted with EtOAc, washed with water and 
brine, dried with Na2SO4(s) and concentrated in vacuo. The product was further purified 
with FC to get 2-26 as white foam. 76 mg, 84 µmol, crude yield: 85%. Clean spectra 









Acceptor 2-26 (0.115 g, 0.128 mmol, 1.0 eq.) and donor 2-5SEt (0.075 g, 0.154 
mmol, 1.2 eq.) were coevaporated with toluene and put under vacuum overnight to 
remove the trace water in them. After being dissolved in a mixed solvent of 
Dioxane:Toluene=4:1 (1.0 mL : 0.25 mL) and 4 Å MS were added, the mixture was 
cooled to -40 °C using acetone-dry ice bath. NIS (0.043 g, 0.192 mmol, 1.5 eq.) and 
TfOH (1.7 μL, 0.019 mmol, 0.15 eq.) were then added sequentially to the mixture and 
the reaction was performed at that temperature until the TLC showed a full conversion 
of 2-26. The reaction was quenched with Na2S2O3(aq., 10%), extracted with EtOAc, 
washed with water and brine, dried with Na2SO4(s) and concentrated in vacuo. The 
crude product was further purified with FC to get 2-27. 0.117 g, 0.089 mmol, crude 






The starting material 2-27 (0.0704 g, 0.053 mmol, 1.0 eq.) was dissolved in 
DCM (1.0 mL) and Et3N (0.5 mL) was added. The solvent was stirred at ambient 
temperature overnight. TLC showed a full conversion of the starting material. The 




for this step > 98%, yield for 3 steps: 50%. 1H NMR (400 MHz, Chloroform-d) δ 7.43 – 
7.09 (m, 36H), 5.59 (dd, J = 3.3, 1.4 Hz, 1H), 5.18 (s, 2H), 4.99 (t, J = 25.2 Hz, 2H), 
4.85 (d, J = 11.7 Hz, 1H), 4.78 (d, J = 10.8 Hz, 1H), 4.70 (d, J = 17.0 Hz, 2H), 4.66 – 
4.59 (m, 4H), 4.53 (d, J = 10.8 Hz, 1H), 4.48 (s, 1H), 4.27 (d, J = 11.7 Hz, 2H), 4.20 – 
4.13 (m, 1H), 4.11 – 3.97 (m, 3H), 3.94 (dd, J = 10.2, 3.3 Hz, 2H), 3.88 (s, 1H), 3.83 
(dd, J = 10.1, 3.5 Hz, 3H), 3.79 – 3.72 (m, 2H), 3.72 – 3.44 (m, 4H), 2.85 – 2.51 (m, 
1H), 2.14 (s, 3H), 2.08 (s, 3H), 1.36 (s, 2H), 1.31 (s, 4H), 1.28 (s, 12H). 13C NMR (101 
MHz, Chloroform-d) δ 170.70, 170.38, 138.35, 137.94, 128.67, 128.52, 128.45, 128.37, 
128.13, 128.05, 127.97, 127.72, 127.57, 127.31, 124.48, 100.26, 97.28, 77.36, 77.04, 
76.72, 76.15, 75.42, 74.33, 72.85, 71.82, 69.65, 68.47, 68.12, 67.86, 67.54, 67.25, 62.46, 
51.22, 31.95, 31.46, 30.20, 29.73, 29.40, 22.73, 20.92, 20.89, 14.17, 1.05. HRMS (Q-
ToF): calculated for C62H67F2NO15Na+ [M+Na]+ 1126.4371, found 1126.4342 m/z. 
[α]D
25 = 60.48̊. IR/cm-1: 2927.19, 1745.22, 1707.37, 1497.87, 1455.42, 1372.50, 1231.18, 







The donor 2-6STol (7.9 mg, 11 μmol, 1.2 eq.) and the acceptor 2-28 (10.3 mg, 
9.33 μmol, 1.0 eq.) were dissolved in DCM and the solution was cooled to -30 °C. After 
5 min, NIS (3.2 mg, 14 μmol, 1.5 eq.) and TfOH (0.1 μL, 0.933 μmol, 0.1 eq.) were 
added sequentially to the mixture and the solution was allowed to be stirred at low 
temperature for 3 h. (-30 °C ~ -10 °C) Most of the starting material were shown reacted 




extraction and wash with water and brine, the mixture was dried with Na2SO4(s), 
concentrated in vacuo and further purified with FC to get white solid like syrup 2-3. 
29.5 mg, 0.018 mmol, yield: 69%. 1H NMR (400 MHz, Chloroform-d) δ 8.04 (d, J = 7.7 
Hz, 4H), 8.00 – 7.93 (m, 2H), 7.78 (d, J = 7.8 Hz, 2H), 7.57 – 7.48 (m, 3H), 7.51 – 7.42 
(m, 3H), 7.41 (t, J = 7.7 Hz, 3H), 7.38 – 7.00 (m, 38H), 6.08 (dt, J = 7.2, 3.7 Hz, 1H), 
5.82 (d, J = 10.2 Hz, 1H), 5.66 (s, 1H), 5.64 – 5.56 (m, 2H), 5.15 (s, 2H), 5.03 (d, J = 
3.2 Hz, 1H), 4.94 (d, J = 36.6 Hz, 1H), 4.76 – 4.40 (m, 11H), 4.36 – 4.21 (m, 4H), 4.24 
– 4.06 (m, 2H), 4.04 – 3.87 (m, 4H), 3.78 (dd, J = 25.2, 12.1 Hz, 2H), 3.73 – 3.46 (m, 
5H), 2.14 (s, 3H), 2.01 (s, 3H), 0.87 (dt, J = 12.9, 7.1 Hz, 1H). 13C NMR (101 MHz, 
Chloroform-d) δ 170.45, 170.32, 166.11, 165.70, 165.64, 165.07, 138.38, 138.07, 
136.98, 133.39, 133.27, 133.13, 130.13, 129.97, 129.79, 129.74, 129.54, 129.40, 128.89, 
128.57, 128.49, 128.47, 128.40, 128.35, 128.33, 128.29, 128.06, 128.01, 127.96, 127.85, 
127.68, 127.52, 127.35, 107.08, 99.84, 97.40, 81.66, 79.31, 78.06, 77.36, 77.04, 76.72, 
75.89, 74.10, 73.44, 72.95, 71.93, 70.22, 67.78, 67.24, 67.11, 63.72, 61.38, 30.99, 29.73, 
21.08, 20.77, 1.05. HRMS (Q-ToF): calculated for C96H93F2NO24Na+ [M+Na]+ 
1704.5948, found 1704.5884 m/z. [α]D
25 = 50.03̊. IR/cm-1: 3022.25, 1711.59, 1419.71, 





Ammonia(g) was liquefied at -78 °C (dry ice-acetone bath) to get ~20 mL NH3(l) 
in a 50 mL three-neck flask with a stirring bar in it. 2-3 (8.5 mg, 5.05 μmol, 1.0 eq.) in a 
5 mL flask was dissolved in 0.5 mL THF and a drop of tBuOH was added as the 
initiator. The solvent of 2-3 was transferred into the NH3(l) and the small flask was 
washed and transferred again with 0.3 mL THF. A thin piece of Na(s) was cut off and 




Na(s) was added and it was stirred at -78 °C for 30 min. Then MeOH (1 mL) was added 
to the mixture dropwise and the solution turned transparent immediately. The mixture 
was slowly warmed to r.t. and stirred overnight. The mixture was then evaporated, 
purified with size-exclusion column and HPLC semi-preparation and lyophilized to get 
2-1 (0.77 mg) as white solid. Yield: 27%. 1H NMR (700 MHz, Deuterium Oxide) δ 5.24 
(d, J = 2.8 Hz, 1H), 5.12 (d, J = 3.8 Hz, 1H), 5.08 (d, J = 3.7 Hz, 1H), 4.27 – 4.20 (m, 
3H), 4.18 – 4.08 (m, 4H), 4.08 – 3.96 (m, 4H), 3.96 – 3.89 (m, 2H), 3.89 – 3.82 (m, 3H), 
3.82 – 3.75 (m, 2H), 3.72 (dd, J = 11.6, 4.7 Hz, 1H), 3.70 – 3.68 (m, 1H), 3.63 (t, J = 
15.4 Hz, 2H). 13C NMR (176 MHz, D2O) δ 109.0, 100.2, 99.1, 82.1, 80.9, 78.2, 76.5, 
76.1, 72.1, 70.9, 70.5, 69.1, 68.9, 67.7, 66.6, 62.7, 60.6, 60.3, 41.5. HRMS (Q-ToF) 
C21H37F2NO16Na+ [M+Na]+ calculated 620.1973, found 620.1978 m/z.  
 
p-Tolyl 5,6-O-isopropylidene-1-thio-β-D-galactofuranoside (2-31) 
 
Thioglycoside 2-19 (669 mg, 2.34 mmol, 1 eq.) was put into a flask and 
anhydrous DCM (10 mL) was added as solvent. 2,2-DMP (0.4 mL, 3.27 mmol, 1.4 eq.) 
was added. After 15 min, CSA (54 mg, 0.23 mmol, 0.1 eq.) was added and the mixture 
was allowed to be stirred at ambient temperature for 2 hours. After the full conversion 
of the starting material, TEA (2 mL) was added to quench the reaction. After 
evaporation and chromatography, 2-31 (694 mg, 2.13 mmol, yield: 91%) was obtained 
as colorless syrup. 1H NMR (400 MHz, Chloroform-d) δ 7.41 – 7.35 (m, 2H), 7.17 – 
7.11 (m, 2H), 5.47 (s, 1H), 4.37 (ddd, J = 8.2, 6.7, 1.7 Hz, 1H), 4.22 (dd, J = 4.0, 2.2 Hz, 
2H), 4.16 (t, J = 1.3 Hz, 1H), 4.11 (dd, J = 10.0, 6.9 Hz, 1H), 4.07 (d, J = 6.8 Hz, 1H), 
3.99 (t, J = 8.1 Hz, 1H), 2.34 (s, 3H), 1.39 (d, J = 3.0 Hz, 6H). 13C NMR (101 MHz, 
Chloroform-d) δ 138.2, 132.8, 130.1, 129.4, 110.3, 93.8, 85.1, 81.0, 79.7, 77.5, 77.4, 






p-Tolyl 2-O-benzoyl-5,6-O-isopropylidene-1-thio-β-D-galactofuranoside (2-32) 
 
Thioglycoside 2-31 (639 mg, 1.96 mmol, 1.0 eq.) was dissolved in DCM (10 mL) 
and the temperature was cooled to 0 °C with ice-water bath. Pyridine (0.50 mL, 3.91 
mmol, 2.0 eq.) and BzCl (0.25 mL, 2.15 mmol, 1.1 eq.) were added sequentially and the 
mixture was allowed to be stirred at that temperature for 1 h. The mixture was washed 
with H2O, 1 M HCl(aq.), NaHCO3(aq.) and brine, dried with Na2SO4(s), concentrated 
and purified by FC to get 2-32 (Rf = 0.4 on TLC with a gradient of 30% EtOAc in Hex), 
369 mg, 0.86 mmol, yield: 44%. 1H NMR (400 MHz, Chloroform-d) δ 8.09 – 7.94 (m, 
2H), 7.67 – 7.56 (m, 1H), 7.52 – 7.40 (m, 4H), 7.20 – 7.07 (m, 2H), 5.64 (d, J = 3.8 Hz, 
1H), 5.07 (t, J = 3.7 Hz, 1H), 4.33 (td, J = 6.7, 4.6 Hz, 1H), 4.22 (qd, J = 7.3, 4.2 Hz, 
2H), 4.08 (dd, J = 8.4, 6.6 Hz, 1H), 4.00 (dd, J = 8.5, 6.8 Hz, 1H), 2.34 (s, 3H), 1.43 (s, 





Thioglycoside 2-32 (369 mg, 0.857 mmol, 1.0 eq.) was dissolved in anhydrous 
DMF (8.0 mL). Imidazole (117 mg, 1.72 mmol, 2.0 eq.) was added to the solution and 
the mixture was cooled to 0 °C (ice-water bath). TBSCl (194 mg, 1.29 mmol, 1.5 eq.) 
was added, the cooling bath was removed and the resultant mixture was stirred 
overnight. The reaction was quenched by the addition of MeOH and the mixture was 
evaporated to remove most of the DMF. After being extracted with EtOAc, washed with 




purified with FC to get 2-33 (304 mg, 0.556 mg, yield: 66%). 1H NMR (400 MHz, 
Chloroform-d) δ 8.17 – 7.94 (m, 2H), 7.66 – 7.55 (m, 1H), 7.52 – 7.38 (m, 4H), 7.10 (d, 
J = 7.8 Hz, 2H), 5.49 (d, J = 2.7 Hz, 1H), 5.37 (t, J = 2.9 Hz, 1H), 4.39 – 4.26 (m, 2H), 
4.22 (dd, J = 6.0, 4.5 Hz, 1H), 4.06 (dd, J = 8.1, 6.6 Hz, 1H), 3.93 (t, J = 7.7 Hz, 1H), 
2.31 (s, 3H), 1.43 (s, 3H), 1.39 (s, 3H), 0.90 (s, 9H), 0.09 (d, J = 3.0 Hz, 6H). 13C NMR 
(101 MHz, Chloroform-d) δ 165.5, 137.8, 133.6, 132.7, 130.8, 130.0, 129.8, 129.4, 
128.6, 109.8, 91.2, 84.3, 83.1, 77.5, 77.2, 76.8, 74.8, 65.7, 32.1, 29.9, 26.5, 25.8, 25.7, 
22.9, 21.3, 18.0, 14.3, -4.4, -4.9. HRMS (Q-ToF): calculated for C29H40NaO6SSi+ 





Thioglycoside 2-33 (251 mg, 0.46 mmol, 1.0 eq.) was dissolved in a mixed 
solvent of AcOH and H2O (5 mL, v/v = 4/1) and the mixture was stirred at 40 °C until 
2-33 was fully converted. The time should be controlled to prevent TBS from cleavage. 
The mixture was then extracted with EtOAc, washed with H2O, NaHCO3(aq.) and brine, 
dried with Na2SO4(s), concentrated in vacuo and used for next step without further 
purification. The crude product was dissolved in pyridine (5 mL) and BzCl (0.16 mL, 
0.69 mmol, 3.0 eq.) was added at 0 °C. After stirring for 1 h, the reaction was quenched 
with EtOAc, washed with H2O, HCl(aq., 1 M), NaHCO3(aq.) and brine, dried with 
Na2SO4(s), concentrated and purified by FC to get colorless syrup 2-6MSTol (397 mg, 
0.417 mmol), yield: 90% for two steps. 1H NMR (400 MHz, Chloroform-d) δ 8.14 – 
8.01 (m, 2H), 8.01 – 7.94 (m, 2H), 7.94 – 7.84 (m, 2H), 7.64 – 7.48 (m, 3H), 7.45 – 7.29 
(m, 8H), 7.05 (d, J = 7.9 Hz, 2H), 5.86 (ddd, J = 7.8, 4.3, 3.3 Hz, 1H), 5.63 – 5.51 (m, 
1H), 5.37 – 5.24 (m, 1H), 4.77 – 4.56 (m, 3H), 4.43 (ddd, J = 5.9, 2.3, 0.9 Hz, 1H), 2.30 
(s, 3H), 0.90 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 
166.2, 166.0, 165.6, 138.0, 133.5, 133.5, 133.3, 133.0, 130.3, 130.0, 129.9, 129.9, 129.8, 




63.8, 32.1, 29.9, 29.5, 25.7, 22.9, 21.3, 17.9, 14.3, -4.6, -5.0. HRMS (Q-ToF) 







The acceptor 2-28 (40 mg, 36 μmol, 1.0 eq.) and the donor 2-6MSTol (38 mg, 
54 μmol, 1.5 eq.) were coevaporated with toluene and put under high vacuum to remove 
the trace water. After being dissolved in DCM, dried with 4 Å MS and cooled to -30 °C, 
the mixture was added NIS (16 mg, 72 μmol, 2.0 eq.) and TfOH (1.0 μL, 4 μmol, 0.2 
eq.) and stirred for 30 min. The reaction was quenched with Na2S2O3(aq., sat.). After 
filtration, extraction and wash with water and brine, the mixture was dried with 
Na2SO4(s), concentrated in vacuo and further purified with FC to get 2-35, 50 mg, 
30 μmol, yield: 82%. 1H NMR (400 MHz, Chloroform-d) δ 8.09 (d, J = 7.6 Hz, 2H), 
8.00 – 7.94 (m, 2H), 7.83 (d, J = 7.7 Hz, 2H), 7.64 – 7.45 (m, 3H), 7.45 – 7.14 (m, 33H), 
7.10 (d, J = 5.6 Hz, 5H), 5.78 (dt, J = 6.3, 3.2 Hz, 1H), 5.61 (dd, J = 3.4, 1.4 Hz, 1H), 
5.56 (d, J = 10.3 Hz, 1H), 5.46 (d, J = 3.9 Hz, 1H), 5.15 (d, J = 2.6 Hz, 2H), 5.10 (d, J = 
3.3 Hz, 1H), 4.98 – 4.83 (m, 1H), 4.77 (dd, J = 11.3, 5.0 Hz, 2H), 4.72 – 4.42 (m, 10H), 
4.38 (dp, J = 9.1, 5.3 Hz, 2H), 4.24 – 4.18 (m, 2H), 4.18 – 4.07 (m, 2H), 4.02 – 3.46 (m, 
11H), 2.13 (s, 3H), 2.10 (s, 3H), 0.85 (s, 9H). 13C NMR (101 MHz, Chloroform-d) δ 
170.6, 170.5, 166.1, 166.0, 165.1, 156.8, 138.7, 138.5, 138.3, 138.2, 137.1, 136.5, 136.3, 
133.5, 133.4, 133.2, 130.0, 129.8, 129.8, 129.7, 129.6, 129.3, 128.6, 128.6, 128.5, 128.5, 
128.4, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 121.6, 
114.2, 107.7, 99.9, 97.8, 84.2, 82.3, 82.2, 79.6, 77.5, 77.2, 76.8, 76.5, 76.3, 75.6, 74.8, 




51.3, 51.1, 47.8, 46.9, 34.0, 32.1, 31.6, 30.3, 29.8, 29.8, 29.8, 29.6, 29.5, 29.3, 29.1, 
25.8, 22.8, 21.2, 21.1, 21.0, 18.0, 14.3, 14.3, 13.9, -4.7, -5.3. HRMS (Q-ToF): 






The trisaccharide 2-35 (13 mg, 7.7 μmol, 1.0 eq.) was dissolved in 0.5 mL THF. 
AcOH (5 μ, 77 μmol, 10 eq.) and TBAF (1 M in THF, 77 μL, 77 μmol, 10 eq.) were 
added to the solution and the mixture was allowed to be stirred at ambient temperature 
until TLC showed a full conversion of the starting material. The resultant was diluted 
with, EtOAc (20 mL), washed with NaHCO3 (sat. aq.) and brine, dried with Na2SO4(s), 
concentrated in vacuo and purified with FC (30% EtOAc in Hexane) to get 12 mg white 
syrup 2-10, 7.6 μmol, yield: 98%. 1H NMR (600 MHz, Chloroform-d) δ 8.02 (d, J = 7.6 
Hz, 2H), 7.98 – 7.93 (m, 2H), 7.88 (d, J = 7.7 Hz, 2H), 7.54 (t, J = 7.6 Hz, 1H), 7.48 (td, 
J = 7.7, 3.5 Hz, 2H), 7.39 – 7.26 (m, 21H), 7.26 – 7.06 (m, 15H), 5.81 (dt, J = 8.4, 4.5 
Hz, 1H), 5.68 (d, J = 22.5 Hz, 1H), 5.60 (dd, J = 3.4, 1.5 Hz, 1H), 5.24 (d, J = 2.3 Hz, 
1H), 5.15 (s, 2H), 5.02 – 4.88 (m, 3H), 4.77 (dd, J = 21.1, 11.2 Hz, 2H), 4.71 (dd, J = 
11.9, 4.1 Hz, 1H), 4.69 – 4.61 (m, 4H), 4.58 (d, J = 11.5 Hz, 1H), 4.53 (d, J = 11.6 Hz, 
1H), 4.51 – 4.46 (m, 2H), 4.44 (t, J = 7.0 Hz, 1H), 4.28 – 4.22 (m, 3H), 4.14 (dt, J = 
20.9, 7.6 Hz, 3H), 4.07 (t, J = 6.7 Hz, 1H), 3.95 (dd, J = 10.2, 3.5 Hz, 3H), 3.88 – 3.81 
(m, 2H), 3.78 (dd, J = 10.2, 3.3 Hz, 2H), 3.74 – 3.58 (m, 4H), 3.55 (t, J = 8.8 Hz, 1H), 
2.11 (s, 3H), 2.10 (s, 3H), 0.94 (t, J = 7.4 Hz, 1H), 0.91 – 0.82 (m, 5H). 13C NMR (151 
MHz, Chloroform-d) δ 171.4, 170.8, 170.5, 166.3, 166.2, 166.0, 156.8, 139.4, 138.5, 
138.5, 138.2, 137.1, 133.6, 133.4, 133.2, 130.0, 130.0, 129.9, 129.8, 129.7, 129.0, 128.7, 




127.6, 127.4, 124.6, 114.2, 107.2, 100.8, 97.4, 84.7, 83.5, 80.4, 77.4, 77.2, 76.9, 76.2, 
76.1, 75.9, 74.6, 74.4, 72.9, 72.8, 72.6, 72.0, 70.7, 70.5, 69.1, 67.9, 67.6, 67.4, 64.5, 
63.5, 61.8, 51.3, 37.3, 34.0, 32.1, 31.6, 30.8, 30.3, 29.8, 29.8, 29.8, 29.7, 29.5, 29.4, 
29.3, 29.1, 22.8, 21.2, 21.1, 21.0, 19.3, 14.3, 13.9. HRMS (Q-ToF): calculated for 




Thioglycoside 2-5SEt (103 mg, 211 μmol, 1.0 eq.) was dissolved in a mixture of 
acetone (5 mL) and water (0.5 mL), the solvent was cooled to 0 °C (ice-water bath) and 
TCCA (59 mg, 253 μmol, 1.2 eq.) was added. Ice-water bath was removed and the 
mixture was stirred at r.t. until TLC showed a full conversion of the starting material. 
The mixture was evaporated in vacuo to remove the acetone, extracted with EtOAc, 
washed with NaHCO3(sat. aq.) and brine, dried with Na2SO4(s), concentrated and 
further purified by FC (25% to 30% EtOAc in Hexane) to get 85 mg colorless syrup 
2-5OH (α:β = 5/3, 191 μmol), yield: 91%. 1H NMR (400 MHz, Chloroform-d) δ 7.39 – 
7.27 (m, 16H), 5.57 (dd, J = 3.5, 1.4 Hz, 1H), 5.50 (dd, J = 3.1, 1.2 Hz, 1H), 5.27 (d, J = 
3.6 Hz, 1H), 4.86 (dd, J = 11.3, 7.7 Hz, 2H), 4.82 – 4.73 (m, 2H), 4.72 – 4.64 (m, 2H), 
4.53 (dd, J = 11.2, 8.3 Hz, 2H), 4.36 (ddd, J = 7.1, 5.7, 1.4 Hz, 1H), 4.22 – 4.02 (m, 4H), 
3.95 (dd, J = 9.8, 3.4 Hz, 1H), 3.83 – 3.75 (m, 2H), 3.60 – 3.55 (m, 1H), 3.13 (s, 1H), 
2.15 (s, 2H), 2.13 (s, 3H), 2.08 (s, 2H), 2.07 (s, 3H). 13C NMR (101 MHz, Chloroform-d) 
δ 170.7, 170.4, 170.4, 138.3, 138.0, 137.8, 137.6, 128.5, 128.4, 128.4, 128.1, 128.1, 
128.1, 128.0, 128.0, 127.9, 127.8, 97.4, 92.0, 79.7, 79.1, 77.4, 77.3, 77.1, 76.8, 75.6, 
75.5, 75.4, 73.9, 72.2, 72.0, 71.0, 67.5, 66.9, 66.5, 62.5, 62.4, 20.9, 20.9. HRMS (Q-








2-5OH (155 mg, 349 μmol, 1.0 eq.) and trifluoro-N-phenylacetimidoyl Chloride 
(340 μL, 2.10 mmol, 6.0 eq.) were dissolved in DCM (2 mL), the solvent was cooled to 
0 °C (ice-water bath) and DBU (178 μL, 1.05 μmol, 3 eq.) was added. The mixture was 
stirred at r.t. until TLC showed a full conversion of the starting material. After 
evaporation, the crude product was further purified by FC (15% EA in Hex) to obtain 
yellowish syrup 2-5a (α:β = 5/3, 111 mg, 180 μmol), yield 98%. 1H NMR (400 MHz, 
Chloroform-d) δ 7.39 – 7.24 (m, 13H), 7.10 (tq, J = 7.4, 1.4 Hz, 1H), 6.79 (d, J = 7.7 Hz, 
2H), 5.65 – 5.48 (m, 1H), 4.86 – 4.67 (m, 3H), 4.57 (dd, J = 21.8, 11.2 Hz, 1H), 4.16 
(qd, J = 11.4, 6.5 Hz, 2H), 3.85 (t, J = 8.7 Hz, 1H), 3.66 (s, 1H), 2.16 (d, J = 23.6 Hz, 
3H), 2.06 (d, J = 21.9 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 170.5, 170.3, 
170.2, 143.4, 138.0, 137.8, 137.7, 137.4, 129.4, 128.8, 128.5, 128.5, 128.4, 128.2, 128.1, 
128.0, 128.0, 128.0, 127.8, 127.8, 127.5, 124.3, 119.1, 79.1, 77.4, 77.0, 76.7, 75.8, 75.4, 
74.7, 73.8, 72.3, 71.8, 69.4, 67.1, 66.1, 62.1, 61.7, 29.7, 20.9, 20.9, 20.8, 20.7, 1.1. 






Thioglycoside 2-7SPh (64 mg, 95 μmol, 1.0 eq.) and 2-5a (70 mg, 114 μmol, 
1.2 eq.) were evaporated with toluene (5 mL x 3) and put into high vacuum to remove 




MS were added to the solution and the mixture was cooled to 0 °C with ice-water bath. 
TMSOTf (2 μL, 11 μmol, 0.1 eq.) was added to the mixture and the reaction was put at 
0 °C until TLC showed the disappearance of the starting material. The reaction was 
quenched with Na2S2O3(aq.), washed with brine, dried with Na2SO4(s), concentrated in 
vacuo and purified with FC to get 2-36, 158 mg, 144 μmol, 72%. 1H NMR (400 MHz, 
Chloroform-d) δ 7.75 (ddt, J = 7.6, 1.7, 0.8 Hz, 2H), 7.71 – 7.66 (m, 2H), 7.59 (dd, J = 
7.5, 1.0 Hz, 1H), 7.54 (dt, J = 7.6, 1.0 Hz, 1H), 7.43 – 7.27 (m, 19H), 7.25 – 7.14 (m, 
11H), 5.60 (dd, J = 3.2, 1.4 Hz, 1H), 4.96 (d, J = 3.7 Hz, 1H), 4.93 (d, J = 11.6 Hz, 1H), 
4.85 (d, J = 10.7 Hz, 1H), 4.83 – 4.79 (m, 1H), 4.76 (d, J = 10.6 Hz, 1H), 4.66 (d, J = 
6.2 Hz, 1H), 4.64 – 4.59 (m, 2H), 4.53 (d, J = 10.6 Hz, 1H), 4.44 – 4.40 (m, 2H), 4.31 
(ddd, J = 7.8, 6.3, 1.5 Hz, 1H), 4.26 (s, 2H), 4.24 (d, J = 3.0 Hz, 1H), 4.18 (d, J = 7.0 Hz, 
1H), 4.06 (d, J = 7.7 Hz, 2H), 3.97 – 3.92 (m, 1H), 3.92 – 3.88 (m, 1H), 3.88 – 3.81 (m, 
2H), 3.74 (dd, J = 7.7, 6.0 Hz, 1H), 3.62 (dd, J = 9.4, 5.9 Hz, 1H), 2.12 (s, 3H), 1.90 (s, 
3H). 13C NMR (101 MHz, Chloroform-d) δ 170.5, 170.5, 154.7, 143.6, 143.0, 141.4, 
141.4, 138.5, 138.1, 137.9, 137.6, 133.4, 132.0, 129.1, 128.6, 128.6, 128.5, 128.5, 128.4, 
128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 127.9, 127.8, 127.8, 127.3, 127.3, 125.2, 125.1, 
120.2, 100.0, 86.6, 79.9, 77.5, 77.4, 77.2, 77.1, 76.8, 76.6, 75.6, 75.1, 74.8, 74.7, 73.7, 
73.2, 71.7, 70.3, 67.3, 66.9, 66.7, 61.2, 46.7, 21.1, 20.9. HRMS (Q-ToF): calculated for 





Disaccharide 2-36 (30 mg, 27 μmol, 1.0 eq.) was dissolved in 2 mL DCM and 1 
mL Et3N was added to the solution. The mixture was stirred at r.t. until TLC showed a 
full conversion of the starting material. The solvent was removed in vacuo and the crude 
product was purified with FC to get 22 mg 2-37 (25 μmol), yield: 92%. 1H NMR (600 




2H), 7.34 – 7.26 (m, 14H), 7.24 – 7.20 (m, 5H), 5.48 (dd, J = 3.3, 1.4 Hz, 1H), 5.00 (d, 
J = 3.6 Hz, 1H), 4.87 (d, J = 11.7 Hz, 1H), 4.82 (t, J = 11.3 Hz, 2H), 4.72 (d, J = 10.9 
Hz, 1H), 4.65 (d, J = 11.7 Hz, 1H), 4.59 (dd, J = 12.2, 10.1 Hz, 2H), 4.28 (d, J = 3.0 Hz, 
2H), 4.08 (ddd, J = 7.0, 5.3, 1.5 Hz, 1H), 4.04 – 4.00 (m, 2H), 3.96 (dd, J = 11.3, 7.5 Hz, 
1H), 3.91 (dd, J = 10.1, 3.2 Hz, 1H), 3.87 (dd, J = 9.6, 6.5 Hz, 1H), 3.82 (dd, J = 10.1, 
3.6 Hz, 1H), 3.71 (t, J = 6.2 Hz, 1H), 3.67 (td, J = 9.9, 4.4 Hz, 2H), 3.49 (t, J = 9.4 Hz, 
1H), 2.12 (s, 3H), 2.01 (s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 170.6, 170.4, 
138.5, 138.1, 138.1, 138.0, 133.4, 132.5, 128.9, 128.7, 128.6, 128.5, 128.5, 128.4, 128.2, 
128.1, 128.0, 128.0, 127.9, 127.9, 127.8, 127.7, 127.4, 100.4, 86.3, 79.1, 77.6, 77.5, 
77.4, 77.2, 77.0, 76.8, 76.0, 75.5, 74.8, 74.5, 74.4, 73.2, 71.9, 68.5, 67.5, 67.4, 62.5, 
29.8, 21.0, 21.0. HRMS (Q-ToF): calculated for C50H58NO12S+ [M+NH4]+ 896.3674, 






Donor 2-6a was prepared using the same procedure for 2-5a and was used for 
this glycosylation directly. The acceptor 2-37 (32 mg, 36 μmol, 1.0 eq.) and donor 2-6a 
(41 mg, 54 μmol, 1.5 eq.) were coevaporated with toluene (5 mL x 3) and put into high 
vacuum to remove trace water before they were dissolved in anhydrous DCM (1 mL). 
Acid washed 4 Å MS were added to the solution and the mixture was cooled to -30 °C 
with dry ice-acetone bath. TMSOTf (2 μL, 8 μmol, 0.2 eq.) was added to the mixture 
and the reaction was put at -30 °C until TLC showed the disappearance of the starting 
material. The reaction was quenched with Na2S2O3(aq.), extracted with EtOAc, washed 




2-9SPh, 40 mg, 27 μmol, 75%. 1H NMR (600 MHz, Chloroform-d) δ 8.09 (d, J = 7.6 
Hz, 2H), 8.04 – 8.00 (m, 6H), 7.98 (d, J = 7.8 Hz, 4H), 7.88 (d, J = 7.7 Hz, 2H), 7.78 (d, 
J = 7.7 Hz, 2H), 7.62 (dd, J = 7.4, 2.2 Hz, 2H), 7.50 (dddd, J = 21.4, 10.9, 8.4, 5.9 Hz, 
10H), 7.40 (dd, J = 11.5, 7.5 Hz, 5H), 7.36 – 7.27 (m, 22H), 7.20 (d, J = 6.5 Hz, 4H), 
7.18 – 7.16 (m, 2H), 7.07 (dd, J = 8.5, 3.0 Hz, 2H), 6.09 (dt, J = 7.4, 3.9 Hz, 1H), 6.04 
(dt, J = 6.8, 3.7 Hz, 1H), 5.10 (d, J = 3.3 Hz, 1H), 4.92 (dd, J = 5.1, 3.7 Hz, 1H), 4.84 (d, 
J = 10.3 Hz, 1H), 4.79 (td, J = 13.2, 12.6, 2.8 Hz, 3H), 4.76 – 4.66 (m, 6H), 4.59 – 4.55 
(m, 2H), 4.51 (d, J = 11.1 Hz, 1H), 4.34 (d, J = 17.2 Hz, 3H), 4.25 (d, J = 7.3 Hz, 2H), 
4.08 – 4.03 (m, 1H), 3.97 – 3.91 (m, 2H), 3.87 (dd, J = 9.6, 2.5 Hz, 1H), 3.80 (d, J = 9.4 
Hz, 1H), 3.79 – 3.75 (m, 1H), 3.69 (ddd, J = 15.6, 9.8, 6.5 Hz, 2H), 3.59 (dd, J = 10.0, 
3.3 Hz, 1H), 2.15 (s, 3H), 1.99 (s, 3H). 13C NMR (151 MHz, Chloroform-d) δ 170.4, 
170.4, 166.3, 166.2, 165.9, 165.8, 165.7, 165.7, 165.3, 138.6, 138.4, 138.3, 138.0, 133.7, 
133.6, 133.5, 133.5, 133.4, 133.4, 133.3, 133.1, 132.3, 130.2, 130.2, 130.1, 130.1, 130.1, 
130.0, 130.0, 130.0, 129.9, 129.9, 129.9, 129.9, 129.7, 129.7, 129.6, 129.5, 129.0, 128.9, 
128.9, 128.6, 128.6, 128.6, 128.5, 128.5, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.8, 
127.8, 127.7, 127.7, 127.4, 107.2, 101.2, 99.8, 87.1, 82.6, 82.3, 82.1, 82.0, 79.0, 78.6, 
78.5, 78.3, 77.6, 77.5, 77.4, 77.2, 76.9, 76.8, 76.0, 75.1, 74.3, 73.2, 71.9, 70.5, 70.4, 
69.7, 67.5, 67.3, 63.9, 63.7, 61.6, 22.8, 21.2, 20.9, 14.3. HRMS (Q-ToF): calculated for 






Thioglycoside 2-9SPh (31 mg, 21 μmol, 1.0 eq.) was dissolved in a mixed 
solvent of acetone and water (v/v = 3/1, 2 mL) and trichloroisocyanuric acid (6 mg, 26 




of the starting material was not converting. The reaction was quenched with NaHCO3 
(sat. aq.), washed with NaCl(aq.), dried with Na2SO4(s), concentrated in vacuo and 
further purified with FC to get white syrup 2-9OH (α:β = 2:1, 21 mg, 15 μmol), yield: 
72%. Starting material 2-9SPh recovered 5 mg. 1H NMR (600 MHz, Chloroform-d) δ 
8.09 – 7.95 (m, 6H), 7.79 (ddd, J = 14.7, 8.3, 1.4 Hz, 2H), 7.57 – 7.45 (m, 4H), 7.42 (dt, 
J = 9.4, 7.7 Hz, 2H), 7.37 – 7.26 (m, 12H), 7.25 – 7.20 (m, 4H), 7.16 (ddd, J = 9.6, 5.2, 
2.7 Hz, 5H), 7.13 – 7.03 (m, 3H), 6.10 – 6.04 (m, 1H), 5.79 (d, J = 11.0 Hz, 1H), 5.67 – 
5.54 (m, 3H), 5.29 (d, J = 3.4 Hz, 1H), 5.10 (dd, J = 55.7, 3.3 Hz, 1H), 5.02 – 4.89 (m, 
1H), 4.79 – 4.70 (m, 4H), 4.69 – 4.65 (m, 1H), 4.62 – 4.55 (m, 2H), 4.54 – 4.42 (m, 3H), 
4.35 – 4.27 (m, 3H), 4.27 – 4.21 (m, 2H), 4.21 – 4.15 (m, 1H), 4.15 – 4.11 (m, 1H), 4.07 
(t, J = 6.7 Hz, 1H), 3.97 – 3.86 (m, 3H), 3.82 – 3.63 (m, 3H), 3.61 – 3.51 (m, 2H), 2.15 
(d, J = 16.5 Hz, 3H), 2.05 (s, 1H), 2.03 (s, 1H), 2.01 (s, 2H). 13C NMR (151 MHz, 
Chloroform-d) δ 170.9, 170.5, 170.4, 170.4, 166.3, 166.3, 165.8, 165.8, 165.8, 165.3, 
147.2, 139.4, 138.5, 138.5, 138.3, 138.3, 138.2, 138.2, 137.9, 133.5, 133.5, 133.4, 133.4, 
133.4, 133.3, 133.2, 130.3, 130.2, 130.1, 130.1, 130.0, 129.9, 129.9, 129.9, 129.7, 129.6, 
129.5, 129.0, 129.0, 129.0, 128.6, 128.6, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.2, 
128.1, 128.1, 128.0, 127.9, 127.9, 127.8, 127.8, 127.8, 127.7, 124.6, 124.1, 114.2, 107.3, 
107.2, 99.9, 99.4, 98.1, 91.5, 82.6, 82.0, 81.9, 81.9, 80.9, 79.5, 78.4, 78.2, 77.4, 77.2, 
76.9, 76.8, 76.1, 74.8, 74.7, 74.1, 74.1, 73.9, 73.5, 73.3, 73.2, 72.1, 72.0, 70.6, 70.4, 
70.4, 70.2, 69.8, 67.4, 67.4, 67.2, 67.1, 64.5, 63.8, 63.8, 61.8, 61.5, 37.2, 35.0, 34.7, 
34.0, 32.1, 31.6, 30.8, 30.5, 30.3, 30.2, 29.8, 29.8, 29.8, 29.7, 29.5, 29.3, 29.2, 29.1, 
27.2, 22.8, 22.8, 21.6, 21.2, 21.2, 21.0, 20.9, 19.3, 14.3, 13.9, 1.2. HRMS (Q-ToF): 









Trisaccharide 2-9OH (20 mg, 15 μmol, 1.0 eq.) and trifluoro-N-
phenylacetimidoyl chloride (15 μL, 90 μmol, 6 eq.) were dissolved in anhydrous DCM 
(2 mL). DBU (8 μL, 45 μmol, 3.0 eq.) was added to the solvent and the resultant was 
stirred at ambient temperature until TLC showed a disappearance of the starting 
material. The crude product was concentrated in vacuo and purified by FC to get white 
syrup as 2-9a (α:β = 1:4, 21 mg, 14 μmol), yield: 93%. 1H NMR (400 MHz, 
Chloroform-d) δ 8.09 – 7.96 (m, 6H), 7.78 (ddd, J = 12.4, 8.3, 1.4 Hz, 2H), 7.61 – 7.27 
(m, 18H), 7.25 – 7.04 (m, 18H), 6.77 (d, J = 7.8 Hz, 1H), 6.08 (ddt, J = 25.6, 6.9, 3.3 Hz, 
1H), 5.87 – 5.73 (m, 1H), 5.68 – 5.58 (m, 3H), 5.09 (dd, J = 26.5, 3.3 Hz, 1H), 4.85 – 
4.60 (m, 6H), 4.59 – 4.40 (m, 3H), 4.36 – 4.24 (m, 4H), 4.23 – 4.05 (m, 2H), 4.05 – 3.52 
(m, 8H), 2.15 (d, J = 3.7 Hz, 3H), 2.03 (d, J = 5.2 Hz, 3H). 13C NMR (101 MHz, 
Chloroform-d) δ 170.6, 170.4, 166.4, 166.3, 165.9, 165.8, 165.8, 165.3, 165.3, 147.2, 
143.5, 139.4, 138.5, 138.4, 138.3, 138.2, 138.2, 138.1, 138.1, 138.1, 137.8, 137.6, 137.6, 
135.2, 133.6, 133.5, 133.4, 133.3, 130.3, 130.2, 130.1, 130.1, 130.0, 129.9, 129.8, 129.7, 
129.6, 129.5, 129.5, 129.4, 129.0, 128.9, 128.9, 128.8, 128.7, 128.7, 128.7, 128.6, 128.6, 
128.5, 128.5, 128.5, 128.5, 128.4, 128.4, 128.3, 128.2, 128.2, 128.1, 128.1, 128.1, 128.0, 
127.9, 127.9, 127.8, 127.8, 127.8, 127.7, 127.7, 127.7, 127.6, 126.5, 124.6, 124.4, 124.1, 
120.5, 120.4, 119.4, 114.2, 107.2, 107.2, 99.9, 91.0, 82.8, 82.4, 82.1, 81.9, 81.8, 78.2, 
77.5, 77.2, 76.8, 75.9, 75.8, 75.2, 74.3, 74.2, 74.1, 74.0, 73.7, 73.4, 73.4, 73.3, 73.2, 
73.1, 72.1, 72.0, 71.9, 70.5, 70.3, 69.7, 67.6, 67.5, 67.5, 67.2, 63.8, 63.7, 61.9, 61.8, 
61.4, 45.4, 37.2, 35.0, 34.0, 33.8, 32.9, 32.1, 31.6, 30.3, 30.2, 29.8, 29.8, 29.8, 29.7, 
29.5, 29.3, 29.1, 28.1, 27.7, 27.6, 27.2, 22.8, 22.8, 21.6, 21.2, 20.9, 20.9, 19.9, 14.3, 1.2. 











Donor 2-9a (5 mg, 3.2 μmol, 1.0 eq.) and acceptor 2-10 (9 mg, 5.7 μmol, 1.7 eq.) 
were coevaporated with toluene and put under high vacuum to remove trace water 
before they were dissolved in anhydrous toluene (0.5 mL). 4 Å molecular sieves were 
added and the mixture was cooled to 0 °C with ice water bath. TMSOTf (0.1 μL, 0.2 
μmol, 0.2 eq.) was added and after TLC showed a full conversion of the donor, the 
reaction was quenched by Et3N(l), diluted with EtOAc, washed with NaCl(sat. aq.), 
dried with Na2SO4(s), concentrated in vacuo and further purified with FC to get 
colorless syrup 2-4 (6 mg, 2 μmol), yield: 63%. 1H NMR (700 MHz, Chloroform-d) δ 
8.12 (d, J = 8.6 Hz, 2H), 8.01 (d, J = 7.8 Hz, 2H), 7.97 (d, J = 7.7 Hz, 4H), 7.86 (t, J = 
7.9 Hz, 4H), 7.74 (d, J = 7.8 Hz, 2H), 7.58 (t, J = 7.5 Hz, 1H), 7.44 (ddq, J = 26.6, 14.0, 
7.8, 4.9 Hz, 9H), 7.35 – 7.27 (m, 17H), 7.19 (dtd, J = 33.8, 17.7, 16.0, 8.4 Hz, 29H), 
7.11 – 7.05 (m, 6H), 7.01 (t, J = 7.5 Hz, 2H), 6.97 (t, J = 9.4 Hz, 4H), 6.92 (dd, J = 10.4, 
6.9 Hz, 3H), 6.04 (dd, J = 7.6, 3.5 Hz, 1H), 5.88 (s, 1H), 5.76 (dd, J = 14.6, 8.5 Hz, 2H), 
5.70 – 5.65 (m, 2H), 5.62 (d, J = 6.2 Hz, 1H), 5.56 – 5.46 (m, 2H), 5.13 (d, J = 11.0 Hz, 




8H), 4.58 – 4.31 (m, 13H), 4.30 – 4.24 (m, 2H), 4.20 – 4.02 (m, 6H), 4.01 – 3.95 (m, 
2H), 3.94 – 3.79 (m, 5H), 3.78 – 3.57 (m, 8H), 3.52 (dd, J = 10.1, 3.1 Hz, 1H), 3.49 (t, J 
= 8.3 Hz, 1H), 3.08 (dd, J = 9.9, 6.0 Hz, 1H), 2.36 (s, 5H), 2.07 (s, 3H), 2.00 (s, 3H), 
1.96 (s, 3H), 1.90 (s, 3H), 0.90 – 0.81 (m, 3H). 13C NMR (176 MHz, Chloroform-d) δ 
207.4, 185.8, 170.6, 170.5, 170.5, 170.4, 166.2, 166.1, 165.9, 165.8, 165.7, 165.1, 165.1, 
158.5, 156.7, 148.8, 138.7, 138.5, 138.3, 138.3, 138.0, 137.1, 133.6, 133.2, 133.2, 133.2, 
133.1, 133.0, 130.2, 130.1, 130.0, 130.0, 129.9, 129.9, 129.9, 129.8, 129.7, 129.6, 129.5, 
129.2, 128.8, 128.7, 128.7, 128.6, 128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 128.2, 128.2, 
128.2, 128.1, 128.1, 127.9, 127.7, 127.6, 127.6, 127.5, 127.5, 127.5, 127.4, 127.4, 127.3, 
127.2, 125.4, 117.2, 108.3, 108.0, 106.9, 100.5, 99.9, 99.7, 98.1, 91.3, 83.2, 81.9, 81.4, 
79.9, 79.4, 79.0, 78.7, 77.3, 77.2, 77.0, 76.4, 76.4, 76.1, 74.4, 74.2, 74.0, 73.9, 73.1, 
73.0, 72.9, 72.8, 72.6, 72.2, 71.9, 70.6, 70.2, 69.2, 68.4, 67.9, 67.5, 67.4, 67.2, 67.1, 
64.0, 61.6, 61.4, 51.3, 34.2, 32.1, 29.9, 29.8, 29.5, 24.9, 22.8, 22.8, 21.6, 21.1, 21.0, 
20.8, 17.0, 14.3, 9.3, 1.2, -0.2. HRMS (Q-ToF): calculated for C167H163F2NO44Na22+ 






Ammonia was liquefied in a 3-necked flask with a stirring bar in it at -78 °C 
(dry ice-acetone bath). A small piece of Na(s) was added to the ammonia(l) and the 
color of the mixture turned dark blue. 2-4 (28 mg, 9.5 μmol) and tBuOH (0.1 mL) was 
transferred to Na(NH3) with anhydrous THF (0.5 mL + 0.2 mL) and the mixture was 
stirred at – 78 °C for 40 min while the color kept dark blue. MeOH was added dropwise 




bubbled slowly until most of the NH3 was taken away and the temperature was slowly 
raised to room temperature. The mixture was stirred overnight, added AcOH until pH ≈ 
7, evaporated in vacuo and purified with Sephadex G-25 and HPLC (hypercarb) to get 
2-2 (1.8 mg, 1.7 μmol), yield: 18%. 1H NMR (600 MHz, Deuterium Oxide) δ 5.27 – 
5.23 (m, 2H), 5.12 (dt, J = 7.7, 2.6 Hz, 2H), 5.07 (d, J = 3.8 Hz, 1H), 5.03 (d, J = 3.8 Hz, 
1H), 4.36 (ddd, J = 5.5, 2.9, 1.1 Hz, 1H), 4.32 (ddd, J = 8.5, 3.0, 1.1 Hz, 1H), 4.28 – 
4.17 (m, 6H), 4.17 – 4.07 (m, 7H), 4.07 – 4.03 (m, 2H), 4.00 (tt, J = 10.6, 2.1 Hz, 3H), 
3.93 (ddd, J = 11.0, 8.9, 3.1 Hz, 4H), 3.90 – 3.82 (m, 7H), 3.82 – 3.79 (m, 1H), 3.79 – 
3.76 (m, 2H), 3.75 – 3.66 (m, 4H), 3.64 – 3.55 (m, 2H). 13C NMR (151 MHz, d2o) δ 
170.9, 109.4, 109.0, 100.2, 100.1, 100.0, 98.9, 84.5, 82.0, 80.8, 80.3, 79.6, 78.1, 76.5, 
76.4, 76.0, 72.2, 72.0, 70.8, 70.5, 70.5, 69.8, 69.0, 69.0, 68.8, 68.5, 67.8, 67.5, 66.7, 
66.5, 66.3, 62.7, 62.6, 60.5, 60.2, 60.2, 59.8, 41.5. HRMS (Q-ToF) m/z [M+H]+ 






4.3 Conjugation of the Antigens 
General Procedure of the Conjugation 
 
The saccharide (2-1 or 2-2) in a vial was dissolved in 200 µL DMSO, 25 µL 
Pyridine and 10 µL TEA were added. The linker [bis(4-nitrophenyl) adipate, 4.90 mg, 
in a vial] was dissolved in 100 µL DMSO and the solution was added to the saccharide 
solution. After stirring for 3 h, the stirring bar was removed and the reaction mixture 
was frozen in liquid nitrogen and lyophilized overnight to remove all the solvent. The 
residue was very carefully washed with chloroform (5x 1 mL) and DCM (3x 1 mL). 
TLC (40% EtOAc in Hexane) showed that all excess linker was washed away and no 
sugar dissolved. The washed residue was solved in DMSO and transferred to a 1.5 mL 
vial for conjugation and lyophilized again. CRM197 (1 mg) was dissolved in 750 µL 
autoclaved water. The CRM197 solution was transferred into Amicon 10k filter and 
washed with water by centrifuge to remove most of the salt. The filtrate (~60 µL) was 
transferred to the conjugation vial with phosphate buffer solution (PBS, 2x 30 µL, pH = 
8) and the solution was stirred at r.t. for 23 h. The solution was then transferred onto 
Amicon 10k filter, washed with PBS (4x 400 µL, pH = 8) by centrifuge, transferred to a 
clean vial and diluted with PBS to 400 µL. The solution of conjugated saccharide was 







Calculation of the loading number: 
MALDI of CRM197 and CRM197-2-1 
 
MALDI DHAP Matrix of CRM197-2-1: 61107 Da 
MALDI DHAP Matrix of CRM197: 58184 Da  
Sugar + Linker: 709 Da 
CRM197-2-1 - CRM197 = 2923 Da 







Calculation of the loading number: 
MALDI of CRM197-2-2 
 
MALDI DHAP Matrix of CRM197-2-2: 64417 Da 
MALDI DHAP Matrix of CRM197: 58184 Da  
Sugar + Linker: 1210 Da 
CRM197-2-2 - CRM197 = 6233 Da 





4.4 Methods for Immunological Evaluations 
Printing of Glycan Arrays 
Synthetic oligosaccharides were dissolved in 50 mM sodium phosphate buffer 
(PH 8.5) and spotted on N-hydroxysuccinimide activated hydrogel coated glass slides 
(CodeLink slides; Surmodics) using an S3 robotic non-contact microarray printer. 
Slides were incubated in a humidified chamber overnight and quenched with 100 mM 
ethanolamine and 50 mM sodium phosphate (PH 9.0) for 1 h at room temperature. 
Slides were washed with water, dried by centrifugation and stored at 4 °C until use. 
General Procedures for Glycan Array Analysis 
Slides were blocked by incubation with 1% bovine serum albumin in phosphate 
buffered saline (1% BSA-PBS) for at least 30 min at r.t.. Slides were washed twice with 
PBS and dried by centrifugation. A 64-well incubation grid (Grace Biolabs) was applied 
to the slide. 1:10, 1:100 and 1:1000 dilutions of human sera from the patients infected 
by Klebsiella pneumoniae were performed in order to find the best signal without 
saturation. The dilutions in 1% BSA-PBS were applied to the wells and incubated for 
1 h at 37 °C in a humid and dark chamber. Wells were washed three times with PBS 
containing 0.1% Tween-20 (PBS-T). Secondary antibody dilutions in 1% BSA-PBS 
were applied to the wells and incubated for 1 h at 37 °C in a humid and dark chamber. 
The following secondary antibodies were used: goat anti-human IgG H+L AlexaFluor 
635 (Thermo Fisher Scientific Invitrogen). Wells were washed twice with PBS-T and 
once with PBS. The incubation grid was removed and the slides were rinsed with water 
and dried by centrifugation. Slides were scanned using a GenePix 4300A microarray 
scanner (Molecular Devices, Sunnyvale, CA, USA) with a wavelength of 635 nm and 
evaluated using GenePix Pro 7.2 (both from Molecular Devices). The photomultiplier 





Immunization of Rabbits 
A group of five rabbits (obtained from BioGenes, Berlin, Germany) were 
immunized with glycoconjugate (antigen CRM197-2-2 per dose) mixed with aluminum 
hydroxide as adjuvant (Brenntag, Mülheim, Germany). The negative control group 
contained three rabbits (BioGenes, Berlin, Germany) and they were injected with only 
PBS with aluminum hydroxide. On days 14 and 28, the rabbits received booster 
immunizations with the same formulation. Rabbits were bled weekly and the antibody 
levels were measured by glycan microarrays. 
 
ELISA Analysis of Blood Samples 
High binding 96-well polystyrene micro titer plates (Corning, USA) were coated 
overnight at 4 °C with 10 μg·mL-1 of CRM197 in PBS, PH = 7.2 (50 μL per well). The 
plates were washed with PBS-T for three times and blocked with 1% BSA in PBS for 
1 h at room temperature. After three times of washing with PBS-T, the plates were 
incubated with each individual rabbit serum at different dilutions in duplicate or 
triplicate for 1 h at room temperature. The plates were washed for four or five times 
with PBS-T and incubated with horseradish peroxidase (HRP) conjugated anti-rabbit 
IgG antibodies H+L (Sigma-Aldrich, USA), then washed thoroughly with PBS-T. The 











Selenoglycoside 3-19L (701 mg, 2.14 mmol, 1.0 eq.) was dissolved in DCM and 
TBSCl (968 mg, 6.41 mmol, 3.0 eq.), imidazole (727 mg, 10.7 mmol, 5.0 eq.) and 
DMAP (130 mg, 1.07 mmol, 0.5 eq.) were added sequentially and the mixture was 
stirred at r.t. overnight. The mixture became turbid and more DMAP was added later till 
the mixture was transparent again. After TLC showed that most of the starting material 
disappeared, MeOH was added to the mixture to quench the reaction. The solvent was 
evaporated directly and the crude was purified by FC. Selenoglycoside 3-20L (871 mg, 
1.97 mmol, yield: 92%) was obtained as white solid. 1H NMR (400 MHz, Chloroform-d) 
δ 7.63 – 7.54 (m, 2H), 7.32 – 7.26 (m, 3H), 5.92 (d, J = 5.3 Hz, 1H), 4.33 (qt, J = 6.5, 
1.5 Hz, 1H), 4.03 (dd, J = 9.8, 5.2 Hz, 1H), 3.79 (dd, J = 9.8, 3.3 Hz, 1H), 3.68 (dt, J = 
2.8, 1.2 Hz, 1H), 2.47 (t, J = 1.3 Hz, 1H), 1.28 (d, J = 6.6 Hz, 3H), 0.95 (s, 9H), 0.23 (s, 
3H), 0.18 (s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 134.5, 134.5, 129.2, 128.8, 
127.9, 85.4, 85.0, 77.5, 77.2, 76.8, 72.9, 71.9, 71.8, 68.6, 62.5, 25.9, 18.1, 16.2, -4.6, -






Selenoglycoside 3-20L (769 mg, 1.74 mmol, 1.0 eq.) was dissolved in DCM (10 




were added sequentially at -10 °C (salt-ice-water bath) and the temperature was slowly 
raised to r.t.. After TLC showed a full conversion of 3-20L, the mixture was evaporated 
in vacuo and then dissolved in anhydrous DMF. NaN3 (1.13 g, 17.36 mmol, 10.0 eq.) 
was added and the mixture was stirred overnight. The crude product was extracted with 
EtOAc, washed with H2O and brine, dried with Na2SO4(s), evaporated in vacuo and 
purified by FC. Selenoglycoside 3-21L (722 mg, 1.543 mmol, yield: 89%) was obtained 
as yellow oil. 1H NMR (400 MHz, Chloroform-d) δ 7.64 – 7.48 (m, 2H), 7.41 – 7.27 (m, 
3H), 5.85 (d, J = 5.2 Hz, 1H), 4.07 (dq, J = 10.1, 6.2 Hz, 1H), 3.71 (dd, J = 9.7, 5.2 Hz, 
1H), 3.52 (t, J = 9.3 Hz, 1H), 3.02 (dd, J = 10.1, 9.1 Hz, 1H), 1.31 (d, J = 6.2 Hz, 3H), 
0.96 (s, 9H), 0.23 (d, J = 1.4 Hz, 6H). 13C NMR (101 MHz, Chloroform-d) δ 134.7, 
129.3, 128.5, 128.2, 84.9, 77.5, 77.4, 77.2, 76.8, 73.4, 70.4, 69.6, 66.8, 25.9, 18.4, 18.2, 
-4.4, -4.6. HRMS (Q-ToF): calculated for C18H28N6O2SeSiNa+ [M+Na]+ 491.1100, 





Selenoglycoside 3-21L (165 mg, 353 μmol, 1.0 eq.) was dissolved in EtOAc 
(2 mL) and a portion of Pd/C was added. The solution was bubbled with N2(g) and H2(g) 
and the resultant was stirred under H2(g) with a balloon at r.t. over night. After LCMS 
showed a full reduction of the azide groups, the suspension was filtrated, concentrated 
and purified with FC to get 3-22L (190 mg, 457 μmol, yield: 73%). Selenoglycoside 
3-22L (103 mg, 248 μmol, 1.0 eq.) was taken and dissolved in a mixed solvent of water 
(1 mL) and DCM (4 mL). NaHCO3 (62 mg, 743 μmol, 3.0 eq.) and TrocCl (157 mg, 
743 μmol, 3.0 eq.) were added and stirred at r.t. for 30 min. After TCL showed a full 
conversion of the starting material, the mixture was extracted with EtOAc, washed with 
HCl(1 M aq.), NaHCO3(sat. aq.) and brine, dried with Na2SO4(s) and concentrated in 
vacuo, the crude product was further purified with FC to get 3-8L (172 mg, 225 μmol, 
yield: 91%). 1H NMR (600 MHz, Chloroform-d) δ 7.59 – 7.54 (m, 2H), 7.31 – 7.27 (m, 




J = 11.9 Hz, 1H), 4.73 (d, J = 11.9 Hz, 1H), 4.63 (dd, J = 12.0, 3.5 Hz, 2H), 4.19 (dq, J 
= 12.2, 6.2 Hz, 1H), 4.05 (td, J = 9.7, 4.6 Hz, 1H), 3.61 (t, J = 9.6 Hz, 1H), 3.48 – 3.34 
(m, 1H), 1.34 (d, J = 6.2 Hz, 3H), 0.86 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H), 0.07 (s, 2H). 
13C NMR (101 MHz, Chloroform-d) δ 167.9, 165.1, 155.4, 154.2, 143.2, 141.4, 138.0, 
137.9, 136.9, 135.4, 133.5, 129.8, 129.6, 129.2, 128.8, 128.6, 128.6, 128.5, 128.4, 128.3, 
128.2, 127.9, 127.9, 127.6, 127.4, 127.3, 125.4, 125.3, 120.3, 101.0, 100.4, 95.5, 82.5, 
77.5, 77.2, 76.8, 76.1, 74.6, 74.5, 73.7, 71.0, 70.8, 70.7, 69.9, 69.5, 67.2, 67.1, 63.2, 
57.6, 56.3, 50.6, 50.3, 47.3, 47.1, 46.5, 46.1, 32.1, 31.9, 29.8, 29.7, 29.5, 29.0, 27.8, 
27.4, 25.6, 23.1, 22.8, 22.8, 21.6, 17.7, 14.3, 14.1, 11.9. HRMS (Q-ToF): calculated for 





Starting material 3-23 (552 mg, 1.09 mmol, 1.0 eq.) was dissolved in methanol 
(10 mL). Sodium methoxide (0.5 M in MeOH, 0.44 mL, 0.22 mmol) was added and the 
mixture was stirred until TLC showed a full conversion of the starting material. 
Amberlite (H+) was added to adjust the pH to 7. After filtration and removal of solvent, 
3-24 was put under high vacuum overnight and used in the next step without further 
purification. DCM (20 mL) was added as solvent. Pyridine (0.26 mL, 3.27 mmol, 
3.0 eq.) and BzCl (0.38 mL, 3.27 mmol, 3.0 eq.) were added and the solution was stirred 
at r.t. overnight. TLC showed a full conversion of 3-24 and the mixture was evaporated 
and purified with FC to get white solid 3-25, 598 mg, 1.05 mmol, yield: 96% for 2 steps. 
1H NMR (400 MHz, Chloroform-d) δ 8.05 – 7.96 (m, 2H), 7.65 – 7.57 (m, 1H), 7.56 – 
7.50 (m, 2H), 7.49 – 7.37 (m, 5H), 7.16 (td, J = 7.4, 6.8, 1.6 Hz, 3H), 7.12 – 7.06 (m, 
2H), 6.92 – 6.85 (m, 2H), 6.78 – 6.72 (m, 2H), 5.65 (s, 1H), 5.58 – 5.50 (m, 1H), 5.07 (d, 
J = 7.9 Hz, 1H), 4.86 (d, J = 12.1 Hz, 1H), 4.73 (d, J = 12.1 Hz, 1H), 4.43 (dd, J = 10.6, 
5.0 Hz, 1H), 4.00 – 3.87 (m, 3H), 3.73 (s, 3H), 3.66 – 3.56 (m, 1H). 13C NMR (101 
MHz, Chloroform-d) δ 165.2, 155.8, 151.2, 137.8, 137.2, 133.4, 130.0, 129.8, 129.2, 




77.9, 77.5, 77.4, 77.2, 76.8, 74.2, 73.4, 68.8, 66.6, 55.7. LCMS (ESI): calculated for 
C34H32O8Na+ [M+Na]+ 591.2, found 591.1 m/z. Data compatible as reported.108 
 
4-Methoxyphenyl 2-O-benzoyl-3-O-benzyl-β-D-glucopyranoside (3-26) 
 
Starting material 3-25 (248 mg, 435 μmol, 1.0 eq.) was dissolved in a mixed 
solvent of DCM (3 mL) and MeOH (3 mL). TsOH·H2O (83 mg, 435 μmol, 1.0 eq.) was 
added and the reaction was monitored by TLC. As soon as the cleavage of benzylidene 
was completed, the reaction was quenched with TEA, concentrated in vacuo and the 
crude product was further purified with FC to give 3-26 (178 mg, 370 μmol, 
yield: 85%). 1H NMR (400 MHz, Chloroform-d) δ 8.09 – 8.04 (m, 2H), 7.62 – 7.56 (m, 
1H), 7.49 – 7.41 (m, 2H), 7.23 (s, 5H), 6.92 – 6.83 (m, 2H), 6.80 – 6.71 (m, 2H), 5.49 
(dd, J = 9.4, 7.9 Hz, 1H), 5.05 (d, J = 7.9 Hz, 1H), 4.78 (d, J = 11.5 Hz, 1H), 4.63 (d, J 
= 11.6 Hz, 1H), 3.97 (ddd, J = 11.9, 5.9, 3.4 Hz, 1H), 3.90 – 3.81 (m, 2H), 3.77 (d, J = 
9.2 Hz, 1H), 3.73 (s, 3H), 3.56 (ddd, J = 9.5, 5.1, 3.4 Hz, 1H), 2.51 (d, J = 3.0 Hz, 1H), 
2.10 (t, J = 6.8 Hz, 1H). 13C NMR (101 MHz, Chloroform-d) δ 165.3, 155.6, 151.3, 
137.8, 133.5, 129.9, 129.7, 128.7, 128.7, 128.2, 128.2, 118.5, 114.7, 100.9, 82.5, 77.5, 
77.4, 77.2, 76.8, 75.6, 74.8, 73.6, 70.4, 62.6, 55.7. LCMS (ESI): calculated for 
C27H28O8Na+ [M+Na]+ 503.2, found 503.1 m/z. Data compatible as reported.109 
 
4-Methoxyphenyl (benzyl 2-O-benzoyl-3-O-benzyl-β-D-glucopyranosyluronate) 
(3-9) 
 
Diol 3-26 (100 mg, 239 μmol, 1.0 eq.) was dissolved in a DCM (2 mL) and H2O 
(1 mL). BAIB (193 mg, 598 μmol, 2.5 eq.) and TEMPO (19 mg, 120 μmol, 0.5 eq.) 
were added to the mixture sequentially. The resultant was stirred at r.t. and after TLC 




crude product was purified by FC (30% EtOAc in Hex) to get 3-27 as white foam 
(486 mg, 0.839 mmol, yield: 84%). 3-27 (100 mg, 239 μmol, 1.0 eq.) was dissolved in a 
DCM (2 mL) and H2O (1 mL). BAIB (193 mg, 598 μmol, 2.5 eq.) and TEMPO (19 mg, 
120 μmol, 0.5 eq.) were added to the mixture sequentially. The resultant was stirred at 
r.t. and after TLC showed a full conversion of the starting material, the solvent was 
evaporated and the crude product was purified by FC (30% EtOAc in Hex) to get 3-9 as 
white foam (486 mg, 0.839 mmol, yield: 84%). 1H NMR (400 MHz, Chloroform-d) δ 
8.07 – 7.96 (m, 2H), 7.64 – 7.54 (m, 1H), 7.45 (t, J = 7.4 Hz, 2H), 7.37 (p, J = 2.7, 2.0 
Hz, 5H), 7.23 – 7.12 (m, 5H), 6.96 – 6.86 (m, 2H), 6.71 (dt, J = 8.9, 1.2 Hz, 2H), 5.50 
(ddt, J = 9.2, 7.7, 1.3 Hz, 1H), 5.33 – 5.18 (m, 2H), 5.00 (dt, J = 7.7, 1.3 Hz, 1H), 4.85 – 
4.72 (m, 2H), 4.21 (t, J = 9.3 Hz, 1H), 4.04 (dt, J = 9.7, 1.4 Hz, 1H), 3.82 – 3.75 (m, 
1H), 3.73 (d, J = 1.2 Hz, 3H), 3.07 (s, 1H), 2.05 (d, J = 1.2 Hz, 1H), 1.29 – 1.21 (m, 2H). 
13C NMR (101 MHz, Chloroform-d) δ 168.7, 165.1, 155.7, 151.1, 137.7, 134.9, 133.3, 
130.0, 129.8, 129.6, 128.7, 128.6, 128.5, 128.3, 128.1, 128.1, 127.8, 119.3, 119.2, 114.4, 
101.3, 80.6, 77.4, 77.1, 76.7, 74.5, 74.3, 72.8, 71.8, 67.5, 60.4, 55.6, 29.7, 21.1, 14.2. 






Donor 3-8L (188 mg, 245 µmol, 1.0 eq.) and acceptor 3-9 (144 mg, 245 µmol, 
1.0 eq.) were coevaporated with toluene for three times and put under high vacuum 
overnight to remove trace water in them. The starting materials were dissolved in 
anhydrous toluene (3 mL), 4 Å molecular sieves were added and the suspension was 




0.15 eq.) were added and the resultant mixture was stirred at that temperature until TLC 
showed a full conversion of the donor. The reaction was quenched with Na2S2O3(aq.), 
extracted with EtOAc, washed with Na2S2O3(aq.) and brine, dried with Na2SO4(s), 
concentrated and purified with FC to get the glycosylation products (257 mg, 
215 µmmol, yield: 88%). 3-28α (107 mg) and 3-28β (150 mg) could be well separated. 
Only desired 3-28β was characterized: 1H NMR (600 MHz, Chloroform-d) δ 8.02 (d, J 
= 7.7 Hz, 2H), 7.58 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 7.7 Hz, 2H), 7.38 (t, J = 6.2 Hz, 4H), 
7.34 (d, J = 7.9 Hz, 3H), 7.29 (d, J = 7.5 Hz, 1H), 7.20 (ddt, J = 29.8, 13.9, 7.0 Hz, 2H), 
6.88 (d, J = 8.8 Hz, 2H), 6.75 – 6.67 (m, 2H), 5.55 (t, J = 8.1 Hz, 1H), 5.26 (d, J = 12.4 
Hz, 1H), 5.10 (d, J = 12.5 Hz, 1H), 5.03 (d, J = 7.3 Hz, 1H), 4.81 (dd, J = 11.8, 6.3 Hz, 
2H), 4.76 (d, J = 11.9 Hz, 1H), 4.66 (t, J = 10.8 Hz, 2H), 4.57 (dd, J = 10.6, 6.8 Hz, 2H), 
4.48 (d, J = 12.0 Hz, 1H), 4.29 (q, J = 8.3, 7.2 Hz, 2H), 4.18 (d, J = 9.4 Hz, 1H), 3.91 (t, 
J = 9.0 Hz, 1H), 3.72 (s, 3H), 3.42 – 3.28 (m, 2H), 3.23 (t, J = 9.5 Hz, 1H), 3.00 (q, J = 
9.5 Hz, 1H), 1.17 (d, J = 6.1 Hz, 3H), 0.81 (s, 9H), -0.12 (s, 3H). 13C NMR (151 MHz, 
Chloroform-d) δ 167.6, 165.2, 155.9, 154.0, 153.9, 151.2, 138.2, 135.5, 133.6, 130.0, 
129.5, 129.2, 128.8, 128.8, 128.7, 128.6, 128.5, 128.4, 128.4, 128.3, 128.1, 127.6, 125.4, 
119.2, 114.6, 101.0, 100.7, 95.3, 82.8, 77.4, 77.2, 76.9, 76.4, 75.1, 74.9, 74.6, 74.5, 73.7, 
72.7, 70.5, 67.1, 60.4, 59.0, 55.7, 25.7, 21.6, 18.0, 18.0, 1.2, -4.2, -4.4. HRMS (Q-ToF): 






Disaccharide 3-28β (134 mg, 112 µmol, 1.0 eq.) was dissolved in a mixed 
solvent of DCM (1 mL), MeCN (2 mL) and H2O (1 mL). CAN (237 mg, 432 µmol, 
4.0 eq.) was added and the mixture was stirred at r.t.. Color of the mixture turned orange. 
The reaction was monitored by TLC and as soon as the starting material was fully 




EtOAc, washed with water and brine, dried with Na2SO4(s), concentrated and purified 
with FC to get 3-29 (116 mg, 107 µmmol, yield: 95%). NMR pure spectra could not be 
obtained. HRMS (Q-ToF): calculated for C45H54Cl6N2O14SiNa+ [M+Na]+ 1107.1368, 




glucopyranosyluronoyl) N-phenyltrifluoroacetimidate (3-30) 
 
Disaccharide 3-29 (98 mg, 90 μmol, 1.0 eq.) and trifluoro-N-phenylacetimidoyl 
chloride (88 μL, 540 µmol, 6.0 eq.) were dissolved in DCM (1 mL), the solvent was 
cooled to 0 °C (ice-water bath) and DBU (40 μL, 270 μmol, 3.0 eq.) was added. The 
mixture was stirred at r.t. until TLC showed a full conversion of the starting material. 
After evaporation, the crude product was further purified by FC (15% EA in Hex) to get 
yellowish syrup 3-30 (108 mg, 86 μmol, yield: 95%). NMR pure spectra could not be 
obtained. HRMS (Q-ToF): calculated for C53H58Cl6F3N3O14SiNa+ [M+Na]+ 1278.1663, 







Disaccharide 3-30 (50 mg, 40 μmol, 1.0 eq.) and 3-7 (32 mg, 100 μmol, 2.5 eq.) 




before they were dissolved in anhydrous DCM (1.0 mL). Acid washed 4 Å molecular 
sieves were added and the mixture was cooled to -10 °C with ice-salt water bath. 
TMSOTf (1.6 μL, 10 μmol, 0.25 eq.) was added and after TLC showed a full 
conversion of the donor, the reaction was quenched by Et3N(l), diluted with EtOAc, 
washed with NaCl(sat. aq.), dried with Na2SO4(s), concentrated in vacuo and further 
purified with FC to get colorless syrup 3-31 (40 mg, 29 μmol), yield: 72%. 1H NMR 
(600 MHz, Chloroform-d) δ 8.06 – 7.92 (m, 2H), 7.52 – 7.27 (m, 19H), 7.25 – 7.04 (m, 
5H), 5.41 – 5.20 (m, 2H), 5.15 (dd, J = 16.2, 9.7 Hz, 4H), 5.04 – 4.88 (m, 1H), 4.85 (d, 
J = 11.8 Hz, 1H), 4.77 (t, J = 12.9 Hz, 2H), 4.68 (dd, J = 22.9, 10.5 Hz, 1H), 4.62 – 4.55 
(m, 2H), 4.55 – 4.45 (m, 3H), 4.43 – 4.28 (m, 3H), 4.20 (d, J = 7.8 Hz, 1H), 4.06 (dt, J = 
11.7, 7.0 Hz, 2H), 3.87 – 3.74 (m, 2H), 3.33 (dd, J = 22.9, 14.1 Hz, 3H), 3.15 (t, J = 9.6 
Hz, 1H), 3.06 – 2.90 (m, 3H), 2.05 (s, 3H), 0.81 (s, 10H), 0.07 (d, J = 1.2 Hz, 2H), -0.07 
(d, J = 5.2 Hz, 3H), -0.14 (d, J = 7.2 Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ 
171.3, 168.0, 165.1, 154.1, 153.9, 139.4, 138.1, 135.6, 133.5, 129.8, 129.7, 128.8, 128.7, 
128.7, 128.6, 128.6, 128.4, 128.2, 128.0, 127.4, 114.2, 101.0, 100.7, 95.3, 77.4, 77.2, 
76.9, 76.6, 75.2, 74.9, 74.4, 73.9, 72.8, 70.5, 69.9, 67.2, 67.0, 64.5, 60.5, 60.4, 58.9, 
50.3, 47.2, 36.8, 34.0, 32.1, 31.6, 30.8, 30.3, 29.8, 29.8, 29.8, 29.7, 29.5, 29.3, 29.1, 
29.1, 28.6, 25.7, 24.9, 24.8, 24.0, 23.5, 23.1, 22.8, 21.2, 21.2, 20.7, 19.3, 18.0, 18.0, 
14.3, 14.3, 13.8, 8.1, 1.2, -4.2, -4.4. HRMS (Q-ToF): calculated for 





Selenoglycoside 3-8L (81 mg, 106 μmol, 1.0 eq.) was dissolved in a mixed 
solvent of DCM (1.5 mL) and MeOH (1.5 mL). CSA (247 mg, 1060 μmol, 10 eq.) was 
added to the solution and the mixture was stirred at r.t. for 48h. TLC showed a full 
conversion of the starting material. The reaction was quenched with TEA and 
concentrated in vacuo. The crude product was extracted with EtOAc, washed with water 




(64 mg, 98 μmol, yield: 93%). 1H NMR (400 MHz, Chloroform-d) δ 7.58 – 7.52 (m, 
2H), 7.32 – 7.26 (m, 3H), 5.85 (d, J = 4.8 Hz, 1H), 5.67 – 5.52 (m, 1H), 5.27 (t, J = 16.6 
Hz, 1H), 4.85 (d, J = 12.1 Hz, 1H), 4.81 – 4.62 (m, 4H), 4.11 (dddd, J = 29.9, 13.7, 9.4, 
5.4 Hz, 2H), 3.55 (dt, J = 23.9, 9.7 Hz, 2H), 1.35 (d, J = 6.2 Hz, 4H), 1.28 – 1.20 (m, 
2H). 13C NMR (151 MHz, Chloroform-d) δ 176.5, 155.2, 154.9, 134.1, 129.6, 129.0, 
128.3, 88.8, 77.4, 77.2, 76.9, 75.0, 74.9, 73.0, 70.7, 70.4, 69.5, 63.2, 59.9, 57.6, 47.3, 
32.1, 31.9, 29.9, 29.8, 29.7, 29.5, 25.6, 22.8, 22.8, 17.9, 14.3, 14.1, 11.9. HRMS (Q-






Disaccharide 3-31 (28 mg, 20 μmol, 1.0 eq.) was dissolved in a mixed solvent of 
DCM (0.5 mL) and MeOH (0.5 mL). CSA (47 mg, 200 μmol, 10 eq.) was added to the 
solution and the mixture was stirred at r.t. for 48h. TLC showed a full conversion of the 
starting material. The reaction was quenched with TEA and concentrated in vacuo. The 
crude product was extracted with EtOAc, washed with water and brine, dried with 
Na2SO4(s), concentrated again and purified with FC to get 3-33 (14 mg, 11 μmol, yield: 
55%). 1H NMR (600 MHz, Chloroform-d) δ 7.96 (s, 2H), 7.50 (t, J = 7.4 Hz, 1H), 7.45 
– 7.27 (m, 14H), 7.23 – 7.07 (m, 4H), 5.36 – 5.28 (m, 1H), 5.23 (d, J = 12.5 Hz, 1H), 
5.18 (d, J = 12.5 Hz, 1H), 5.16 – 5.10 (m, 2H), 4.85 (s, 1H), 4.77 (t, J = 11.1 Hz, 3H), 
4.71 – 4.60 (m, 3H), 4.58 – 4.49 (m, 1H), 4.47 (d, J = 8.4 Hz, 1H), 4.39 (d, J = 10.6 Hz, 
2H), 4.18 (s, 1H), 4.07 (s, 1H), 3.92 (dt, J = 46.3, 7.6 Hz, 1H), 3.79 (d, J = 31.7 Hz, 1H), 
3.59 – 3.47 (m, 1H), 3.40 – 3.11 (m, 6H), 3.05 (s, 1H), 2.95 (s, 1H), 1.26 (s, 6H), 1.21 
(dd, J = 7.0, 1.4 Hz, 4H), 1.15 (dd, J = 6.4, 1.3 Hz, 2H), 0.90 – 0.85 (m, 2H). 13C NMR 
(151 MHz, Chloroform-d) δ 133.5, 129.8, 128.8, 128.6, 128.6, 128.3, 128.0, 127.6, 77.4, 
77.2, 76.9, 75.0, 74.7, 73.9, 67.3, 59.1, 29.9, 17.9, 15.3, 1.2. HRMS (Q-ToF): calculated 








Selenoglycoside 3-22L (50 mg, 120 μmol, 1.0 eq.) was taken and dissolved in a 
mixed solvent of water (0.3 mL) and DCM (1.2 mL). NaHCO3 (30 mg, 360 μmol, 
3.0 eq.) and TCACl (43 µL, 360 μmol, 3.0 eq.) were added and stirred at r.t. for 30 min. 
After TCL showed a full conversion of the starting material, the mixture was extracted 
with EtOAc, washed with HCl(1 M aq.), NaHCO3(sat. aq.) and brine, dried with 
Na2SO4(s) and concentrated in vacuo, the crude product was further purified with FC to 
get 3-34L (85 mg, 111 µmol, yield: 93%). HRMS (Q-ToF): calculated for 





The donor 3-35 (225 mg, 370 μmol, 1.0 eq.) and the acceptor 3-7 (145 mg, 
445 μmol, 1.5 eq.) were coevaporated with anhydrous toluene three times and put under 
high vacuum overnight to remove trace water inside. The mixture was dissolved in 
DCM (1 mL) and 4 Å MS was added. After being stirred for 15 min, the mixture was 
cooled to -17 °C and TMSOTf (7 μL, 37 μmol, 0.1 eq.) was added and the resultant 
mixture continued to be stirred until TLC showed a full conversion of the starting 
material. The reaction was quenched with Na2S2O3(aq.), extracted with EtOAc, washed 




3-36 (195 mg, 110 μmol, yield: 68%). 1H NMR (600 MHz, Chloroform-d) δ 7.95 (d, J = 
7.7 Hz, 2H), 7.54 – 7.47 (m, 3H), 7.43 – 7.25 (m, 13H), 7.13 (ddt, J = 33.0, 24.3, 6.6 Hz, 
7H), 5.60 (s, 1H), 5.26 (t, J = 8.0 Hz, 1H), 5.13 (d, J = 8.2 Hz, 2H), 4.82 (d, J = 12.1 Hz, 
1H), 4.70 (d, J = 12.1 Hz, 1H), 4.54 (dd, J = 28.5, 8.4 Hz, 1H), 4.42 – 4.32 (m, 3H), 
3.88 – 3.75 (m, 4H), 3.48 (s, 1H), 3.44 – 3.31 (m, 1H), 3.08 – 2.90 (m, 2H), 1.61 – 1.26 
(m, 6H), 1.13 (d, J = 31.4 Hz, 2H). 13C NMR (151 MHz, Chloroform-d) δ 165.0, 137.9, 
137.2, 133.1, 129.9, 129.8, 129.8, 129.0, 128.5, 128.3, 128.3, 128.3, 128.1, 128.0, 127.8, 
127.5, 126.1, 126.0, 101.8, 101.3, 81.7, 77.8, 77.2, 77.0, 76.8, 73.9, 73.4, 70.0, 68.7, 
67.1, 66.3, 50.5, 50.2, 47.0, 46.0, 29.0, 27.6, 27.2, 23.0. HRMS (Q-ToF): calculated for 





Starting material 3-36 (166 mg, 215 μmol, 1.0 eq.) was dissolved in DCM 
(1.0 mL). EtSH (0.5 mL) was added and the solution was stirred at r.t. followed by 
addition of TsOH·H2O (8 mg, 43 μmol, 0.2 eq.). As soon as TLC showed full 
conversion of the starting material, the reaction was quenched with TEA, concentrated 
in vacuo and purified with FC to get 3-37 (110 mg, 161 μmol, yield: 75%). 1H NMR 
(600 MHz, Chloroform-d) δ 8.01 (d, J = 8.2 Hz, 2H), 7.50 (t, J = 7.4 Hz, 1H), 7.40 – 
7.15 (m, 16H), 7.15 – 7.07 (m, 1H), 5.21 (t, J = 8.8 Hz, 1H), 5.13 (d, J = 6.7 Hz, 2H), 
4.73 (d, J = 11.5 Hz, 1H), 4.60 (dd, J = 11.5, 5.2 Hz, 1H), 4.51 (dd, J = 27.5, 7.9 Hz, 
1H), 4.36 (d, J = 15.6 Hz, 2H), 3.91 (dd, J = 11.9, 3.3 Hz, 1H), 3.81 (dd, J = 12.1, 5.1 
Hz, 2H), 3.76 – 3.71 (m, 1H), 3.67 (t, J = 9.1 Hz, 1H), 3.46 – 3.29 (m, 2H), 3.09 – 2.88 
(m, 2H), 0.85 (dt, J = 22.3, 6.6 Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ 165.2, 
138.0, 133.3, 130.0, 129.8, 128.7, 128.7, 128.6, 128.6, 128.6, 128.1, 128.1, 128.0, 127.9, 
127.4, 127.3, 101.5, 82.6, 77.4, 77.2, 76.9, 75.5, 74.6, 73.8, 70.7, 69.9, 67.3, 62.7, 50.6, 
50.4, 47.2, 46.2, 32.1, 31.6, 29.8, 29.5, 29.2, 27.8, 27.2, 23.1, 22.8, 14.3. HRMS (Q-








Starting material 3-37 (33 mg, 48 µmol, 1.0 eq.) was dissolved in a mixed 
solvent of DCM (0.6 mL) and H2O (0.3 mL). BAIB (47 mg, 145 µmol, 3.0 eq.) and 
TEMPO (4 mg, 24 µmol, 0.5 eq.) were added and the mixture was stirred at r.t. until 
LC-MS showed a full conversion of the starting material. The mixture was extracted 
with EtOAc, dried with Na2SO4(s) and filtrated with silica gel to get crude product 3-38 
(30 mg, 43 µmol, yield: 89%). Crude 3-38 (30 mg, 43 µmol, 1.0 eq.) was put under high 
vacuum overnight and dissolved in anhydrous DMF (0.8 mL). NaHCO3 (36 mg, 
430 µmol, 10 eq.) and BnBr (26 µL, 215 µmol, 10 eq.) were added sequentially and the 
mixture was stirred at r.t. until TLC showed the disappearance of the starting material. 
The mixture was filtrated, evaporated and purified with FC to get 3-39 (26 mg, 33 µmol, 
yield: 77%). 1H NMR (400 MHz, Chloroform-d) δ 8.03 – 7.93 (m, 2H), 7.51 (t, J = 7.4 
Hz, 1H), 7.41 – 7.27 (m, 17H), 7.23 – 7.10 (m, 7H), 5.14 (d, J = 4.7 Hz, 2H), 4.75 (d, J 
= 2.2 Hz, 2H), 4.70 (s, 1H), 4.54 (dt, J = 20.2, 11.2 Hz, 1H), 4.42 – 4.32 (m, 2H), 4.08 
(td, J = 9.3, 2.4 Hz, 1H), 3.95 (dd, J = 9.5, 3.8 Hz, 1H), 3.89 – 3.74 (m, 1H), 3.71 (t, J = 
9.1 Hz, 1H), 3.45 – 3.27 (m, 1H), 3.12 – 2.86 (m, 3H). 13C NMR (101 MHz, 
Chloroform-d) δ 169.1, 165.1, 156.7, 156.2, 141.0, 138.0, 138.0, 137.9, 137.0, 136.8, 
135.1, 133.3, 130.1, 129.8, 128.8, 128.7, 128.7, 128.6, 128.6, 128.5, 128.5, 128.4, 128.4, 
128.2, 128.0, 128.0, 127.9, 127.8, 127.7, 127.4, 127.3, 127.2, 127.1, 101.6, 80.8, 80.8, 
77.5, 77.4, 77.2, 76.8, 74.5, 73.0, 72.1, 72.0, 70.1, 70.0, 67.6, 67.2, 65.4, 50.5, 50.2, 
47.1, 46.1, 32.0, 29.8, 29.5, 29.0, 27.7, 27.3, 23.1, 22.8, 14.3. HRMS (Q-ToF): 











Acceptor 3-34L (28 mg, 36 µmol, 1.1 eq.) and donor 3-39 (26 mg, 33 µmol, 
1.0 eq.) were coevaporated with toluene for three times and put under high vacuum 
overnight to remove trace water in them. The starting materials were dissolved in 
anhydrous DCM (1.0 mL), 4 Å molecular sieves were added and the suspension was 
stirred at -20 °C for 5 min. NIS (11 mg, 49 µmol, 1.5 eq.) and TfOH (0.5 µL, 5 µmol, 
0.15 eq.) were added and the resultant mixture was stirred at that temperature until TLC 
showed a full conversion of the donor. The reaction was quenched with Na2S2O3(aq.), 
extracted with EtOAc, washed with Na2S2O3(aq.) and brine, dried with Na2SO4(s), 
concentrated and purified with FC to get 3-40 (β only, 35 mg, 26 µmmol, yield: 79%). 
1H NMR (600 MHz, Chloroform-d) δ 7.98 – 7.92 (m, 2H), 7.52 – 7.47 (m, 1H), 7.47 – 
7.43 (m, 2H), 7.41 (t, J = 7.6 Hz, 2H), 7.39 – 7.27 (m, 8H), 7.25 – 7.21 (m, 4H), 7.20 – 
7.16 (m, 2H), 7.11 (d, J = 7.3 Hz, 1H), 6.58 (d, J = 8.2 Hz, 1H), 6.47 (d, J = 9.3 Hz, 1H), 
5.44 – 5.25 (m, 5H), 5.19 – 5.10 (m, 3H), 5.00 (d, J = 8.4 Hz, 1H), 4.66 (s, 2H), 4.54 
(dd, J = 23.7, 6.9 Hz, 1H), 4.41 – 4.30 (m, 3H), 4.05 (d, J = 9.5 Hz, 1H), 4.02 (t, J = 9.3 
Hz, 1H), 3.84 (t, J = 8.5 Hz, 1H), 3.78 (s, 1H), 3.62 (d, J = 31.4 Hz, 1H), 3.34 (q, J = 
9.5 Hz, 2H), 3.21 (dd, J = 10.3, 6.3 Hz, 2H), 3.00 (d, J = 61.8 Hz, 2H), 2.21 (t, J = 7.6 
Hz, 2H), 2.01 (q, J = 6.5 Hz, 2H), 1.66 – 1.58 (m, 4H), 1.13 (d, J = 6.1 Hz, 4H), 0.88 (t, 
J = 7.0 Hz, 5H), 0.84 (s, 9H). 13C NMR (151 MHz, Chloroform-d) δ 168.0, 165.1, 161.8, 
161.7, 138.2, 135.6, 133.5, 130.2, 129.9, 129.8, 129.7, 128.8, 128.6, 128.6, 128.6, 128.5, 
128.5, 128.0, 128.0, 127.9, 127.9, 100.9, 97.6, 92.6, 92.5, 82.5, 77.4, 77.2, 76.9, 74.7, 
74.3, 73.6, 73.5, 71.0, 70.2, 67.2, 67.1, 60.9, 36.1, 32.1, 32.0, 29.9, 29.8, 29.8, 29.7, 




18.1, 17.9, 14.3, 14.3, 1.2, -3.7, -3.9. HRMS (Q-ToF): calculated for 





Disaccharide 3-40 (32 mg, 24 μmol, 1.0 eq.) was dissolved in a mixed solvent of 
DCM (0.4 mL) and MeOH (0.4 mL). CSA (56 mg, 240 μmol, 10 eq.) was added to the 
solution and the mixture was stirred at r.t. for 48h. TLC showed a full conversion of the 
starting material. The reaction was quenched with TEA and concentrated in vacuo. The 
crude product was extracted with EtOAc, washed with water and brine, dried with 
Na2SO4(s), concentrated again and purified with FC to get 3-41 (22 mg, 18 μmol, yield: 
75%). 1H NMR (600 MHz, Chloroform-d) δ 7.92 (t, J = 6.3 Hz, 2H), 7.50 (t, J = 7.4 Hz, 
1H), 7.46 – 7.27 (m, 14H), 7.25 – 7.23 (m, 1H), 7.21 – 7.07 (m, 7H), 6.91 (d, J = 7.0 Hz, 
1H), 6.60 (d, J = 8.5 Hz, 1H), 5.41 (d, J = 30.1 Hz, 1H), 5.36 – 5.30 (m, 2H), 5.28 (d, J 
= 12.9 Hz, 1H), 5.21 – 5.07 (m, 4H), 4.86 (d, J = 8.3 Hz, 1H), 4.69 (d, J = 11.4 Hz, 1H), 
4.62 (d, J = 11.5 Hz, 1H), 4.57 – 4.48 (m, 1H), 4.42 – 4.35 (m, 2H), 4.32 (t, J = 9.3 Hz, 
1H), 4.12 – 3.96 (m, 3H), 3.87 (t, J = 8.9 Hz, 1H), 3.82 – 3.76 (m, 2H), 3.62 (d, J = 32.2 
Hz, 4H), 3.43 (ddd, J = 26.5, 14.1, 7.4 Hz, 3H), 3.37 – 3.26 (m, 1H), 3.10 – 2.92 (m, 
3H), 2.32 (dq, J = 13.8, 7.2 Hz, 1H), 2.21 (t, J = 7.7 Hz, 1H). 13C NMR (151 MHz, 
Chloroform-d) δ 168.0, 165.1, 163.2, 162.7, 137.5, 135.5, 133.5, 130.2, 129.9, 129.8, 
129.6, 128.9, 128.7, 128.6, 128.6, 128.6, 128.4, 128.1, 127.9, 127.8, 124.4, 99.1, 81.8, 
77.4, 77.2, 76.9, 75.5, 74.5, 73.3, 73.0, 71.6, 70.4, 67.2, 60.1, 60.1, 39.9, 36.1, 32.1, 
32.1, 29.9, 29.9, 29.8, 29.8, 29.7, 29.5, 29.5, 29.4, 29.4, 29.3, 29.0, 28.8, 28.4, 27.4, 
27.3, 26.9, 26.8, 25.7, 22.8, 19.3, 17.9, 14.3, 13.9. HRMS (Q-ToF): calculated for 








Selenoglycoside 3-20L (1.99 g, 4.5 mmol, 1.0 eq.) was dissolved in EtOH 
(25 mL). NH4Cl (477 mg, 9.0 mmol, 2.0 eq.) and activated zinc power (439 mg, 
6.8 mmol, 1.5 eq.) were added into the solution. The mixture was stirred at r.t. until 
TLC showed a full conversion of the starting material. The mixture was filtrated, and 
EtOH was removed in vacuo. Further purification gave the product 3-44L (1.86 g, 
4.5 mmol, yield 99%). 1H NMR (400 MHz, Chloroform-d) δ 7.64 – 7.56 (m, 2H), 7.29 
– 7.23 (m, 4H), 5.88 (d, J = 4.7 Hz, 1H), 4.33 (qd, J = 6.6, 1.5 Hz, 1H), 3.64 (dd, J = 3.3, 
1.4 Hz, 1H), 3.54 (dd, J = 9.8, 3.3 Hz, 1H), 3.32 (dd, J = 9.8, 4.7 Hz, 1H), 2.40 (s, 1H), 
1.47 (d, J = 6.6 Hz, 2H), 1.32 (d, J = 6.5 Hz, 3H), 0.94 (s, 9H), 0.17 (d, J = 8.9 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 134.0, 129.8, 129.2, 127.5, 91.2, 90.8, 77.5, 77.4, 
77.2, 76.8, 75.5, 71.8, 69.1, 52.4, 25.9, 18.2, 16.4, -4.2, -4.3. HRMS (Q-ToF): 





Selenoglycoside 3-44L (1408 mg, 3.38 mmol, 1.0 eq.) was dissolved in a mixed 
solvent of water (6 mL) and DCM (24 mL). NaHCO3 (426 mg, 5.08 mmol, 1.5 eq.) and 
TCACl (570 µL, 5.08 mmol, 1.5 eq.) were added and stirred at r.t. for 30 min. After 
TCL showed a full conversion of the starting material, the mixture was extracted with 
EtOAc, washed with HCl (1 M aq.), NaHCO3 (sat. aq.) and brine, dried with Na2SO4(s) 
and concentrated in vacuo, the crude product was further purified with FC to get 3-45L 
(1663 mg, 2.96 mmol, yield: 86%). 1H NMR (400 MHz, Chloroform-d) δ 7.60 – 7.52 




4.47 (m, 1H), 4.35 – 4.20 (m, 1H), 3.72 (d, J = 9.0 Hz, 2H), 2.51 (t, J = 1.2 Hz, 1H), 
1.41 (d, J = 6.5 Hz, 3H), 0.91 (s, 9H), 0.16 (d, J = 0.8 Hz, 6H). 13C NMR (101 MHz, 
Chloroform-d) δ 161.5, 134.1, 134.1, 129.5, 128.9, 128.2, 92.4, 90.1, 77.4, 77.3, 77.1, 
76.7, 71.8, 71.6, 70.0, 52.4, 25.7, 17.9, 16.3, -4.3, -4.7. HRMS (Q-ToF): calculated for 





Selenoglycoside 3-45L (496 mg, 883 µmol, 1.0 eq.) was dissolved in DCM (5 
mL). Pyridine (0.43 mL, 5.3 mmol, 6.0 eq.) and Tf2O (0.18 mL, 1.06 mmol, 1.2 eq.) 
were added sequentially at -10 °C (salt-ice-water bath) and the temperature was slowly 
raised to r.t.. After TLC showed full conversion of 3-45L, the mixture was evaporated 
in vacuo and then dissolved in anhydrous DMF. NaN3 (574 mg, 8.83 mmol, 10.0 eq.) 
was added and the mixture was stirred overnight. The crude product was extracted with 
EtOAc, washed with H2O and brine, dried with Na2SO4(s), evaporated in vacuo and 
purified by FC to obtain 3-46L (478 mg, 814 µmol, yield: 92%). 1H NMR (600 MHz, 
Chloroform-d) δ 7.94 (d, J = 7.7 Hz, 2H), 7.51 (t, J = 7.4 Hz, 1H), 7.46 – 7.39 (m, 4H), 
7.39 – 7.27 (m, 9H), 7.25 – 7.08 (m, 8H), 6.76 (d, J = 5.8 Hz, 1H), 5.36 – 5.31 (m, 1H), 
5.29 (d, J = 12.5 Hz, 1H), 5.17 (d, J = 12.6 Hz, 1H), 5.13 (d, J = 8.8 Hz, 2H), 4.68 – 
4.61 (m, 3H), 4.53 (dd, J = 27.2, 7.2 Hz, 1H), 4.37 (d, J = 22.7 Hz, 2H), 4.28 (t, J = 9.2 
Hz, 1H), 4.07 (d, J = 9.5 Hz, 1H), 3.89 (t, J = 9.0 Hz, 1H), 3.84 – 3.74 (m, 1H), 3.52 – 
3.41 (m, 2H), 3.33 (d, J = 37.5 Hz, 1H), 3.13 (d, J = 19.8 Hz, 1H), 3.09 – 2.89 (m, 3H), 
2.77 (t, J = 9.1 Hz, 1H). 13C NMR (151 MHz, Chloroform-d) δ 167.9, 165.1, 163.5, 
137.4, 135.5, 133.5, 129.8, 129.6, 128.9, 128.8, 128.7, 128.6, 128.6, 128.6, 128.3, 128.2, 
128.0, 127.6, 101.1, 99.3, 81.9, 77.4, 77.2, 76.9, 75.3, 74.4, 72.8, 70.9, 70.0, 68.5, 67.2, 
67.1, 59.2, 29.8, 29.0, 23.1, 18.6, 18.3. HRMS (Q-ToF): calculated for 









Donor 3-46L (128 mg, 218 µmol, 1.1 eq.) and acceptor 3-9 (116 mg, 198 µmol, 
1.0 eq.) were coevaporated with toluene for three times and put under high vacuum 
overnight to remove trace water in them. The starting materials were dissolved in 
anhydrous DCM (2 mL), 4 Å molecular sieves were added and the suspension was 
stirred at -20 °C for 5 min. NIS (67 mg, 297 µmol, 1.5 eq.) and TfOH (3.5 µL, 40 µmol, 
0.2 eq.) were added and the resultant mixture was stirred at that temperature until TLC 
showed a full conversion of the donor. The reaction was quenched with Na2S2O3(aq.), 
extracted with EtOAc, washed with Na2S2O3(aq.) and brine, dried with Na2SO4(s), 
concentrated and purified with FC to get 3-47 (183 mg, 180 µmmol, yield: 83%). 1H 
NMR (600 MHz, Chloroform-d) δ 8.05 – 7.98 (m, 2H), 7.62 – 7.55 (m, 1H), 7.47 – 7.37 
(m, 6H), 7.35 – 7.30 (m, 1H), 7.24 – 7.18 (m, 5H), 6.91 – 6.85 (m, 2H), 6.76 – 6.68 (m, 
2H), 6.31 (d, J = 8.9 Hz, 1H), 5.55 (dd, J = 8.4, 7.0 Hz, 1H), 5.35 (d, J = 12.6 Hz, 1H), 
5.08 (d, J = 12.6 Hz, 1H), 5.06 (d, J = 7.0 Hz, 1H), 4.74 (d, J = 8.4 Hz, 1H), 4.73 – 4.66 
(m, 2H), 4.41 (t, J = 8.8 Hz, 1H), 4.20 (d, J = 9.2 Hz, 1H), 3.91 (t, J = 8.4 Hz, 1H), 3.73 
(s, 3H), 3.46 (q, J = 9.0 Hz, 1H), 3.34 (t, J = 9.3 Hz, 1H), 3.07 (dq, J = 9.9, 6.1 Hz, 1H), 
2.51 (t, J = 9.3 Hz, 1H), 1.23 (d, J = 6.1 Hz, 3H), 0.88 (s, 9H), 0.13 (s, 3H), -0.01 (s, 
3H), -0.03 (s, 3H). 13C NMR (151 MHz, Chloroform-d) δ 207.1, 167.7, 165.2, 161.7, 
155.8, 151.2, 138.0, 135.7, 133.6, 129.9, 129.6, 128.8, 128.7, 128.6, 128.5, 128.1, 128.0, 
127.5, 119.2, 114.6, 100.7, 98.8, 92.6, 82.2, 77.4, 77.2, 76.9, 74.6, 74.4, 73.5, 73.1, 72.7, 
70.9, 70.5, 66.9, 59.2, 58.6, 55.7, 53.6, 31.1, 25.9, 18.6, 18.4, 18.1, 1.2, -4.2, -4.4. 








glucopyranosyluronoyl) N-phenyltrifluoroacetimidate (3-49) 
 
Disaccharide 3-47 (47 mg, 46 µmol, 1.0 eq.) was dissolved in a mixed solvent of 
MeCN (1 mL) and H2O (0.5 mL). CAN (76 mg, 139 µmol, 3.0 eq.) was added and the 
mixture was stirred at r.t.. Color of the mixture turned orange. The reaction was 
monitored by TLC and as soon as the starting material was fully hydrolyzed, the 
reaction was quenched with TEA. The product was extracted with EtOAc, washed with 
water and brine, dried with Na2SO4(s), concentrated and purified with FC to get 3-48 
(38 mg, 42 µmmol, yield: 90%). Disaccharide 3-48 (37 mg, 41 μmol, 1.0 eq.) and 
trifluoro-N-phenylacetimidoyl chloride (40 μL, 244 µmol, 6.0 eq.) were dissolved in 
DCM (1 mL), the solvent was cooled to 0 °C (ice-water bath) and DBU (18 μL, 
122 μmol, 3.0 eq.) was added. The mixture was stirred at r.t. until TLC showed a full 
conversion of the starting material. After evaporation, the crude product was further 
purified by FC to get yellowish syrup 3-49 (38 mg, 35 μmol, yield: 90%). 1H NMR (400 
MHz, Chloroform-d) δ 8.06 – 7.97 (m, 2H), 7.64 – 7.57 (m, 1H), 7.13 – 7.04 (m, 1H), 
6.72 (d, J = 7.8 Hz, 2H), 6.28 (d, J = 8.5 Hz, 1H), 5.52 (t, J = 6.1 Hz, 1H), 5.37 (d, J = 
12.7 Hz, 1H), 5.12 (d, J = 12.7 Hz, 1H), 4.80 (d, J = 8.3 Hz, 1H), 4.69 (q, J = 11.7 Hz, 
2H), 4.44 (d, J = 7.4 Hz, 1H), 4.12 (q, J = 7.1 Hz, 3H), 3.88 (s, 1H), 3.46 (t, J = 9.3 Hz, 
1H), 3.36 (h, J = 8.5 Hz, 1H), 3.11 (dq, J = 12.1, 6.1 Hz, 1H), 2.48 (dd, J = 10.0, 8.6 Hz, 
1H), 2.05 (s, 4H), 1.30 – 1.19 (m, 9H), 0.87 (s, 9H), 0.13 (s, 3H), 0.07 (s, 2H), -0.03 (s, 
3H). HRMS (Q-ToF): calculated for C49H53Cl3F3N5O11SiNa+ [M+Na]+ 1100.2421, 











The donor 3-46 (20 mg, 18.5 μmol, 1.0 eq.) and the acceptor 3-7 (12 mg, 
37.0 μmol, 2.0 eq.) were coevaporated three times with anhydrous toluene and put 
under high vacuum overnight to remove trace water inside. The mixture was dissolved 
in DCM (1 mL) and 4 Å MS was added. After being stirred for 15 min, the mixture was 
cooled to -10 °C and TMSOTf (1.2 μL, 7.4 μmol, 0.4 eq.) was added and the resultant 
mixture continued to be stirred until TLC showed a full conversion of the starting 
material. The reaction was quenched with Na2S2O3(aq.), extracted with EtOAc, washed 
with Na2S2O3(aq.) and brine, dried with Na2SO4(s), and further purified with FC to get 
3-50 (18 mg, 14.8 μmol, yield: 80%). 1H NMR (600 MHz, Chloroform-d) δ 7.99 – 7.90 
(m, 2H), 7.50 (t, J = 7.4 Hz, 1H), 7.46 (d, J = 7.5 Hz, 2H), 7.41 (t, J = 7.5 Hz, 2H), 7.39 
– 7.27 (m, 9H), 7.25 – 7.16 (m, 8H), 7.11 (d, J = 7.2 Hz, 1H), 6.29 (d, J = 9.1 Hz, 1H), 
5.38 (d, J = 12.8 Hz, 1H), 5.30 (d, J = 1.0 Hz, 7H), 5.17 – 5.08 (m, 4H), 4.69 – 4.61 (m, 
3H), 4.52 (d, J = 20.3 Hz, 1H), 4.43 – 4.31 (m, 2H), 4.26 (t, J = 9.0 Hz, 1H), 4.06 (d, J 
= 9.6 Hz, 1H), 3.84 (d, J = 8.7 Hz, 1H), 3.72 (q, J = 7.0 Hz, 12H), 3.48 (q, J = 9.2, 8.0 
Hz, 1H), 3.40 – 3.24 (m, 2H), 3.08 – 2.92 (m, 3H), 2.46 (t, J = 9.4 Hz, 1H), 0.12 (s, 3H), 
0.07 (d, J = 1.1 Hz, 9H). MS (MALDI-ToF) calculated for C61H72Cl3N5O13SiNa+ 









Disaccharide 3-50 (15 mg, 12 µmol, 1.0 eq.) was dissolved in THF (1.0 mL). 
TBAF (1 M in THF, 14 µL, 14 µmol, 1.2 eq.) was added dropwise and the solution was 
stirred at r.t. until TLC showed a full conversion of the starting material. The product 
was extracted with EtOAc, washed with H2O and brine, dried with Na2SO4(s), 
concentrated and purified with FC to obtain 3-51 (10 mg, 9 µmol, yield: 74%). 1H NMR 
(600 MHz, Chloroform-d) δ 7.94 (d, J = 7.7 Hz, 2H), 7.51 (t, J = 7.4 Hz, 1H), 7.46 – 
7.39 (m, 4H), 7.39 – 7.27 (m, 9H), 7.25 – 7.08 (m, 8H), 6.76 (d, J = 5.8 Hz, 1H), 5.36 – 
5.31 (m, 1H), 5.29 (d, J = 12.5 Hz, 1H), 5.17 (d, J = 12.6 Hz, 1H), 5.13 (d, J = 8.8 Hz, 
2H), 4.68 – 4.61 (m, 3H), 4.53 (dd, J = 27.2, 7.2 Hz, 1H), 4.37 (d, J = 22.7 Hz, 2H), 
4.28 (t, J = 9.2 Hz, 1H), 4.07 (d, J = 9.5 Hz, 1H), 3.89 (t, J = 9.0 Hz, 1H), 3.84 – 3.74 
(m, 1H), 3.52 – 3.41 (m, 2H), 3.33 (d, J = 37.5 Hz, 1H), 3.13 (d, J = 19.8 Hz, 1H), 3.09 
– 2.89 (m, 3H), 2.77 (t, J = 9.1 Hz, 1H). 13C NMR (151 MHz, Chloroform-d) δ 167.9, 
165.1, 163.5, 137.4, 135.5, 133.5, 129.8, 129.6, 128.9, 128.8, 128.7, 128.6, 128.6, 128.6, 
128.3, 128.2, 128.0, 127.6, 101.1, 99.3, 81.9, 77.4, 77.2, 76.9, 75.3, 74.4, 72.8, 70.9, 
70.0, 68.5, 67.2, 67.1, 59.2, 29.8, 29.0, 23.1, 18.6, 18.3. HRMS (Q-ToF) calculated for 












The donor 3-51 (10 mg, 9 μmol, 1.5 eq.) and the acceptor 3-49 (7 mg, 6 μmol, 
1.0 eq.) were coevaporated three times with anhydrous toluene and put under high 
vacuum overnight to remove trace water inside. The mixture was dissolved in DCM 
(1 mL) and 4 Å MS was added. After being stirred for 15 min, the mixture was cooled 
to -10 °C and TMSOTf (0.5 μL, 3 μmol, 0.5 eq.) was added and the resultant mixture 
continued to be stirred until TLC showed a full conversion of the starting material. The 
reaction was quenched with Na2S2O3(aq.), extracted with EtOAc, washed with 
Na2S2O3(aq.) and brine, dried with Na2SO4(s), and further purified with FC to get 10 mg 
3-52. But the spectra were not clean. Further purification by prep TLC gave much 
cleaner 3-52 (2.5 mg, 1.25 μmol, yield: 20%). 1H NMR (600 MHz, Chloroform-d) δ 
8.11 – 8.04 (m, 2H), 7.93 – 7.85 (m, 2H), 7.60 (td, J = 7.4, 1.4 Hz, 1H), 7.51 – 7.28 (m, 
20H), 7.24 – 7.04 (m, 16H), 6.98 (d, J = 6.2 Hz, 1H), 6.91 – 6.83 (m, 1H), 6.25 (d, J = 
9.2 Hz, 1H), 5.40 – 5.31 (m, 3H), 5.30 (d, J = 1.4 Hz, 1H), 5.26 (td, J = 8.1, 7.4, 1.3 Hz, 
1H), 5.21 (t, J = 8.3 Hz, 1H), 5.15 – 5.09 (m, 3H), 5.05 (t, J = 12.4 Hz, 2H), 4.89 (dd, J 
= 7.4, 1.2 Hz, 1H), 4.67 (d, J = 11.3 Hz, 1H), 4.66 – 4.58 (m, 4H), 4.53 (d, J = 11.4 Hz, 
1H), 4.51 – 4.44 (m, 1H), 4.37 (d, J = 9.0 Hz, 2H), 4.25 (ddd, J = 6.9, 3.9, 1.5 Hz, 4H), 
4.20 – 4.13 (m, 2H), 4.08 (d, J = 9.6 Hz, 2H), 3.82 (td, J = 8.5, 1.2 Hz, 1H), 3.78 (t, J = 
8.9 Hz, 2H), 3.71 – 3.68 (m, 4H), 3.64 (d, J = 1.2 Hz, 4H), 3.49 (t, J = 6.9 Hz, 2H), 3.40 
(q, J = 9.2 Hz, 1H), 3.36 – 3.26 (m, 1H), 3.23 (q, J = 9.8, 8.2 Hz, 1H), 3.08 – 2.88 (m, 




Chloroform-d) δ 176.5, 168.0, 167.5, 164.9, 162.6, 161.7, 137.8, 135.9, 135.4, 133.7, 
133.3, 130.1, 129.9, 129.8, 129.3, 129.0, 128.8, 128.8, 128.7, 128.6, 128.5, 128.4, 128.3, 
128.3, 128.3, 128.1, 128.0, 128.0, 127.8, 127.5, 100.9, 100.0, 98.7, 82.7, 82.4, 77.4, 
77.2, 76.9, 75.4, 74.9, 74.4, 74.2, 74.1, 73.9, 73.4, 73.2, 72.7, 70.9, 70.7, 70.2, 69.5, 
68.0, 67.2, 66.9, 66.4, 63.2, 58.9, 56.4, 47.3, 32.1, 32.1, 31.9, 29.9, 29.8, 29.8, 29.7, 
29.7, 29.5, 29.5, 29.4, 29.3, 29.0, 27.4, 25.9, 25.9, 25.6, 22.8, 22.8, 18.3, 18.1, 17.9, 
14.3, 14.1, 11.9, 1.2, -4.3, -4.5. HRMS (Q-ToF) calculated for C96H105Cl6N9O23SiNa+ 
[M+Na]+ 2012.5116, found 2012.5253 m/z. 
 
Phenyl 2-azido-6-iodo-2,6-di-deoxy-1-seleno-α-D-galactopyranoside (3-55) 
 
Selenoglycoside 3-53 (426 mg, 1235 µmol, 1.0 eq.) was dissolved in anhydrous 
pyridine (12 mL). TsCl (307 mg, 1605 µmol, 1.3 eq.) was added and the solution was 
stirred at r.t. overnight until TLC showed a full conversion of the starting material. Most 
of the solvent was removed by evaporation and the crude product was purified by FC to 
get 3-54 (466 mg, 934 µmol, yield: 76%). 3-54 was used in the next step without further 
characterization. 3-54 (460 mg, 922 µmol, 1.0 eq.) was dissolved in anhydrous acetone 
(30 mL). NaI (691 mg, 4609 µmol, 5.0 eq.) was added and the solution was stirred and 
fluxed overnight. The solvent was removed by evaporation and further purification by 
FC gave 3-55 (315 mg, 692 µmol, yield: 75%). 1H NMR (400 MHz, Chloroform-d) δ 
7.69 – 7.58 (m, 2H), 7.31 (dd, J = 5.2, 2.0 Hz, 3H), 5.93 (d, J = 5.3 Hz, 1H), 4.40 (t, J = 
7.2 Hz, 1H), 4.28 (td, J = 3.4, 1.5 Hz, 1H), 4.09 (dd, J = 10.3, 5.3 Hz, 1H), 3.78 (ddd, J 
= 10.3, 5.4, 3.2 Hz, 1H), 3.38 (dd, J = 10.1, 7.8 Hz, 1H), 3.19 (dd, J = 10.1, 6.5 Hz, 1H), 
2.60 (d, J = 5.5 Hz, 1H), 2.41 (d, J = 3.4 Hz, 1H). 13C NMR (101 MHz, Chloroform-d) 
δ 134.6, 129.4, 128.3, 128.2, 85.2, 77.5, 77.4, 77.2, 76.8, 73.2, 71.2, 68.8, 61.6, 1.2. 
LCMS (ESI) calculated for C12H14IN3O3SeNa+ [M+NH4]+ 477.9, found 477.5 m/z. Data 





Phenyl 2-azido-2,6-di-deoxy-1-seleno-α-D-galactopyranoside (3-19) 
 
Selenoglycoside 3-55 (112 mg, 246 µmol, 1.0 eq.) was dissolved in anhydrous 
DMF (5 mL) and NaCNBH3 (77 mg, 1231 µmol, 5.0 eq.) was added to the solution. The 
mixture was stirred and refluxed for 20 h and TLC showed a full conversion of the 
starting material. The product was extracted with EtOAc and washed with water and 
brine. After each wash, the product was extracted several times until TLC showed its 
disappearance from the aq. phase. Organic layers were combined, dried with Na2SO4(s), 
filtrated, concentrated and further purified with FC to get 3-19 (64 mg, 195 µmol, yield: 
80%). 1H NMR (400 MHz, Chloroform-d) δ 7.66 – 7.54 (m, 2H), 7.30 (hd, J = 4.8, 1.7 
Hz, 3H), 5.91 (d, J = 5.3 Hz, 1H), 4.39 (qd, J = 6.6, 1.4 Hz, 1H), 4.05 (dd, J = 10.1, 5.3 
Hz, 1H), 3.84 (d, J = 3.3 Hz, 1H), 3.80 (dd, J = 10.2, 3.3 Hz, 1H), 2.68 (s, 1H), 2.34 (s, 
1H), 1.27 (d, J = 6.6 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 134.6, 129.3, 
128.0, 85.1, 77.5, 77.4, 77.2, 76.8, 71.6, 71.4, 68.8, 62.0, 16.1. LCMS (ESI) calculated 
for C12H15N3O3SeNa+ [M+NH4]+ 352.0, found 352.0 m/z. [α]D
25 = 274.43°. Data 





Imidate 3-17 was prepared according to known procedure, starting from β-D-
glucose pentaacetate. The anomeric acetate of the starting material was selectively 
hydrolysed with N2H4·AcOH and following coupling with trifluoro-N-





4-Methoxyphenyl 6-O-triisopropylsilyl-β-D-galactopyranoside (3-59) 
 
Monosaccharide 3-57 was prepared according to known procedure.112 Starting 
material 3-57 (3.69 g, 8.13 mmol, 1.0 eq.) was dissolved in MeOH (80 mL) and MeONa 
(44 mg, 0.8 mmol, 0.1 eq.) was added to the solution. The mixture was stirred at r.t. 
until LC-MS showed a full conversion of the starting material to get 3-58. Amberlite(H+) 
was added to the mixture to adjust the pH to 7. After filtration, 3-58 was concentrated in 
vacuo and put under high vacuum overnight. Crude 3-58 (1.52 g, 5.3 mmol, 1.0 eq.) 
from the previous step was dissolved in anhydrous DMF (25 mL). Imidazole (722 mg, 
10.6 mmol, 2.0 eq.) and TIPSCl (1.7 mL, 8.0 mmol, 1.5 eq.) was added and the mixture 
was stirred until TLC showed a full conversion of the starting material. The mixture was 
evaporated in vacuo to remove most of DMF and further purified with FC to obtain 
3-59 (2.286 g, 5.16 mmol, 97% for 2 steps). 1H NMR (400 MHz, Chloroform-d) δ 7.07 
– 6.98 (m, 2H), 6.87 – 6.75 (m, 2H), 4.74 (d, J = 7.8 Hz, 1H), 4.14 (s, 1H), 4.01 (tt, J = 
10.4, 5.4 Hz, 2H), 3.97 – 3.88 (m, 1H), 3.77 (s, 3H), 3.73 – 3.65 (m, 1H), 3.60 (t, J = 
5.4 Hz, 1H), 3.08 (s, 1H), 2.90 (s, 1H), 2.72 (s, 1H), 1.25 (s, 3H), 1.05 (d, J = 6.0 Hz, 
19H). 13C NMR (101 MHz, Chloroform-d) δ 155.6, 151.3, 118.9, 114.6, 102.5, 77.5, 
77.2, 76.8, 74.8, 73.8, 72.0, 69.2, 63.3, 55.8, 32.1, 29.8, 29.8, 29.5, 22.8, 18.1, 18.0, 






Starting material 3-59 (1389 mg, 3.14 mmol, 1.0 eq.) was dissolved in 
anhydrous acetonitrile (15 mL). 2,2-DMP (0.77 mL, 6.27 mmol, 2.0 eq.) and CSA 




showed a full conversion of the starting material. The reaction was quenched with TEA, 
concentrated in vacuo and purified by FC to get 3-16 (1105 mg, 2.29 mmol, yield: 73%). 
1H NMR (400 MHz, Chloroform-d) δ 7.07 – 6.98 (m, 2H), 6.80 (dd, J = 9.0, 1.7 Hz, 
2H), 4.65 (dd, J = 8.3, 1.5 Hz, 1H), 4.27 (dd, J = 5.4, 2.0 Hz, 1H), 4.14 (dd, J = 7.4, 5.3 
Hz, 1H), 4.04 – 3.88 (m, 3H), 3.81 (t, J = 7.8 Hz, 1H), 3.76 (d, J = 1.6 Hz, 3H), 1.55 (s, 
3H), 1.35 (s, 3H), 1.06 (d, J = 5.9 Hz, 18H). 13C NMR (101 MHz, Chloroform-d) δ 
155.5, 151.3, 118.7, 114.6, 110.4, 102.0, 78.8, 78.7, 77.5, 77.2, 76.8, 74.4, 73.7, 73.3, 
62.6, 55.7, 28.4, 26.4, 18.1, 18.1, 12.0. HRMS (Q-ToF): calculated for C25H42O7SiNa+ 





The donor 3-17 (372 mg, 770 μmol, 1.5 eq.) and the acceptor 3-16 (423 mg, 
815 μmol, 1.05 eq.) were coevaporated three times with anhydrous toluene and put 
under high vacuum overnight to remove trace water inside. The mixture was dissolved 
in DCM (1 mL) and 4 Å MS was added. After being stirred for 15 min, the mixture was 
cooled to -0 °C and TMSOTf (0.5 μL, 3 μmol, 0.5 eq.) was added and the resultant 
mixture continued to be stirred until TLC showed full conversion of the starting 
material. The reaction was quenched with Na2S2O3(aq.), extracted with EtOAc, washed 
with Na2S2O3(aq.) and brine, dried with Na2SO4(s), and further purified with FC to get 
3-60 (515 mg, 633 µmol, yield: 82%). 1H NMR (400 MHz, Chloroform-d) δ 7.04 – 6.95 
(m, 2H), 6.82 – 6.73 (m, 2H), 5.24 (t, J = 9.4 Hz, 1H), 5.10 (t, J = 9.7 Hz, 1H), 5.01 (td, 
J = 9.5, 8.8, 2.1 Hz, 1H), 4.89 (dd, J = 7.9, 2.1 Hz, 1H), 4.79 (dd, J = 7.9, 2.1 Hz, 1H), 
4.26 – 4.21 (m, 1H), 4.15 (tt, J = 12.3, 5.3 Hz, 2H), 4.01 – 3.88 (m, 2H), 3.88 – 3.78 (m, 
3H), 3.75 (d, J = 1.3 Hz, 3H), 3.71 – 3.62 (m, 1H), 2.08 (d, J = 2.1 Hz, 3H), 2.00 (d, J = 




18H). 13C NMR (101 MHz, Chloroform-d) δ 170.8, 170.5, 169.7, 169.5, 155.4, 151.3, 
118.7, 117.0, 114.5, 110.2, 101.4, 100.9, 81.9, 78.6, 77.5, 77.4, 77.2, 76.8, 73.8, 73.1, 
72.9, 72.1, 71.8, 68.4, 62.5, 61.8, 60.5, 55.7, 36.7, 29.8, 28.2, 26.4, 20.9, 20.8, 20.7, 
18.1, 18.0, 14.3, 12.3, 12.0, 11.7, 1.1. HRMS (Q-ToF): calculated for C39H60O16SiNa+ 





Disaccharide 3-60 (502 mg, 617 µmol, 1.0 eq.) was dissolved in THF (6 mL). 
AcOH (35 µL, 617 µmol, 1.0 eq.) and TBAF (1 M in THF, 617 µL, 617 µmol, 1.0 eq.) 
were added sequentially and the mixture was stirred at r.t. until TLC showed a full 
conversion of the starting material. The solvent was removed in vacuo and the mixture 
was extracted with EtOAc. After being washed with water, NaHCO3 (sat. aq.), and brine, 
dried with Na2SO4(s) and concentration in vacuo, the crude product was further purified 
by CF to give 3-61 (378 mg, 575 µmol, yield: 93%). 1H NMR (400 MHz, Chloroform-d) 
δ 6.96 (dd, J = 8.8, 1.7 Hz, 2H), 6.84 – 6.75 (m, 2H), 5.24 (td, J = 9.4, 1.6 Hz, 1H), 5.09 
(t, J = 9.7 Hz, 1H), 5.06 – 4.97 (m, 1H), 4.87 (t, J = 8.7 Hz, 2H), 4.22 – 4.12 (m, 3H), 
4.00 – 3.77 (m, 5H), 3.76 (d, J = 1.6 Hz, 3H), 3.66 (ddd, J = 10.2, 4.3, 2.3 Hz, 1H), 2.08 
(d, J = 1.6 Hz, 3H), 2.00 (d, J = 1.6 Hz, 6H), 1.97 (d, J = 1.7 Hz, 3H), 1.55 (d, J = 9.9 
Hz, 3H), 1.33 (s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 170.8, 170.5, 169.7, 169.5, 
155.5, 151.0, 118.4, 114.7, 110.7, 101.4, 100.5, 81.7, 78.7, 77.5, 77.4, 77.2, 76.8, 73.6, 








Disaccharide 3-60 (515 mg, 633 µmol, 1.0 eq.) was dissolved in MeOH (12 mL). 
MeONa (5 M in THF) was added and the pH was adjusted to around 11. After TLC 
showed a full conversion of the starting material, Amberlite(H+) was added to the 
mixture and the pH was adjusted to 7. After filtration and removal of the solvent, 3-66 
was obtained (316 mg, 490 µmol, yield: 78%). 1H NMR (700 MHz, Chloroform-d) δ 
7.00 (dd, J = 8.7, 4.7 Hz, 2H), 6.79 (dd, J = 9.0, 4.7 Hz, 2H), 4.78 (dd, J = 8.3, 4.5 Hz, 
1H), 4.69 (dd, J = 7.8, 4.4 Hz, 1H), 4.26 (d, J = 4.7 Hz, 2H), 4.01 – 3.93 (m, 2H), 3.92 – 
3.84 (m, 3H), 3.75 (d, J = 4.6 Hz, 3H), 3.73 – 3.68 (m, 2H), 3.60 (t, J = 7.1 Hz, 2H), 
3.45 (q, J = 8.2, 7.1 Hz, 1H), 3.41 – 3.33 (m, 1H), 2.66 (s, 1H), 1.76 (s, 2H), 1.34 (d, J = 
4.6 Hz, 3H), 1.13 – 1.08 (m, 3H), 1.05 (d, J = 6.6 Hz, 18H). 13C NMR (176 MHz, 
Chloroform-d) δ 155.6, 151.4, 118.6, 114.7, 110.8, 104.1, 101.1, 81.1, 78.5, 77.3, 77.2, 
77.0, 76.1, 74.7, 73.9, 73.3, 70.1, 62.5, 62.1, 55.8, 28.0, 26.3, 18.1, 18.1, 12.0. HRMS 





Disaccharide 3-66 (316 mg, 490 µmol, 1.0 eq.) was dissolved in anhydrous 
DMF (5 mL). The mixture was cooled to 0 °C and NaH (60% in mineral oil, 158 mg, 
3.92 mmol, 8.0 eq.) was added to the mixture. BnBr (0.47 mL, 3.92 mmol, 8.0 eq.) was 
added dropwise, the cooling bath was removed and the mixture was stirred overnight. 




with MeOH. Most of the solvent was removed by evaporation in vacuo and the residue 
was extracted with EtOAc, washed with water and brine, dried by Na2SO4(s), 
concentrated and further purified by FC to obtain 3-67 (417 mg, 415 µmol, yield: 85%). 
1H NMR (600 MHz, Chloroform-d) δ 7.42 – 7.35 (m, 2H), 7.31 – 7.26 (m, 11H), 7.26 – 
7.22 (m, 5H), 7.13 (dd, J = 7.4, 2.1 Hz, 2H), 6.97 – 6.90 (m, 2H), 6.75 – 6.68 (m, 2H), 
5.01 (d, J = 11.0 Hz, 1H), 4.99 (d, J = 7.3 Hz, 1H), 4.92 (d, J = 10.9 Hz, 1H), 4.83 – 
4.79 (m, 2H), 4.78 (d, J = 8.4 Hz, 1H), 4.73 (d, J = 11.0 Hz, 1H), 4.53 (d, J = 3.6 Hz, 
1H), 4.52 (d, J = 2.0 Hz, 1H), 4.34 (d, J = 12.3 Hz, 1H), 4.31 (t, J = 5.9 Hz, 1H), 4.26 
(dd, J = 5.9, 1.8 Hz, 1H), 4.04 (dd, J = 7.2, 5.9 Hz, 1H), 3.98 (dd, J = 9.8, 6.6 Hz, 1H), 
3.94 (dd, J = 9.8, 6.2 Hz, 1H), 3.87 (td, J = 6.4, 1.9 Hz, 1H), 3.73 (s, 3H), 3.71 (d, J = 
9.5 Hz, 1H), 3.65 (t, J = 9.1 Hz, 1H), 3.55 (dd, J = 11.0, 3.2 Hz, 1H), 3.47 (dd, J = 9.0, 
7.9 Hz, 1H), 3.29 (dt, J = 9.8, 2.4 Hz, 1H), 3.09 (dd, J = 11.0, 2.0 Hz, 1H), 1.46 (s, 3H), 
1.32 (s, 3H), 1.06 (dd, J = 6.8, 1.9 Hz, 18H). 13C NMR (151 MHz, Chloroform-d) δ 
155.0, 151.4, 138.9, 138.9, 138.4, 138.4, 128.5, 128.4, 128.4, 128.3, 128.1, 128.0, 127.9, 
127.8, 127.7, 127.7, 127.6, 117.8, 114.5, 110.4, 102.7, 100.6, 84.9, 82.7, 79.8, 78.6, 
77.7, 77.4, 77.2, 76.9, 75.8, 75.1, 75.0, 73.7, 73.6, 73.0, 68.0, 62.7, 55.8, 27.8, 26.4, 
18.1, 18.1, 12.1. HRMS (Q-ToF): calculated for C59H76O12SiNa+ [M+Na]+ 1027.4998, 





Disaccharide 3-67 (412 mg, 410 µmol, 1.0 eq.) was dissolved in THF (4 mL). 
TBAF (1 M in THF, 500 µL, 500 µmol, 1.2 eq.) was added and the mixture was stirred 
at r.t. until TLC showed a full conversion of the starting material. The solvent was 
removed in vacuo and the mixture was extracted with EtOAc. After being washed with 
water, NaHCO3 (sat. aq.), and brine, dried with Na2SO4(s) and concentration in vacuo, 




95%). 1H NMR (400 MHz, Chloroform-d) δ 7.38 – 7.31 (m, 2H), 7.29 – 7.18 (m, 17H), 
7.08 (dq, J = 7.8, 2.6 Hz, 2H), 6.90 – 6.83 (m, 2H), 6.74 – 6.66 (m, 2H), 5.04 (d, J = 7.0 
Hz, 1H), 4.96 (dd, J = 11.2, 2.2 Hz, 1H), 4.89 (dd, J = 11.0, 2.2 Hz, 1H), 4.79 – 4.67 (m, 
4H), 4.47 (dd, J = 11.3, 3.9 Hz, 2H), 4.33 – 4.24 (m, 2H), 4.13 (dd, J = 6.1, 1.9 Hz, 1H), 
4.00 (dd, J = 7.0, 5.9 Hz, 1H), 3.95 – 3.85 (m, 2H), 3.81 – 3.72 (m, 1H), 3.69 (s, 3H), 
3.67 (d, J = 9.4 Hz, 1H), 3.61 (dd, J = 10.0, 7.9 Hz, 1H), 3.48 (dd, J = 10.9, 3.1 Hz, 1H), 
3.43 (dd, J = 8.9, 7.9 Hz, 1H), 3.23 (ddd, J = 9.5, 3.1, 1.9 Hz, 1H), 2.99 (dd, J = 10.8, 
2.0 Hz, 1H), 2.05 – 1.97 (m, 1H), 1.42 (s, 3H), 1.29 (s, 3H). 13C NMR (101 MHz, 
Chloroform-d) δ 155.0, 150.9, 138.8, 138.7, 138.3, 138.2, 128.5, 128.5, 128.4, 128.4, 
128.3, 128.1, 128.0, 128.0, 127.9, 127.7, 127.7, 127.7, 117.3, 114.6, 110.8, 102.7, 100.0, 
84.8, 82.6, 79.6, 78.4, 77.5, 77.5, 77.4, 77.2, 76.8, 75.8, 75.1, 75.0, 74.9, 73.5, 73.4, 
73.1, 67.8, 62.6, 55.8, 27.6, 26.3. HRMS (Q-ToF): calculated for C50H56O12Na+ 





Disaccharide 3-68 (318 mg, 375 µmol, 1.0 eq.) was dissolved in a mixed solvent 
of DCM (2 mL) and H2O (1 mL). BAIB (362 mg, 1124 µmol, 3.0 eq.) and TEMPO 
(29 mg, 187 µmol, 0.5 eq.) were added and the mixture was stirred at r.t. until LC-MS 
showed a full conversion of the starting material. The mixture was extracted with 
EtOAc, dried with Na2SO4(s) and purified with FC to get product 3-69 (274 mg, 
317 µmol, yield: 85%). 1H NMR (600 MHz, Chloroform-d) δ 7.43 – 7.08 (m, 21H), 
6.97 (d, J = 8.4 Hz, 2H), 6.75 (d, J = 8.4 Hz, 2H), 5.38 – 5.13 (m, 1H), 4.92 (d, J = 11.0 
Hz, 1H), 4.89 (d, J = 10.9 Hz, 1H), 4.84 – 4.78 (m, 2H), 4.73 (dd, J = 35.6, 9.5 Hz, 2H), 
4.51 (t, J = 11.3 Hz, 3H), 4.34 (d, J = 14.0 Hz, 2H), 4.09 (s, 1H), 3.76 – 3.55 (m, 6H), 
3.40 – 3.31 (m, 1H), 3.29 (s, 1H). 13C NMR (151 MHz, Chloroform-d) δ 155.5, 138.7, 




84.9, 82.5, 77.6, 77.4, 77.2, 76.9, 75.8, 75.1, 75.0, 73.5, 68.2, 55.7. HRMS (Q-ToF): 





Disaccharide 3-69 (209 mg, 242 µmol, 1.0 eq.) was put under high vacuum 
overnight and dissolved in anhydrous DMF (5.0 mL). NaHCO3 (203 mg, 2422 µmol, 
10 eq.) and BnBr (144 µL, 1211 µmol, 5.0 eq.) were added sequentially and the mixture 
was stirred at r.t. until TLC showed the disappearance of the starting material. The 
mixture was filtrated, evaporated and purified with FC to get 3-64 (197 mg, 207 µmol, 
yield: 85%). 1H NMR (400 MHz, Chloroform-d) δ 7.35 (qdt, J = 5.6, 3.3, 2.0 Hz, 7H), 
7.31 – 7.21 (m, 19H), 7.13 (dt, J = 6.6, 2.3 Hz, 2H), 7.03 – 6.97 (m, 2H), 6.77 – 6.70 (m, 
2H), 5.34 (d, J = 12.3 Hz, 1H), 5.22 (d, J = 12.4 Hz, 1H), 5.12 (d, J = 5.8 Hz, 1H), 4.92 
(dd, J = 11.0, 5.2 Hz, 2H), 4.83 – 4.71 (m, 4H), 4.55 – 4.48 (m, 3H), 4.45 (d, J = 2.3 Hz, 
1H), 4.38 (dd, J = 6.3, 5.0 Hz, 1H), 4.33 (d, J = 12.2 Hz, 1H), 4.16 – 4.10 (m, 1H), 3.73 
(s, 3H), 3.70 (d, J = 9.3 Hz, 1H), 3.66 (d, J = 8.8 Hz, 1H), 3.58 (dd, J = 10.9, 3.3 Hz, 
1H), 3.46 (t, J = 8.3 Hz, 1H), 3.32 (ddd, J = 9.5, 3.4, 1.9 Hz, 1H), 3.21 (dd, J = 10.8, 2.0 
Hz, 1H), 1.31 (s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 167.0, 155.3, 151.2, 138.7, 
138.7, 138.2, 138.2, 135.5, 128.6, 128.5, 128.5, 128.5, 128.4, 128.3, 128.1, 128.1, 128.0, 
127.9, 127.9, 127.8, 127.8, 127.7, 118.7, 114.5, 111.0, 103.0, 101.1, 84.8, 82.5, 78.2, 
77.6, 77.5, 77.4, 77.2, 77.0, 76.8, 75.8, 75.1, 75.1, 75.0, 73.6, 73.3, 71.7, 68.0, 67.1, 
55.7, 27.2, 26.0. HRMS (Q-ToF): calculated for C57H60O13Na+ [M+Na]+ 975.3926, 








Disaccharide 3-64 (197 mg, 207 µmol, 1.0 eq.) was dissolved in a mixed solvent 
of AcOH (3.2 mL) and H2O (0.8 mL). The mixture was heated and stirred at 60 °C until 
TLC showed a full conversion of the starting material. The product was extracted with 
EtOAc (100 mL), washed with H2O (100 mL x 2), NaHCO3 (sat. aq., 100 mL) and brine, 
dried with Na2SO4(s), concentrated in vacuo and purified with FC to get 3-70 (100 mg, 
110 µmol, yield: 53%). 1H NMR (400 MHz, Chloroform-d) δ 7.39 – 7.22 (m, 26H), 
7.16 (dd, J = 7.1, 2.5 Hz, 2H), 7.11 – 7.03 (m, 2H), 6.75 – 6.64 (m, 2H), 5.29 (d, J = 
12.3 Hz, 1H), 5.17 (d, J = 12.3 Hz, 1H), 4.94 – 4.82 (m, 5H), 4.79 (d, J = 10.8 Hz, 1H), 
4.68 (d, J = 7.8 Hz, 1H), 4.58 (dd, J = 11.5, 7.3 Hz, 2H), 4.45 (d, J = 12.1 Hz, 1H), 4.28 
(td, J = 3.6, 1.6 Hz, 1H), 4.18 (d, J = 1.5 Hz, 1H), 3.98 (dd, J = 9.0, 7.4 Hz, 1H), 3.43 
(ddd, J = 9.4, 3.7, 1.9 Hz, 1H), 2.53 (d, J = 3.8 Hz, 1H). 13C NMR (101 MHz, 
Chloroform-d) δ 167.5, 155.6, 151.5, 138.4, 138.2, 138.1, 137.7, 135.3, 128.7, 128.7, 
128.6, 128.6, 128.5, 128.4, 128.2, 128.2, 128.1, 128.0, 127.9, 127.9, 127.8, 127.7, 119.5, 
114.4, 104.0, 101.0, 85.3, 82.1, 81.0, 78.0, 77.5, 77.4, 77.2, 76.8, 75.7, 75.4, 75.1, 73.6, 
73.6, 72.8, 69.3, 68.4, 67.3, 55.7. HRMS (Q-ToF): calculated for C54H56O13Na+ 





Disaccharide 3-70 (31 mg, 34 µmol, 1.0 eq.) was dissolved in triethyl 




solution was stirred at r.t. for 30 min and TLC showed a full conversion of the starting 
material. The mixture was evaporated in vacuo and dissolved in acetonitrile (1 mL). The 
temperature was cooled to 0 °C, TFA (50% aq., 0.3 mL) was added to the solution and 
TLC showed a completion of the reaction after 5 min. The mixture was extracted with 
EtOAc, washed with water, NaHCO3 (aq.) and brine, dried with Na2SO4 (s), 
concentrated and further purified by FC to get 3-74 (28 mg, 29 µmol, yield: 79%). 1H 
NMR (600 MHz, Chloroform-d) δ 7.96 (d, J = 7.7 Hz, 2H), 7.55 – 7.48 (m, 3H), 7.46 – 
7.07 (m, 24H), 5.61 (s, 1H), 5.27 (t, J = 8.0 Hz, 1H), 5.15 (t, J = 9.2 Hz, 2H), 4.83 (d, J 
= 12.1 Hz, 1H), 4.71 (d, J = 12.1 Hz, 1H), 4.55 (dd, J = 28.6, 8.4 Hz, 1H), 4.43 – 4.33 
(m, 3H), 3.91 – 3.81 (m, 4H), 3.79 – 3.66 (m, 1H), 3.49 (s, 1H), 3.44 – 3.33 (m, 1H), 
3.10 – 2.89 (m, 2H). 13C NMR (151 MHz, Chloroform-d) δ 165.1, 138.0, 137.4, 133.2, 
130.0, 129.9, 129.9, 129.2, 128.6, 128.5, 128.5, 128.4, 128.3, 128.2, 127.9, 127.7, 126.2, 
126.2, 102.0, 101.4, 81.9, 78.0, 77.4, 77.2, 76.9, 74.1, 73.6, 70.2, 68.9, 67.2, 66.5, 50.6, 
50.3, 47.2, 46.2, 29.2, 27.8, 27.4, 23.1. HRMS (Q-ToF): calculated for C56H58O14Na+ 





Disaccharide 3-74 (13 mg, 14 µmol, 1.0 eq.) was dissolved in a mixed solvent of 
DCM (0.9 mL) and pyridine (0.1 mL). FmocCl (18 mg, 68 µmol, 5.0 eq.) was added 
and the solution was stirred at r.t. until TLC showed a full conversion of the starting 
material. The mixture was evaporated and purified with FC to obtain 3-12 (15 mg, 
13 µmol, yield: 94%). 1H NMR (700 MHz, Chloroform-d) δ 7.72 (dd, J = 13.3, 7.6 Hz, 
2H), 7.54 (d, J = 7.6 Hz, 1H), 7.48 (d, J = 7.5 Hz, 1H), 7.41 – 7.32 (m, 7H), 7.28 (d, J = 
8.6 Hz, 9H), 7.25 – 7.17 (m, 8H), 7.13 (dd, J = 4.8, 2.6 Hz, 3H), 7.08 – 7.03 (m, 2H), 
6.72 – 6.64 (m, 2H), 5.89 – 5.84 (m, 1H), 5.24 (dd, J = 12.0, 1.8 Hz, 1H), 5.12 (dd, J = 




13.7, 9.3, 3.6 Hz, 3H), 4.80 – 4.73 (m, 2H), 4.63 – 4.56 (m, 3H), 4.46 (dd, J = 12.2, 1.7 
Hz, 1H), 4.37 (s, 1H), 4.37 – 4.32 (m, 2H), 4.18 (ddd, J = 10.1, 7.5, 1.7 Hz, 1H), 4.11 (t, 
J = 7.5 Hz, 1H), 3.73 (d, J = 1.9 Hz, 4H), 3.67 (dt, J = 10.6, 2.9 Hz, 1H), 3.63 (td, J = 
9.1, 1.7 Hz, 1H), 3.40 (ddd, J = 16.6, 10.7, 3.5 Hz, 3H), 1.88 (d, J = 1.8 Hz, 3H). 13C 
NMR (176 MHz, Chloroform-d) δ 169.9, 165.7, 155.8, 154.2, 151.5, 143.6, 143.4, 
141.4, 141.4, 138.7, 138.6, 138.5, 138.4, 135.0, 129.2, 128.8, 128.8, 128.5, 128.5, 128.5, 
128.4, 128.3, 128.1, 128.0, 128.0, 127.9, 127.8, 127.8, 127.7, 127.7, 127.6, 127.5, 127.3, 
125.4, 125.4, 120.1, 120.1, 119.2, 114.6, 103.1, 101.8, 85.1, 82.7, 77.8, 77.3, 77.2, 77.0, 
76.6, 75.8, 75.2, 75.0, 74.8, 74.5, 73.7, 72.0, 70.5, 68.5, 68.0, 67.7, 55.8, 46.7, 20.5. 
HRMS (Q-ToF): calculated for C71H68O16Na+ [M+Na]+ 1199.4400, found 1199.4390 
m/z. 
 
Phenyl 2-azido-4,6-di-O-benzylidene-2-deoxy-1-seleno-α-D-galactopyranoside (3-75) 
 
Selenoglycoside 3-53 (9.01 g, 26 mmol, 1.0 eq.) was dissolved in anhydrous 
acetonitrile (52 mL). Benzaldehyde dimethyl acetal (12 mL, 78 mmol, 3.0 eq.) and CSA 
(177 mg, 2.6 mmol, 3.0 eq.) were added to the solution and the mixture was stirred at r.t. 
for 30 min. TLC showed a full conversion of the starting material and the reaction was 
quenched with TEA. After evaporation in vacuo, the mixture was extracted with EtOAc, 
washed with water and brine, dried with Na2SO4 (s), concentrated in vacuo and further 
purified by FC to get 3-77 (10.88 g, 25 mmol, yield: 96%). 1H NMR (600 MHz, 
Chloroform-d) δ 7.58 (dd, J = 7.2, 2.3 Hz, 2H), 7.52 – 7.47 (m, 2H), 7.40 (q, J = 3.2, 2.3 
Hz, 3H), 7.32 – 7.26 (m, 3H), 6.04 (d, J = 5.1 Hz, 1H), 5.61 (s, 1H), 4.31 (d, J = 3.7 Hz, 
1H), 4.18 (dd, J = 11.1, 1.9 Hz, 2H), 4.14 (dd, J = 10.2, 5.1 Hz, 1H), 4.09 (dd, J = 13.1, 
2.4 Hz, 1H), 3.94 (td, J = 10.2, 3.5 Hz, 1H), 2.59 (dd, J = 10.2, 1.9 Hz, 1H). 13C NMR 
(151 MHz, Chloroform-d) δ 137.3, 133.9, 129.6, 129.4, 129.3, 128.7, 128.5, 127.9, 









Selenoglycoside 3-75 (1.063 g, 2.46 mmol, 1.0 eq.) was dissolved in anhydrous 
DCM (25 mL). TBSCl (743 mg, 4.92 mmol, 2.0 eq.), imidazole (418 mg, 6.15 mmol, 
2.5 eq.) and DMAP (60 mg, 0.49 mmol, 0.2 eq.) were added sequentially and the 
mixture was stirred at r.t. overnight. After TLC showed a full conversion of the starting 
material, MeOH was added to the mixture to quench the reaction. The solvent was 
evaporated and the crude was purified by FC to get 3-76 (1.236 g, 2.26 mmol, 
yield 92%). 1H NMR (400 MHz, Chloroform-d) δ 7.60 – 7.55 (m, 2H), 7.54 – 7.49 (m, 
2H), 7.40 – 7.33 (m, 3H), 7.27 (d, J = 2.2 Hz, 2H), 6.06 (d, J = 5.1 Hz, 1H), 5.57 (s, 1H), 
4.26 (dd, J = 10.0, 5.1 Hz, 1H), 4.21 – 4.13 (m, 2H), 4.13 – 4.05 (m, 2H), 3.93 (dd, J = 
10.0, 3.4 Hz, 1H), 0.95 (s, 9H), 0.21 (s, 3H), 0.18 (s, 3H). 13C NMR (101 MHz, 
Chloroform-d) δ 137.7, 133.8, 129.3, 129.0, 129.0, 128.3, 127.8, 126.1, 100.8, 85.9, 
77.5, 77.4, 77.2, 76.8, 76.3, 72.1, 69.3, 65.4, 61.9, 25.8, 18.2, -4.3, -4.6. LCMS (ESI): 





Selenoglycoside 3-76 (1227 mg, 2.24 mmol, 1.0 eq.) was dissolved in a mixture 
of AcOH (8 mL) and H2O (2 mL). The mixture was stirred at 60 °C and TLC showed a 
full conversion of the starting material and two spots. After being extracted with EtOAc, 
washed with water, NaHCO3 (sat. aq.) and brine, dried with Na2SO4 (s), concentrated in 
vacuo and purified with FC, 3-77 (247 mg, 0.54 mmol, yield: 24%) was obtained. 1H 




= 5.3 Hz, 1H), 4.26 (td, J = 4.6, 2.2 Hz, 1H), 4.07 (dd, J = 9.8, 5.2 Hz, 1H), 3.94 – 3.91 
(m, 1H), 3.91 – 3.88 (m, 1H), 3.81 (dd, J = 9.8, 3.3 Hz, 1H), 3.78 – 3.68 (m, 1H), 2.65 
(s, 1H), 1.97 – 1.85 (m, 1H), 0.95 (s, 9H), 0.24 (s, 3H), 0.19 (s, 3H). 13C NMR (151 
MHz, Chloroform-d) δ 171.3, 135.0, 129.4, 128.2, 128.0, 84.7, 84.4, 77.4, 77.2, 76.9, 
72.4, 72.3, 70.7, 62.9, 62.5, 60.5, 25.9, 21.2, 18.1, 14.3, 1.2, -4.5, -4.7. LCMS (ESI): 
calculated for C18H29N3O4SeSiNa+ [M+Na]+ 482.1, found 482.0 m/z. 
 
Phenyl 2-azido-4,6-di-O-benzyl-2-deoxy-1-seleno-α-D-galactopyranoside (3-15) 
 
Selenoglycoside 3-77 (244 mg, 533 µmol, 1.0 eq.) was dissolved in anhydrous 
DMF (6 mL). The mixture was cooled to 0 °C and NaH (60% in mineral oil, 128 mg, 
3.20 mmol, 6.0 eq.) was added to the mixture. BnBr (0.38 mL, 3.20 mmol, 6.0 eq.) was 
added dropwise, the cooling bath was removed and the mixture was stirred overnight. 
TLC showed a full conversion of the starting material and the reaction was quenched 
with MeOH. Most of the solvent was removed by evaporation in vacuo and the residue 
was extracted with EtOAc, washed with water and brine, dried by Na2SO4(s), 
concentrated and further purified by FC to obtain crude 3-78 which was used in the next 
step directly. After 3-78 from the previous step was dissolved in THF (2 mL), TBAF 
(1 M in THF, 0.6 mL) was added to the solution and the reaction was monitored by 
TCL. After the starting material was fully converted, the mixture was extracted with 
EtOAc, washed with water and brine, dried by Na2SO4(s), concentrated and further 
purified by FC to obtain 3-15 (230 mg, 439 µmol, 82% for two steps). 1H NMR (600 
MHz, Chloroform-d) δ 7.43 – 7.08 (m, 21H), 6.97 (d, J = 8.4 Hz, 2H), 6.75 (d, J = 8.4 
Hz, 2H), 5.38 – 5.13 (m, 1H), 4.92 (d, J = 11.0 Hz, 1H), 4.89 (d, J = 10.9 Hz, 1H), 4.84 
– 4.78 (m, 2H), 4.73 (dd, J = 35.6, 9.5 Hz, 2H), 4.51 (t, J = 11.3 Hz, 3H), 4.34 (d, J = 
14.0 Hz, 2H), 4.09 (s, 1H), 3.76 – 3.55 (m, 6H), 3.40 – 3.31 (m, 1H), 3.29 (s, 1H). 13C 
NMR (151 MHz, Chloroform-d) δ 155.5, 138.7, 138.3, 138.2, 128.5, 128.5, 128.5, 
128.1, 128.0, 127.9, 127.8, 127.8, 127.7, 114.8, 103.1, 84.9, 82.5, 77.6, 77.4, 77.2, 76.9, 








Selenoglycoside 3-15 (93 mg, 177 µmol, 1.0 eq.) was dissolved in a mixture of 
anhydrous DCM (0.8 mL), pyridine (0.1 mL) and Ac2O (0.1 mL). The solution was 
stirred at r.t. until TLC showed a full conversion of the starting material. The product 
was extracted with EtOAc, washed with water and brine, dried by Na2SO4(s), 
concentrated and further purified by FC to obtain 3-18 (99 mg, 439 µmol, yield: 98%). 
Donor 3-15 (39 mg, 69 µmol, 1.0 eq.) and acceptor 3-7 (29 mg, 89 µmol, 1.3 eq.) were 
coevaporated with toluene for three times and put under high vacuum overnight to 
remove trace water in them. The starting materials were dissolved in anhydrous toluene 
(0.8 mL), 4 Å molecular sieves were added and the suspension was stirred at -0 °C for 
5 min. NIS (67 mg, 297 µmol, 1.5 eq.) and TfOH (1.2 µL, 14 µmol, 0.2 eq.) were added 
and the resultant mixture was stirred at that temperature until TLC showed a full 
conversion of the donor. The reaction was quenched with Na2S2O3(aq.), extracted with 
EtOAc, washed with Na2S2O3(aq.) and brine, dried with Na2SO4(s), concentrated and 
purified with FC to get 3-13, 46 mg, α/β = 5.6, 62 µmmol, yield: 91%, yield for 3-13α: 
77%. 1H NMR of 3-13α (600 MHz, Chloroform-d) δ 7.44 – 7.22 (m, 20H), 7.17 (s, 1H), 
5.17 (d, J = 17.4 Hz, 2H), 4.92 (d, J = 11.6 Hz, 1H), 4.74 (d, J = 3.0 Hz, 2H), 4.62 (d, J 
= 11.6 Hz, 1H), 4.49 (d, J = 10.6 Hz, 2H), 4.20 (dd, J = 11.2, 6.5 Hz, 1H), 4.18 – 4.11 
(m, 1H), 4.06 (dd, J = 11.2, 6.3 Hz, 1H), 3.87 (s, 1H), 3.81 (dd, J = 10.4, 8.0 Hz, 1H), 
3.74 (d, J = 2.7 Hz, 1H), 3.50 – 3.38 (m, 2H), 3.29 (dd, J = 10.5, 2.7 Hz, 1H), 3.23 (d, J 
= 39.5 Hz, 2H), 1.97 (d, J = 0.7 Hz, 3H), 1.61 (d, J = 7.7 Hz, 6H), 1.45 – 1.18 (m, 4H). 






4.6 Spectra of Important Compounds 
1H NMR of 2-1 
 
 






Decoupled H-C HSQC of 2-1 
 
 






13C NMR of 2-2 
 
 
















13C NMR of 2-3 
 
 






1H NMR of 2-4 
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